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The aim of this review is to propose a Unified Theory of Alzheimer’s disease (UTAD) that integrates all key behavioural,
genetic and environmental risk factors in a causal chain of etiological and pathogenetic events. It is based on
three concepts that emanate from human’s evolutionary history: (1) The grandmother-hypothesis (GMH), which
explains human longevity due to an evolutionary advantage in reproduction by trans-generational transfer of
acquired knowledge. Consequently it is argued that mental health at old-age must be the default pathway of
humans’ genetic program and not development of AD. (2) Therefore, mechanism like neuronal rejuvenation (NRJ)
and adult hippocampal neurogenesis (AHN) that still function efficiently even at old age provide the required
lifelong ability to memorize personal experiences important for survival. Cumulative evidence from a multitude of
experimental and epidemiological studies indicate that behavioural and environmental risk factors, which impair
productive AHN, result in reduced episodic memory performance and in reduced psychological resilience. This
leads to avoidance of novelty, dysregulation of the hypothalamic–pituitary–adrenal (HPA)-axis and cortisol
hypersecretion, which drives key pathogenic mechanisms of AD like the accumulation and oligomerization of
synaptotoxic amyloid beta, chronic neuroinflammation and neuronal insulin resistance. (3) By applying to AHN
the law of the minimum (LOM), which defines the basic requirements of biological growth processes, the UTAD
explains why and how different lifestyle deficiencies initiate the AD process by impairing AHN and causing
dysregulation of the HPA-axis, and how environmental and genetic risk factors such as toxins or ApoE4,
respectively, turn into disease accelerators under these unnatural conditions. Consequently, the UTAD provides a
rational strategy for the prevention of mental decline and a system-biological approach for the causal treatment
of AD, which might even be curative if the systemic intervention is initiated early enough in the disease process.
Hence an individualized system-biological treatment of patients with early AD is proposed as a test for the
validity of UTAD and outlined in this review.
Keywords: Unified theory Alzheimer’s disease (UTAD), Grandmother-hypothesis (GMH), Neuronal rejuvenation (NRJ),
Adult hippocampal neurogenesis (AHN), Law of the minimum (LOM), Curative AD therapy, Causal AD prevention
Background
Alzheimer’s disease (AD) is characterized by impair-
ment of hippocampal episodic memory performance
followed by a progressive decline of cognitive and social
capabilities. Since AD is the major cause of cognitive
decline and no curative drug has been developed, re-
search worldwide is intense and highly competitive.
Epidemiological, biochemical, molecular, genetic and
animal studies provide different entry points into the
complex disease process, which led to different theories
about the aetiology of AD. Starting with age as the
main cause and primary risk factor, AD is being ex-
plained by the oligomeric amyloid beta (Aβ) cascade
hypothesis, which includes hyperphosphorylated and
dysregulated tau [1], the intoxication hypothesis [2–4],
chronic infections [5–7], microbiome composition [8],
neuronal insulin resistance [9, 10], physical and functional
breakdown of the blood–brain-barrier (BBB) [11, 12],
chronic neuroinflammation, due to multiple causes [13],
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impaired neuronal rejuvenation (NRJ) [14], synaptic fail-
ure [15], and a growing list of many others.
All of these theories are more or less deeply embed-
ded in the belief that aging per se is the main etiological
cause. In fact, the thought that aging per se is the pri-
mary cause of AD is so deeply engrained in our think-
ing and appears in almost every introduction in any
scientific paper about AD to be a compulsory state-
ment, which is rarely challenged. But as I will argue,
not only are there a number of serious arguments chal-
lenging the “age-is-the-primary-cause-dogma”, ageing
as the overarching cause also hinders the development
of a “unified theory of AD” (UTAD), which incorpo-
rates all key findings including the long list of well-
known environmental and behavioural risk factors,
hence explaining the aetiology and pathogenesis of this
debilitating disease. In fact, the lack of a UTAD con-
tinues to limit the development of effective preventive
measures and a curative treatment to trial and error.
Therapeutic interventions that focus on such singled
out mechanisms continue to fail [16]. In addition, pre-
vention trials, which rather base their regimen on the
correction of more or less arbitrarily selected risk fac-
tors than on a complete theory of AD, were so far also
limited in their overall success [17, 18]. In contrast, the
proposed UTAD overcomes our concept of age per se
as the major cause for AD, and provides an encompass-
ing explanation of the aetiology and pathogenesis of
Alzheimer’s. It also allows proposing a number of re-
quired individual life changing interventions in order to
prevent AD with high probability. In addition, the UTAD
might provide the logical framework for a curative regi-
men, as will be outlined at the end of this review.
I would like to point out that I have termed the pro-
posed theory “UTAD” because it presents a systemic
neurobiological framework of how all currently known
major behavioural, environmental or genetic risk factors
individually or in combinations initiate or accelerate the
AD process, despite certain caveats that apply for most
if not all theories: Although I tried to be as comprehen-
sive and exhaustive as possible in my search using key
words like for instance “AD risk factor”, “factors inhi-
biting AHN” or “neuroinflammation” in the PubMed
database of the National Center for Biotechnology
Information, some minor risk factors might have been
overlooked, it needs to be seen if they will verify or fals-
ify the UTAD. The same goes for risk factors, which are
already acting today but have not been identified yet, or
which emanate from future individual lifestyle choices
or cultural developments. Conversely, in some cat-
egories of risk factors (e.g. environmental toxins and
chemicals), I purposely listed only examples, since a
comprehensive list (e.g. of all currently known chemi-
cals that negatively influence critical mechanism of the
AD process as proposed by the UTAD), would not add
to its understanding and therefore go beyond the
scope of this review. It is my hope that once the prin-
cipal concept of the UTAD is accepted, all risk factors
that interfere with the neurobiological mechanisms,
which, according to the UTAD, are at the centre of
AD can be recognized and investigated more effi-
ciently. Last but not least, behavioural risk factors in
context of the UTAD might lead to discussions about
free will or freedom of action, which would also go be-
yond the scope of this review.
Aging is required but not causal for AD
Measurement of insulin resistance of the hippocampal/
temporal lobe by positron emission tomography with 2-
deoxy-2-[fluorine-18] fluoro-D-glucose integrated with
computed tomography (FDG-PET/CT) has become, be-
sides amyloid-PET diagnostics [19] a highly specific and
sensitive biomarker for AD, having predictive value even
decades before the first clinical symptoms of AD mani-
fest themselves [20]. One may conclude that the devel-
opment of AD obviously requires time and, therefore,
the logical consequence is that the risk of developing
AD will increase with age. But correlation does not a
priori equal causation. In this case, for a disease requir-
ing time to develop, age might simply be a precondition
but not necessarily a cause. If age was indeed the cause
of the disease, AD would not only be a natural outcome
of human aging but the fight against AD would be a
fight against human nature, which is highly difficult to
win.
But, fortunately, many lines of evidence disagree with
this explanation (for example see [21, 22]). Particularly
from a human’s life history point of view, if age per se
was indeed the main causative risk factor, why was AD
essentially unknown around the beginning of the last
century? According to a recent estimate, age would have
caused approximately 36 thousand new cases per year in
the USA alone, making the disease very common [3].
But a textbook on neurology published in the late 19th
century did not even mention an AD-like pathology
[23], and in 1906, when Alois Alzheimer first published
report about the pathology appeared, he described it as
a peculiar brain disease [24], suggesting that it has
been unknown before. And still in 1938, 32 years later,
Alzheimer’s description of amyloid plaques and neuro-
fibrillary tangles as hallmarks of AD brain pathology
had not found their way in a comprehensive textbook
of pathology [25]. It may be proposed that, at that time,
death as a consequence of AD was a very rare event.
AD prevalence was maybe similar rare as in Japan at
the mid of last century. A recent study provided signifi-
cant evidence that not age but rather certain lifestyle fac-
tors explain the sevenfold (!) increase in AD prevalence
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over the last half of the 20th century [26]. This dramatic
increase was strongly associated with a change from the
traditional Japanese diet/lifestyle towards a Western one,
which mainly took place between 1961 and 1985. In par-
ticular, besides a large increase in alcohol intake, the
consumption of meat and animal products rose by
seven- and fourfold, respectively. Animal products and
meat are known to increase the risk of AD because they
contain compounds such as excess iron (which particu-
larly enhances the risk for ApoE4 carriers, as will be de-
tailed below), advanced glycation end products (AGEs)
and arachidonic acid that have been shown to increase
oxidative stress and inflammation in the brain (which
also will be detailed below). The dietary changes paral-
leled the dramatic increase in AD prevalence for those
people aged 65+ years in Japan, which rose from a low
1 % in 1985 to about 7 % in 2008, with a lag time of
about 20 years. This trend in disease prevalence can nei-
ther be explained by a change in life expectancy nor by a
genetic drift. Such relatively short intervals are rather
known for other behavioural diseases like e.g. lung can-
cer from smoking [27].
According to the author of this groundbreaking study,
the AD prevalence rates in Japan may have reached a
peak - like in other highly industrialized societies - and
will not increase further, as these AD-causing behav-
ioural factors have changed only modestly since 1985.
Consequently they one reviewer of the study warns, “un-
less Japanese people return to the traditional Japanese
diet, AD rates in Japan are unlikely to decrease” [28]. A
similar increase in AD incidence from low to high rates
can be observed in emerging economies. For instance,
the age-specific AD incidence rate in rural India was
shown to be about four times lower than in the USA
[29], its rise rather parallels the rate of economic growth,
which strongly influences the lifestyle [30]. Similarly, the
prevalence of AD among African-American populations
living in the US is several-fold higher when compared
to age matched Africans in their homelands [31, 32].
Japanese who migrated to the US and adopted the
American way of life increased their AD-risk [33].
Hence, not ethnical origin, but rather the adopted mod-
ern lifestyle has an impact on AD risk [34]. In other
words, our individual life history might play a decisive
role in shaping the AD risk.
According to a reanalysis of the Framingham Heart
Study, the incidence of dementia over three decades al-
most halved [35]: The 5-year age- and sex-adjusted cu-
mulative hazard rates for dementia were 3.6 per 100
persons during the first epoch (late 1970s and early
1980s), 2.8 per 100 persons during the second epoch
(late 1980s and early 1990s), 2.2 per 100 persons during
the third epoch (late 1990s and early 2000s), and 2.0 per
100 persons during the fourth epoch (late 2000s and
early 2010s). Compared to the incidence during the first
epoch, the rate declined by 22, 38, and 44 % during the
second, third, and fourth epochs, respectively. Again,
these data are inconsistent with age per se being the
major cause of AD. According to the authors of the
study, the key contributing factor to this decline have
not been identified, but it is important to note that this
positive trend was observed only (!) among persons with
at least a high school diploma. For those with lower edu-
cation, the AD-risk was actually rising by 66 % over the
four decades. This indicates that education and/or in-
come, hence socioeconomic factors, might play a pivotal
role. But we can certainly rule out age, as low socioeco-
nomic status reduces, rather than increases, lifespan
[36]. According to the authors of another study [37],
which reported a similar decline, the increased use of
antihypertensive, lipid lowering and antidiabetic drugs
might have contributed to these positive trends, as well
as experiencing less stressful life events like wartimes,
which particularly afflicted the older generations in
former studies, from which the earliest estimates were
derived. Taken together, life choices and life experiences
appear to be of etiological significance for AD.
Results from research based on animal models also
argues against aging being causative for AD. Laboratory
animals are kept under so-called standard housing con-
ditions which represents their “lifestyle”, which is in
some aspects quite similar to the life in western soci-
eties. This “Western-type-lifestyle” is sedentary, lacks
social activities and, comparably, the animals suffer
chronic sleep deprivation since they are constrained to
an unnatural but standard 12 h dark/light-rhythm. Fur-
thermore, an unnatural ad libitum feeding pattern is
also applied routinely to animals in experimental re-
search, leading to a misinterpretation of experimental
results, particularly in AD research. Not the animal liv-
ing in its wild habitat, where e.g. physical activity and
intermittent fasting (IMF) is natural, but the sedentary
caged animal, which is fed ad libitum, became the
standard to which we tend to correlate and to interpret
all data down to the cellular and molecular level. In
contrast, a more natural housing, named environmental
enrichment (EE), which includes social activity in larger
enclosures and environmental complexity (e.g. the
presence of objects that can be manipulated, structures
for climbing or exercise, foraging opportunities, hiding
or nesting areas), hence a more natural situation, is
regarded as a experimental condition [38]. But it
should be vice versa, since the conditions under an EE
mimic in important aspects those of our own pre-
modern lifestyle, hence the general conditions to which
our genetic program is adapted too. The standard
housing condition should therefore be regarded as the
experimental condition, in which important factors for
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the physical and mental well-being are eliminated and
the consequences for aging and AD being studied. This
change of perspective would help to regard AD primar-
ily as a deficiency disease, i.e. a result of discrepancies
between behavioural requirements of an organism and
its actual lifestyle conditions.
In line with the proposed UTAD, even old mice
maintained in EE show a robust fivefold increase in
adult hippocampal neurogenesis (AHN) [39], which is
an important aspect in regard to AD, as will be outlined
in detail below. Furthermore, they exhibit reduced anx-
iety and depression-like behaviours [40], and show im-
proved memory performance compared to animals
maintained under standard housing condition [41].
Therefore, once we start looking at animal models of
aging or AD from an evolutionary perspective, experi-
mental deficiencies (under current standard housing
conditions) in physical exercise, IMF, social activities or
essential nutrients would become obvious causes of AD
(see below). For example, one year of IMF prevented
cognitive decline even in a triple-transgenic mouse
model of AD (which express the APPswe, PS1M146V,
and tauP301L mutations [42]), providing evidence that
not aging but rather the feeding pattern have long-lasting
effects on memory [43]. More examples will follow, which
in combination have one important consequence: Most
results obtained from animal research (as well as from epi-
demiological studies) regarding aging and AD need to
be reinterpreted from an evolutionary point of view:
“Normal” aging under “Western-style” housing is not
natural, and the same might apply to AD in humans.
Lifestyle choices initiate and genetic predispositions
accelerate AD pathogenesis
Evolution drives primarily by the selection of advanta-
geous genetic variants. The dramatic trends in AD inci-
dence in industrialized countries over the last century
and the similar rise in emerging economies nowadays
can therefore not easily be explained by genetic influ-
ence. It is more likely that AD follows similar lifestyle
changes that parallel the well-known increases of type-
2-diabetes, obesity, high blood pressure and arterio-
sclerosis, all well-known risk-factors for AD [44].
Another rather crude example serving to explain the
interplay between a certain lifestyle choice and AD risk
and demonstrating interplays with a presumed genetic
predisposition comes from the USA. Compared to the
general population, players in the national football
league (NFL) have a threefold increased risk of develop-
ing major depression [45] and those who incurred three
or more concussions during their careers had a fivefold
higher risk for amnestic mild cognitive impairment
(MCI) [46]. According to the authors of the NFL-study,
traumatic brain injury is a causative risk factor for AD
and other forms of dementia. The average age at AD
diagnosis was 53.8 years, which indicates that, in these
cases, it is definitely not age which increases AD risk.
Several other studies confirmed these finding (for review
see [47]): In particular speed players who commonly
build up considerable momentum prior to tackling or
being tackled, showed even a significant sixfold higher
mortality resulting from AD and from amyotrophic
lateral sclerosis in comparison with the general US
population. Interestingly, ApoE4-carriers (i.e. carriers
of a specific genotype variant of the apolipoprotein
polymorphism) are more susceptible to concussion-
mediated AD-risk, which is in line with the experi-
mental observation that ApoE4, in contrast to ApoE2
and ApoE3, makes particularly the BBB more vulner-
able to proinflammatory insults. This alterations lead
to an increased neuronal uptake of multiple blood-
derived neurotoxic proteins, as well as microvascular
cerebral blood flow disturbances. In ApoE4-expressing
animal models, those vascular defects precede neur-
onal dysfunction and can initiate neurodegenerative
changes [48].
The ApoE4 polymorphism is known as the most
common genetic risk factor for sporadic AD with 15 %
Caucasians being carriers. Although ApoE4 is neither
necessary nor sufficient for the development of AD,
having one or two copies of the ApoE4 allele increases
late-onset AD risk about 3- to 12-fold, respectively
[49]. Interestingly, ApoE4 is a uniquely human allele
and the most ancestral, and its appearance in evolution
marks the dramatic increase in the human lifespan (for
review see [50]). In contrast, the human ApoE3 allele
appears to be neutral regarding AD risk, and its muta-
tion emerged much later in human history; its fre-
quency increased during human evolution with 75 % of
Caucasians now being carriers. Why has the ApoE4 al-
lele not been completely replaced by natural selection
with the health-beneficial ApoE3 or ApoE2 allele,
which even appear to lower AD risk? There are several
possible explanations. For instance it is assumed that
alleles that are detrimental to health in older age might
persist in populations because they confer, by means of
antagonistic pleiotropy, some benefit to younger indi-
viduals [51]. ApoE is a major supplier of the cholesterol
precursor for the production of oestrogen and proges-
terone. According to one recent study, women who
carry at least one ApoE4 allele have significantly higher
levels of mean luteal progesterone than women that
carry only ApoE2 or ApoeE3 alleles. ApoE4 might
therefore be advantageous regarding fertility and there-
fore in reproductive performance [52]. Another study
found an association of ApoE4, when compared to
ApoE2 and ApoE3, with good episodic memory and an
economic use of memory-related neural resources in
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young, healthy humans [53], albeit other studies failed
to provide evidence for such a benefit [54].
Whatever the advantage of ApoE4 for some might be,
we should be aware that all our observations regarding
the disadvantages of any genetic variant with respect to
AD were observed in human populations (or caged ani-
mals) that dramatically changed their lifestyle in recent
history. We simply do not know if ApoE4 would be
neutral or might even provide a benefit for cognitive
health in the elderly, if current behavioural and envir-
onmental deficiencies are omitted. Indeed, it is notice-
able that particularly the detrimental effects of the
ApoE4 polymorphism on cognition may strongly de-
pend on modifiable risk factors (for review see [50]).
For example, in some studies, engagement in physical
activity seems to reduce AD risk primarily in ApoE4
carriers [55], in line with the “grandmother hypothesis”
(see below), which argues that the evolution of the long
human lifespan likely required older individuals to
maintain high levels of both physical and cognitive
health. Like the NFL-example discussed above, recent
cohort studies provided evidence that ApoE4 makes us
more vulnerable to unhealthy lifestyle choices. In one
study, hypercholesterolemia was associated with cogni-
tive impairment mainly among ApoE4 carriers [56].
Hence the advantage in fertility, as has been outlined
above, might turn into a disadvantage upon altered
behaviour that leads to increased cholesterol levels. In
another study, which will be detailed below, ApoE4-
subjects adhering to a healthy Mediterranean diet
(MeDi) had the greatest benefit regarding brain health
when compared to other genotypes [57]. This tendency
was confirmed by the finding, that particularly carriers
of the ApoE4 allele profited from nutritional consump-
tion of fish, as their AD risk dropped by a factor of
two, whereas non-ApoE4-carriers had no such advan-
tage [58]. Furthermore, a recent study provided evi-
dence that ferritin levels in the cerebrospinal fluid
(CSF) are negatively associated with cognitive perform-
ance in cognitively normal (i.e. averagely mentally de-
clining with age), MCI and AD subjects, and predicted
speed of MCI conversion to AD [59]. Interestingly, the
elevated CSF-ferritin levels were found to be strongly
associated with the ApoE4 genotype. From an evolu-
tionary point of view, ApoE4 carriers might have had
an advantage as their brain was provided with suffi-
cient iron in situations of low nutritional iron avail-
ability. Since nowadays diets usually contain large
amounts of iron-rich animal products (as outlined
above for the modern Japanese society), the potential
physiological advantages of ApoE4 in iron metabolism
might fire back, leading to elevated brain iron, which
promotes enhanced production of reactive oxygen spe-
cies (ROS) and adversely impacts on AD progression.
Hence it is conceivable that the most common gen-
etic risk factor for sporadic AD, namely ApoE4, might
be important for brain health under those conditions
that prevailed for the longest part of our evolution [50].
Therefore, it might now only be regarded as a risk fac-
tor under unhealthy lifestyle choices (like professionally
acquired head traumata, favouring life-styles that lead
to increased cholesterol levels or iron intake, or low
physical activity etc.). The ApoE4-allel might therefore
not be a cause of AD but might rather act as an acceler-
ator under such (unhealthy) conditions. Indeed, each
ApoE4 allele exerts a dose-related earlier onset of AD
[60]. The situation might be similar to the so-called
obesity alleles, which simply provide the carrier with a
genetic variant that actually improved the fitness of his
ancestors by being particular efficient in energy conserva-
tion under living conditions, which alternated between
IMF and feasts after successful foraging. Nowadays, under
lifestyle conditions that provide a steady energy supply
under minimal physical expenditure, the same genes are
regarded as “disease genes”. The good news, both for car-
riers of “obesity genes” and particularly of ApoE4 is that
they will benefit most from a return to a healthy lifestyle.
Taken together, the aetiology of AD appears not to be
different from any other current “culture-borne dis-
eases”, which are caused by well-known deficits in
physical exercise, intake of healthy food, intermittent
fasting and social activity. The AD epidemic might sim-
ply be due to the development of a highly sedentary,
overindulgent and occupation-specific lifestyle that
largely eliminates extended family bonds and time to
relax. In order to prevent and treat AD, we might need
a better understanding of how the true causative risk
factors interact. But, much more, we need to become
more open-minded: We should stop regarding AD as a
natural (genetic) disease or a causal consequence of
aging and begin to accept that AD is caused by envir-
onmental factors and behavioural deficiencies (i.e. the
well known risk factors). Consequently, AD should be
preventable and, in the early stages of the disease,
might even get cured, provided that we (re-) assume a
lifestyle that satisfies all essential requirements of our
brain, which result from our human’s particular evolu-
tionary life history.
Evolution of human longevity
We are a product of evolution. Therefore, any explan-
ation of a human ailment like AD must be footed on
evolutionary theory if we want to regard the aetiology
and pathogenesis as fully understood.
The second law of thermodynamics describes the nat-
ural instability of any information content, which in-
cludes the one encoded in the DNA in all our cells.
Hence life had to overcome a principal obstacle and find
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a way to preserve genetic information. Nature’s solution
was the repetitive duplicating of genetic material (analo-
gous to the need to frequently copy our favourite data
stores if we do want to avoid losing their information
content). The quality control mechanism after the copy-
ing process is selection of those copies that provide their
carrier with the ability to efficiently continue the DNA
duplication process. This mechanism allowed adaptation
to an ever-changing environment and the evolution of
quite different reproduction strategies. Bacteria on one
end of the spectrum engage in mass production and
mass genetic variation to increase the probability of sur-
vival of at least a few genetic copies. Humans, on the
other end, only have to generate relatively low numbers
of descendents in order to survive as a species, since
their large brain permits them to engage in complex
social collaborations and to use acquired knowledge to
enhance the chance of their progeny’s survival: Accord-
ing to large and complete multi-generational demo-
graphic records of pre-modern Canada and Finland, for
every post-reproductive decade at least two more of
their grandchildren reached reproductive age, when
compared to families with the grandmother dying earl-
ier [61]. Therefore, the older the grandmother beyond
60, i.e. 70, 80, or 90 (i.e. the age, when age supposedly
causes mental decline), the more she was able to in-
crease the number of her grandchildren and the chance
of their survival into adulthood, longevity became a se-
lected trait acting by transgenerational generativity.
Generativity in a psychosocial sense refers to the hu-
man concern for establishing and guiding the next
generation.
This particular evolutionary strategy developed early in
human history and is known today as the grandmother-
hypothesis (GMH) [62]. The GMH explains the evolution-
ary origin of our exceptional longevity when compared to
our genetically closest cousins, the chimpanzees, which
die a few years after reaching menopause [63]. The ob-
jection to the GMH, that longevity is a rather modern
phenomenon, since hunter-gatherer societies have low
average life expectancies, can be repudiated, as those
low averages reflect high infant mortality and not indi-
vidual life expectancy. Indeed, in still existing hunter-
gatherer societies that are insulated from modern life,
about two thirds of those who reach adulthood actually
survive up to an age of 70 years, even encountering an
80-year old might be no exception [64]. Reproductive
age in hunter-gatherer populations was between 15 and
45 years of age, hence a grandmother became first inde-
pendent of rearing her own children when her last own
child reached the childbearing age of about 15 years.
Hence exclusive grand-motherhood, i.e. the years inde-
pendent of motherhood, started at around 60 years of
age and had to last for at least another 15 years, until
the first grandchildren of her latest child reached adult-
hood. Interestingly, the GMH was recently supported
by observations of extended Orca whale families [65].
As in humans, female Orcas can live several decades
beyond menopause and their reproduction strategy also
relies on the use of lifelong acquired knowledge. In par-
ticular, the oldest post-menopausal females lead their
groups in salmon foraging grounds and organize the
hunt especially when salmon abundance is low, which
would otherwise reduce reproductive success and drive
mortality rates.
Taken together, the GMH contradicts principally with
the theories of AD being a general error in our genetic
program or simply being caused by aging, since the evo-
lution of longevity as a reproduction strategy requires a
brain functioning well particularly at higher age to
endow the kinship with the acquired life experience.
Furthermore and as the GMH predicts, under conditions
closer to those that were active during the long pre-
modern area of human development and to which our
genetic program is exquisitely adapted, the human
brain maintains the lifelong facility to acquire empiric
knowledge [66]. One key mechanism is the lifelong
growth of our memory store by adding new neurons
through AHN, another is the lifelong maintenance of
already existing neurons, i.e. neuronal rejuvenation
(NRJ) through the mechanism of autophagy and regen-
eration of subcellular structures and organelles. Both
mechanisms, NRJ [67] and AHN [68] appear to be effi-
ciently functioning even at high age, which is in line
with GMH (see below), but require certain environ-
mental cues and depend on our lifestyle choices, and if
defunct, both are also closely and causally linked to the
aetiology of AD, as I will also show below.
Lifelong neuronal rejuvenation (NRJ)
Mitochondria sustain cellular bioenergetic homeostasis
by playing key roles in a broad range of core cellular
functions, including energy production, metabolic and
calcium signalling, and in a number of biosynthetic
pathways [69]. They also perform a variety of functions
in processes such as the transduction of metabolic and
stress signals and the production of free radicals such as
reactive oxygen species (ROS). Originally envisioned as a
“necessary evil”, i.e. a by-product of an imperfect oxida-
tive metabolism, ROS are now recognized for having an
essential signalling function in cellular physiology [70].
Only in case of mitochondrial damage, excess accumu-
lation of ROS evoke an inflammatory response, which
inhibits AHN, but also leads the mitochondrial host to
engage the cell death program, which in case of neu-
rons leads to apoptotic neurodegeneration [71]. Hence
chronic perturbance of mitochondrial function aggra-
vates the pathogenesis of many neurodegenerative
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diseases. A complex defence mechanisms against this
type of oxidative stress has been resourcefully adapted,
which consists of endogenously generated ROS seques-
tering molecules and enzymes (e.g., α-lipoic acid, super
oxide dismutase, glutathione) and many bioactive nu-
trients (e.g., plant-derived vitamins and polyphenols),
which detoxify the harmful effects of ROS, while main-
taining their signalling capacity.
In addition, cells like neurons that have a low or no
turnover at all only survive up to high age of the indi-
vidual by maintaining intracellular youth through the
process of NRJ [72]. Central to maintaining cellular
bioenergetic homeostasis is to sustain a healthy mito-
chondrial population to ensure that cellular energy de-
mands are met by energy supply [71]. To this end, the
exchange of damaged macromolecules and cellular or-
ganelles including mitochondria evolved as an active
and highly regulated process [73], requiring behavioural
cues to initiate. Accordingly, accelerated aging [74],
memory decline and AD [75] might be caused by a lack
of these cues. Conversely, the accumulation of non-
functional macromolecular and damaged mitochondria
affect cell function with symptoms arising, when over
many years the rate of damage exceeds the rate of re-
pair and turnover [76]. Accordingly, autophagy is im-
portant to slow aging, inflammatory processes and cell
death [77].
The master regulator/inhibitor of autophagy is the
mammalian target of rapamycin (mTOR) [78]. This intra-
cellular kinase functions as a key signalling node that inte-
grates information regarding extracellular growth factor
stimulation, nutrient availability and energy supplies
[79]. The fungal metabolite rapamycin was accidently
found to block mTOR and became not only the ep-
onym of mTOR but also the main molecular tool to
dissect mTOR-function. Rapamycin treatment was
found to activate autophagy by inhibiting mTOR [80],
thereby slowing down both aging and cognitive decline
of caged mice [81], suggesting that inefficient autoph-
agy as part of the NRJ-program might be a central
element of both processes. Conversely, caging (standard
housing) might eliminate an important behavioural
cues (like for instance physical activity or intermittent
fasting, see below), which leads to unnaturally high activity
of mTOR and low activity of peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α) [82], the
master controller of mitochondrogenesis [83] (see below),
thereby inhibiting neuron-rejuvenating and protecting
autophagy [84]. Hence the observed aging and cognitive
decline in murine models of AD might be regarded as
artificial and not reflecting the aging process under nat-
ural conditions.
Other behavioural cues that inactivate mTOR are, be-
sides physical exercise, which was shown to promote
autophagy of defunct organelles and macromolecules in
the brain [85], chronic caloric restriction (CCR), which
is well known to delay aging and extend life-span in es-
sentially all eukaryotic organism [86]. But is CCR a
physiological cue or rather an artefact of experimental
research that simulates, to some extent, a more natural
dietary pattern, namely intermittent fasting (IMF),
which from an evolutionary point of view is more nat-
ural (see below)? But IMF is experimentally more
labour-intensive than CCR and therefore less well stud-
ied. Nevertheless, autophagy and in particular mito-
phagy was found to being activated by CCR through
inhibition of mTOR in essentially all species investi-
gated, ranging from yeast, to flies, worms, fish, rodents
and even to rhesus monkeys [87], thereby decelerating
mTOR-driven aging [88]. CCR not only extends life-
span, it also protects the central nervous system from
neurodegenerative disorders, whereas excessive caloric
intake is clearly associated with accelerated aging of the
brain and increased the risk of neurodegenerative disor-
ders due to suppressed autophagy [89].
Nevertheless, IMF was shown to create a more ro-
bust and steady inhibition of mTOR-accelerated aging
and cognitive decline when compared to CCR [90].
This is explained by the fact that the main hormone-
like signalling molecules of the metabolic status dur-
ing IMF, the ketone bodies acetoacetate (AcAc) and
D-β-hydroxybutyrate (βOHB), are more efficiently
generated during fasting than by CCR [91]. These two
respiratory fuels can endogenously be produced by the
liver in large quantities (up to 150 g/day) from mobi-
lized fatty acids in a variety of physiological [92] or
pathological conditions [93]. In humans, basal serum
levels of βOHB are in the low micromolar range, but
rise up to several hundred micromole after 12 to 16 h
of fasting [92]. Importantly, when blood glucose and
insulin are low [94], up to 60 % of the brain energy
needs can be derived from ketone bodies, replacing
glucose as its primary fuel [95]. Similar high levels of
up to 1 to 2 millimole βOHB are reached after pro-
longed endurance exercise [96]. A physiologically rele-
vant increase in ketone body production is already
achieved by fasting overnight, which can even be en-
hanced if we are physically active before breaking the
fasting in the morning [97]. This most likely mimics
the situation that faced our foraging ancestors who
went out for hunting or gathering food with their sto-
machs empty.
Since neither long- nor medium-chain saturated
fatty acids can pass the BBB, only their transformation
into ketone bodies allows our energy-demanding brain
to access the largest energy store, our adipose tissue.
In fact, ketone body production reduces glucose re-
quirement and preserves gluconeogenic protein stores
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during fasting, which enables a profound increase in
the capacity for survival [98]. Interestingly and again
in line with the GMH, elderly generate ketone bodies
at least as efficient as younger adults during IMF [99]
and the metabolic response to a ketogenic diet appears
also to be unaffected by aging [100].
As hinted at above, the observation that IMF is su-
perior to CCR makes also a lot of sense from an evolu-
tionary perspective, as not chronic starvation but
rather periodic alteration between fasting and intake of
high-caloric meals after successful foraging was ancient
normality. Importantly, recent evidence suggests that
our phylogenetically conserved genetic program uses
the metabolic changes that originate from intermittent
fasting (IMF) as a behavioural cue of for the initiation
of subcellular renewal [101]. This is a good thing, since
in order to maintain cellular youth, we do not have to
starve by CCR. It is sufficient to alternate phases of
fasting, which just need to be sufficiently long to in-
duce ketone body production (for instance 12 h over-
night) and phases of eating, in which the total energy
demand of our body can be met. In contrast, current
normality consists of constant feeding pattern, which
results in permanent high mTOR activity (and low
PGC-1α-levels, see below), which suppresses cellular
rejuvenation. A sedentary lifestyle aggravates this pro-
aging effect, whereas prolonged physical exercise re-
duces mTOR-activity [102], possibly also by increasing
ketone body production.
Taken together, inhibiting mTOR by being physically
active and by IMF is a natural way to stay healthy. But
there are always hopes that instead we can put a healthy
lifestyle in a pill: Rapamycin is an approved immunosup-
pressant in humans used to prevent rejection in organ
transplantation and meanwhile clinical trials are under
way to test efficacy in AD (for review see [103]). But
given the fact that IMF, a nutrient-rich diet and regular
aerobic exercise and sleep have more beneficiary func-
tions than just inhibiting mTOR, it is questionable if
long-term health can be achieved by a drug without a
lifestyle change. For instance, many of the well known
beneficiary effects of intermittent fasting (IMF) as well
as physical exercise are mediated by the upregulation
of PGC-1α. But activation of PGC-1α also reduces
neuroinflammation [66], for instance by inducing the
expression of ROS-detoxifying enzymes [104]. Hence
two potential causes of aging, chronic mitochondrial
dysfunction and neuroinflammation (see below), can
be explained by reduced levels of PGC-1α [105], and
might originate from either a lack in physical exercise,
IMF, or both; or from many other behavioural deficien-
cies, which will be discussed in detail below. Hence I
doubt that behavioural deficiencies can be compen-
sated by providing a single drug.
In summary, behaviourally suppressed cellular reju-
venation affects all organ systems and leads to frailty
when we age. But we should not fall into the trap of
blaming frailty or aging per se as the primary cause of
physical and in particular cognitive decline [106].
“Normality”, as we usually define and see it, might be
misleading, since it only reflects a statistical mean of
current behaviour and its consequences (like e.g. the
average decline of cognitive abilities with age). In fact,
we prolong our lifespan despite unhealthy aging be-
cause we nowadays benefit from intense medical care
[107]. But the ability to reversing the trend is in our
own hands, thanks to the genetic program that evolved
with our ancestral grandmothers.
Physiological role of amyloid beta (Aβ)
The hippocampus complex (HC), i.e. the archecortical
hippocampus and entorhinal cortex, is the central
organ for remembering personal life experiences [108].
Since every moment in life is unique and cannot be re-
peated like vocabulary, this old part of our brain has
maintained the ability to learn essential information in-
stantaneously. This capability is a prerequisite for
spatial navigation in new terrain like during gathering
and hunting, as well as social learning from personal
interactions, narrations and is even important when
remembering long-term ones’ own thoughts. As an in-
dicator of their potential significance for survival and
reproduction, the HC selects experiences for memorization
by their emotional effect. (Unfortunately, vocabulary is
rarely exiting enough to be fast remembered). The HC
thereby memorizes at least three interrelated aspects of the
life episode: what happened (content information), where it
happened (spatial information) and when it happened
(temporal information). As the HC has a limited mem-
ory capacity, the daily acquired content information is
stored only transiently. In order to remember import-
ant (emotionally exiting) life events lifelong, the con-
tent information is being consolidated in the neocortex
during the slow-wave sleep (SWS) phases in the early
part of the following nocturnal sleep [109]. In the sec-
ond part of nocturnal sleep, the new memory is being
cross-linking with former experiences during the rapid
eye movement (REM) phases, a process thought to in-
spire insight while we dream [110]. The spatiotemporal
information, i.e. the contextual “where and when” of
the memorized event, is maintained long-term in the
dentate gyrus (DG) network of the hippocampus and
used as an index for retrieval (reactivation) of the neo-
cortical memory traces (see below).
Hippocampal fast learning relies on the mechanisms
of synaptic long-term potentiation (LTP) using glutamate
as a key neurotransmitter. Glutamate alters the strength
(weight) of specific synaptic connections thereby creating
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 8 of 52
a new hippocampal memory trace. Any increase of
neuronal activity induces concomitantly an increase of
β-amyloid (Aβ) production and release on the same
synapses, where Aβ plays an important role in learning
memory formation [111]. Aβ is mainly secreted in
monomeric form with 40 amino acids (Aβ40), which
has a slight tendency to aggregate. Conversely, Aβ42 is
produced in low quantities and is more prone to the
formation of oligomers, protofibrils and fibrils. These
aggregates represent the main form of Aβ contained in
AD brain plaques [112]. This observation and the fact
that conglomerating Aβ42 is produced in higher quan-
tities by certain AD-mutations [113], has led to ascribe
pathological effects to the oligomers and the physiologic
properties of Aβ almost solely to monomers. It was also
the foundation of the amyloid cascade hypothesis.
However, a certain degree of oligomerization is likely
to occur even at low Aβ concentrations, hence the native
state characteristics of the peptide and in which it exerts
its multiple functions are difficult to elucidate [114], par-
ticularly, as the oligomeric states of Aβ vary [115]. In
any case, the concentration of soluble Aβ in the normal
healthy brain has been estimated in the picomolar range
with species ranging from monomers to higher oligo-
mers [116]. One important physiological function of Aβ
might be as a regulator of glutamate release probability
[117], whereby the activity-dependent modulation of Aβ
production acts as a negative feedback regulator of
synaptic plasticity [118]. It has been shown, that at
lower, picomolar concentrations, Aβ increase LTP,
whereas at higher, nanomolar concentrations, Aβ leads
to a reduction of potentiation [119]. This is in line
with the proposed mode of action, in that Aβ, depend-
ing on the dose, either acts as an agonist, supporting
the fast formation of new memories, or antagonist,
preserving new memory traces from being overridden
by subsequent events that are to be memorized [120].
If this negative feedback loop gets compromised, ei-
ther to much Aβ is being produced or to little might
get cleared. Subsequently, higher concentrations of
soluble oligomeric Aβ form and exert synaptotoxic ef-
fects, even without plaque formation [121]. This might
explain the relative high proportion of symptomatic
patients with clinical signs of early AD and a negative
scan for Aβ-depositions, the so-called suspected non-
amyloid pathology [122]. With the realization that sol-
uble Aβ oligomere distribution correlates better with
cognitive decline in AD than the prototypical amyloid
plaques [123], the former amyloid cascade hypotheses
was replaced by the oligomeric cascade hypothesis
[124].
The build-up of high amounts of oligomeric Aβ in-
duces neuroinflammation, causes oxidative damage and
negatively influences multiple signal transduction events
including the activation of glycogen synthase kinase-3β
(GSK-3β) [125], a pivotal kinase in AD but also for
memory consolidation, which limits its use as a target
for AD therapy. For instance, activation of GSK-3β in-
hibits AHN and promotes neuroinflammation and
apoptosis (for review see [126]). Furthermore, its upreg-
ulation leads to phosphorylation of the amyloid precur-
sor protein (APP) and tau, both associated with the
pathological processes that lead to the hallmarks of
Alzheimer’s disease (AD), i.e. Aβ-plaques and neurofibril-
lary tangles, respectively [127]. GSK-3β activity thereby
shifts tau, a stabilizer of microtubules, to a hyperpho-
sphorylated non-functioning state (p-tau) [128]. Tau
pathology is progressive and detrimental to affected
neurons via both, loss of tau function [129] and gain
of toxic function from pathologic p-tau aggregates
[130]. Hence not only high concentrations of oligo-
meric Aβ but maybe rather dysfunctional p-tau might
be regarded as a key driver of AD progression, which
is corroborated by the fact that p-tau deposition more
closely correlates with disease stage [131].
But are Aβ or p-tau the initiators of consequences of
AD pathogenesis? This question has been debated for a
long time. For example, the proponents of the amyloid
cascade hypothesis blamed primarily age as the causative
factor for Aβ-plaque formation and the focus of pharma-
cological efforts were therefore driven towards the elim-
ination of amyloid plaques. Ironically, not the insoluble
plaques but, as mentioned above, rather the excess of
soluble oligomers were recently shown to be harmful
[132]. But even the removal of Aβ-oligomers by current
pharmacological strategies that evolved from the newly
proposed oligomeric cascade hypothesis might turn out
to be harmful. Not only because the primary causes of
AD remain ignored (see below), but also, because Aβ
is in fact required for synaptic plasticity. For instance,
the healthy physiological function in LTP and memory
appears to depend on a delicate balance between the
secreted Aβ monomer (in different length and concen-
trations) and multiple oligomeric states (for review see
[133]). This caveat might explain why in experimental
animal models for AD, the removal of Aβ by different
antibodies against Aβ, which have also used in study
settings for human treatment, was not only ineffective
at repairing neuronal dysfunction, but also caused det-
rimental cortical hyperactivity [134]. It has been con-
cluded that this unexpected finding provides a possible
cellular explanation for the lack of cognitive improve-
ment by immunotherapy in human studies [135, 136].
In other words, the sole attack against Aβ interferes
with neuronal homeostasis, causing a further impover-
ishment of learning and memory.
Hence the current key strategy to cure or AD at least
to delay disease progression might even worsen the
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status of the patients. As Puzzo et al. recently put it
[133]: “the vision of Aβ exclusively as a”bad’ protein has
probably prevented us to focus on other important as-
pects of the disease. “The authors point out further tha-
t”Aβ is already present inside neurons in infant brains,
and even increases up to 8 years of age, a period of high
brain plasticity, when about half of the neurons are Aβ-
immunopositive. In adulthood, Aβ is present in the
major part of the neurons whereas in aged people there
is a 20 % reduction. “Furthermore, for the deposition of
Aβ in the brain, only Aβ seeds are critical but not the
age of animal models [22]. But if not age, what other fac-
tors might lead to Aβ seed formation? Only the answer
to this critical question will open a pathway to AD pre-
vention strategies and an AD therapy that is truly causal.
But it becomes more and more clear that a rise of Aβ-
concentrations is neither inevitable nor a natural conse-
quence of aging. Rather other factors are playing a role
and, intriguingly, most of them can be modified in vari-
ous ways, one of them being sleep.
Memory growth during sleep
One key function of sleep is the consolidation of new
hippocampal memory traces in the neocortex for long-
term storage and gaining lifelong experience by integra-
tion them into the existing body of knowledge. Accord-
ing to the synaptic-homeostasis hypothesis, this is
achieved by repetition of the memory content during
SWS but also by the differential renormalization of syn-
aptic weights, which includes selective long-term depres-
sion, essentially the reversal of the effects of LTP [137].
Correspondingly, in order to enable hippocampal encod-
ing of new memories during the following wake-phase,
Aβ levels, which accumulated during the information
collection phase the previous day, needs to be reduced
in order to reactivate the full potential of LTP. Hence
Aβ-clearance might have developed as another active
function of sleep and is accomplished via an enlarge-
ment of the interstitial space, which results in a striking
increase in convective exchange of interstitial fluid with
cerebrospinal fluid and export of Aβ across the BBB
[138]. This restorative action regarding memory function
also reduces the risk of the concentration-dependent ag-
gregation of larger quantities of potentially oligomeric
synaptotoxic Aβ [139]. It is therefore an important find-
ing that lack of sleep in mice and humans increases Aβ
concentration above the critical threshold where massive
oligomeric aggregation occurs [140, 141].
Another important function of sleep is to provide the
temporal space for AHN. During sleep, cortisol, which
in high concentrations inhibits AHN, is downregulated,
whereas insulin-like growth factor 1 (IGF-1), growth
hormone (GH), melatonin as well as BDNF, which all
promote AHN, are upregulated. Hence prolonged sleep
deprivation is detrimental to AHN [142] and thereby de-
creases the number of possible distinct codes (indexes)
that boost hippocampal memory capacity and perform-
ance (see below) [143]. Similarly, posttraining ablation of
adult-born neurons was shown to destroy previously ac-
quired memories [144]. New granular cells in the DG
are particularly important in differentiating former from
similar but novel experiences by remembering their spa-
tiotemporal context, and thereby reducing interference
of new with former memories [145, 146]. Furthermore,
in order to remember, i.e. to access, retrieve the respect-
ive event-specific neocortically distributed stored mem-
ory traces and to reconstruct the contextual experience,
the hippocampal spatiotemporal information of an re-
membered event is required [147], as originally outlined
by the hippocampal memory index theory (HMIT). Ac-
cording to the HMIT, hippocampal–cortical system con-
solidation of remote memories requires the maintenance
of hippocampal indexes [148]. Hence, we remember epi-
sodes of our life by the spatiotemporal context stored by
the new neurons generated by AHN [144]. Therefore,
remote memories are best maintained by the lifelong
creation of new adult-born DG-neurons [149]. The ex-
pansion of the spatiotemporal memory capacity thereby
becomes also a prerequisite for the continuous expan-
sion of autobiographic memory [150]. This explains, why
a disturbed AHN not only causes the hippocampal arch-
ive of indexes that link to episodic neocortical engrams
running out of storage capacity, but also, why it causes
discrimination errors (interferences) between former and
new experiences which leads to an overgeneralization of
fear and sustained posttraumatic stress [151]. Recently it
was shown that in transgenic mouse models of early AD,
direct optogenetic activation of hippocampal memory
engram (index) cells results in memory retrieval despite
the fact that these mice are amnesic in long-term mem-
ory tests when natural recall cues are used, which reveals
a retrieval, rather than a storage impairment [152]. Inter-
estingly, optogenetic induction of LTP at perforant path
synapses of dentate gyrus engram cells restores both
“age-dependent” spine density and long-term memory of
the caged animals, explaining, why for instance social ac-
tivity prevents memory decline in an AD model of envir-
onmental enrichment, and, thus, not age, but rather an
unnatural lifestyle causes AD in these models [153], as
will be outlined in more detail below.
The reduced interference of new with former experi-
ences in an expanding archive of indexes explains com-
prehensively the importance of AHN and how this
process promotes persistence [154], as well as precision
of contextual memory [155]. In order to remember effi-
ciently, adult-born hippocampal brain cells show a lower
threshold for LTP, i.e. learning, while in turn, LTP up-
regulates dentritic spine density, with the largest changes
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occurring during the early phase in their maturation,
when they begin to form synapses with the existing cir-
cuitry [156]. Via these mechanisms maturating young
adult-born DG-cells are being converted into high infor-
mation neurons specifically by the newly experienced
events. Interestingly, conditions, like for example volun-
tary exercise, that are required to stimulate AHN, also
increase spine density in the hippocampus, leading to
increased synapse formation and decreased synapse
elimination as well as increased survival rates of the ma-
turing neurons [157]. Following this observation, some
researchers suggested the hypothesis, that a primary
function of AHN involves the production not only of
new neurons per se, but of new neurons with the synap-
tic properties of relatively young neurons [158]. As this
mechanism provides for a turnover of almost or 2 % of
the cells per year in the DG, AHN has the potential to
keep this brain region, critical for acquiring novel expe-
riences, young even at old age [159]. But only, in line
with the UTAD, if we provide the behavioural cues for
the initiation of AHN as well as the maturation and inte-
gration of the new DG-neurons (see below).
AHN regulates mood and has antidepressant properties,
implications for AD
It is of interest that in AD, the perirhinal (PRH) and lat-
eral entorhinal cortex (LEC) of the HC are among the
first cortical regions to be affected [160, 161]. Both re-
gions were found to provide the most critical content
information (i.e. “what is happening”) to the newborn
DG-neurons via the perforant pathway projections (for
review see [162]). In addition, back-projecting signals
from the CA3 region of the hippocampus, which re-
ceives direct signals from the medial entorhinal cortex
(MEC) provide the required spatiotemporal information
(i.e. “where and when is it happening”) to the newborn
DG-neurons [163]. Both inputs appear to be required
for event or pattern separation [164]. The findings that
hippocampus degeneration is one of the most promin-
ent and earliest characteristics of AD [165] with the
perforant pathway being one of the very first structures
to suffer damage [166], and that intra-hippocampal
white matter lesion load is strongly associated with pro-
gressive MCI [167], supports the hypothesis that chron-
ically disturbed AHN might play a etiological key role
in AD pathogenesis. This hypothesis is further sup-
ported by the evidence that all behavioural deficiencies
as well as environmental toxins are known to impair
ADH and to increase the risk of AD (see below). There-
fore, a non-productive AHN might connect not only
histopathologically but also functionally with the aeti-
ology of AD. Hence the understanding of this connec-
tion and the requirements for a productive AHN might
help to develop a new understanding of AD and a causal
strategy for prevention and therapeutic intervention.
Besides being required for spatial navigation, episodic
learning and memory retrieval [168], new neurons gen-
erated by AHN also regulate mood and in particular
psychological resilience (resistance to stress) by con-
trolling the HPA-axis either directly [169] or indirectly
[170, 171]. If AHN is disturbed, corticosterone levels
are slower to recover to baseline following moderate
stress, and the HPA-axis is less suppressed by dexa-
methasone, showing impaired HPA-axis feedback, in
older mice that experimentally lack new adult-born
DG-neurons. This decisive involvement of active AHN
in regulating psychological resilience is further evi-
denced by the observation that antidepressants like flu-
oxetine, member of the selective serotonin reuptake
inhibitor (SSRI) class, were shown to require an intact
hippocampal neurogenic niche and a productive AHN
to exert their antidepressant effect [172]. This anti-
depressant mechanism was identified in rodents and
confirmed in non-human primates [173]. Similarly, a
recent human study reported a significant increase in
hippocampal volume due to antidepressant treatment
[174]. Conversely, impairment of AHN leads to anxiety
(inhibition of a novelty-seeking behaviour), major de-
pression [175] and chronically elevated cortisol, all
three distinctive warning signs of early AD and poten-
tial causative risk factors [176, 177]. Interestingly, HPA-
axis dysregulation was shown to occur at least as early
as at the MCI stage of AD and to accelerate disease
progression [178]. Furthermore, a reanalysis of the data
of the Framingham Heart study found that depression
at old age develops prior to cognitive decline and was a
significant risk factor for dementia and AD [179].
Another hint that disturbed HPA-axis regulation
caused by a chronically disturbed AHN might lead to
AD, is the finding that early-stage AD patients consist-
ently show increased basal plasma cortisol levels [180]
and also decreased sensitivity to low-dose DEX suppres-
sion [181]. For this reason, cortisol measurements have
been suggested as a reliable AD biomarker [182]. Fur-
ther evidence, that one the earliest pathogenic events in
AD might be caused by an inefficient AHN came from
magnetic resonance imaging (MRI) studies: hippocampal
atrophy more so than Aβ measures predicted the time-
to-progression from MCI to AD [183].
Further support for the hypothesis that HPA axis dys-
regulation might be an important causal contributor to
memory decline in AD comes from the recent prospect-
ive Washington/Hamilton Heights Inwood Columbia
Aging Project, whose findings clearly revealed that de-
pressive symptoms in late life precede memory decline,
but not vice versa [184]. In addition, higher scores on
the depression measures predicted steeper cognitive
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decline even among individuals whose cognition was not
pathologically altered at baseline, independent of age,
sex, education and illness burden including vascular dis-
ease. This observation is in line with evidence of former
studies that showed that co-morbidity with depression is
associated with a greater extent and progression of AD
pathology, such as increased neurofibrillary tangle load
[185] and faster rate of cognitive decline [186].
Chronic HPA axis dysregulation promotes AD pathology
Acute stress leads to immediate physiological changes
that promote an increase in sensory input. While
heightened senses in life threatening situations are im-
portant for survival, these alterations harbour the risk
of information overload and hippocampal neurotox-
icity due to excessive excitatory glutamate release
[187, 188]. Hence it appears to be a useful adaptation
that stress-induced HPA-axis upregulation concomi-
tantly increases the production of hippocampal Aβ
[189], which acts, as discussed above, as regulator of
glutamate release. Furthermore, Aβ monomers activate
the phosphatidylinositol-3-kinase pathway, thereby inhi-
biting apoptosis and protecting neurons from excitotoxic
death [190].,Monomeric Aβ was also shown to be neu-
roprotective by increasing neuronal activity-dependent
glucose uptake through activation of the type-1 IGF-1-
receptor, which is vital for maintaining neuronal glu-
cose homeostasis [191]. In addition, monomeric Aβ
protects neurons against oxidative stress in situations
of high energy metabolism [192, 193].
How does activation of the HPA axis increase synap-
tic Aβ release? One recently identified mechanism is
up-regulation of amylogenic γ-secretase activity by the
stress-response neuropeptide corticotropin releasing
factor (CRF) [194]. Moreover, experimental administra-
tion of glucocorticoids was found to increase hippo-
campal Aβ concentrations in aged nonhuman primates
due to reduced production of insulin-degrading en-
zyme, which is known to degrade excess Aβ [195]. Fur-
ther in vitro and in vivo experiments provided evidence
that glucocorticoid treatment also enhances Aβ produc-
tion by increasing steady-state levels of amyloid precur-
sor protein (APP) and Aβ cleaving enzymes [196].
Interestingly, these experiments also showed that glu-
cocorticoids augment tau accumulation, indicating that
this hormone, if chronically active, might accelerate the
development of neurofibrillary tangles. The authors
conclude that notoriously high levels of glucocorticoids,
found in AD patients, might not merely be a conse-
quence of the disease process but rather play a central
role in the development and progression of AD. In sup-
port of this idea, chronic hypersecretion of cortisol in pa-
tients with lifetime major depression results in significant
accumulation of Aβ in the brain, even in the absence of
MCI or AD symptoms [197].
Taken together, while enhanced release of hippocam-
pal Aβ in acute stress situations appears to be a useful
neuroprotective mechanism, this up-regulation might
turn into a problem, when chronic stress or a chronic-
ally disturbed HPA axis regulation due to an impaired
AHN leads to reduced psychological resilience (weak-
ened stress resistance) and chronic cortisol hypersecre-
tion. Hence the question arises, how our organism
sustains a lifelong productive AHN and functioning
HPA axis regulation.
Key requirements for productive AHN and the law of
the minimum (LOM)
Since its discovery in animals and particularly in humans,
numerous studies revealed that AHN is a highly regulated
phenomenon, which is under the control of local factors
(the neurogenic niche), cytokines, growth factors and
many hormones [198, 199], most of which are directly or
indirectly controlled by behavioural or environmental
cues. The study of food-storing [200] and song-learning
birds [201] revealed the phenomenon of seasonal growth
of functionally hippocampus-like brain structures and that
AHN and behaviour (e.g. food-storing or song-learning)
are dynamically interrelated [202]. This type of research
has been extended to mammals, in which it was shown
that the hippocampal size for example in kangaroo rats
(Dipodomys) tightly depends on their natural space-use
pattern [203], or that photoperiodic organisms like
white-footed mice (Peromyscus leucopus) monitor en-
vironmental day length to engage in seasonally appro-
priate adaptions in physiology and behaviour, which is
preceded by adjustment in brain volume via AHN
[204]. This tight environmental and behavioural control
of AHN makes sense from an evolutionary point of
view, since brain size corresponds to energy expend-
iture. Hence the size of the hippocampus either grows
or shrinks, depending on the individual’s vital need for
memory capacity. Since our identity and the principles
of the GMH depend on our lifelong ability to remem-
ber, AHN in humans has the propensity not only for
seasonal but rather lifelong growth.
What are the environmental and behavioural cues
and key requirements for lifelong productive AHN?
Since mankind survived for the largest part of its his-
tory as hunter-gatherers, it is reasonable to assume that
the complex regulation of a productive AHN was
strongly adapted to the principle conditions, under
which mankind survived for hundreds of thousands of
years. From an evolutionary perspective, survival of the
tribe depended on memorizing the foraging ground
under conditions of physical activity and hunger until
hunting or gathering was successful, whereby social
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bonding (hunting in groups) and learning from elders
(for instance hunting strategies) were critically import-
ant. It is therefore of no surprise that social and phys-
ical activity, daily new challenges that provide eustress,
IMF interrupted by ingestion of fresh and highly vari-
able food, rich in essential nutrients, are all positive
regulators of AHN (see below). Hence the basic re-
quirements for a productive neurogenesis were natur-
ally provided for by the pre-modern way of life. In
contrast and as will be detailed below, lack of physical
exercise, loneliness (actual or perceived), chronic dis-
tress or an unhealthy Western diet (WeDi) combined
with a constant (ad libitum) eating pattern are negative
regulators of AHN, with the detrimental consequences
outlined above.
Starting from the proliferation of the neuronal stem
cells, expansion of progenitor cells, followed by their
growth and maturation (branching and synaptogenesis)
to the final integration into the existing DG network
takes about three month, maybe even longer [198, 205].
Besides the fact, that proliferation itself is tightly con-
trolled, requiring both activation and removal from
inhibitory signals, only a single digit percentage of new-
born progenitor cells become mature, integrated DG-
neurons, with most of the cells dying early [206, 207].
AHN requires at each step specific environmental cues
(usually transmitted through hormones), but also spe-
cific brain building-blocks (essential polyunsaturated
fatty acids, cholesterol etc.), social input (new memor-
able life experiences) and energy. Since each of these
factors might individually limit the AHN, the “law of
the minimum” applies. This is an important aspect of
the proposed UTAD, as this “law” allows us to under-
stand, how AD can be effectively prevented and treated,
and why monotherapeutic interventions might continue
to fail.
The principle that productive growth is restricted by
limiting factors was first formulated in agricultural sci-
ence by Carl Sprengel in 1828 [208] and was extended
and popularized by Justus von Liebig as the law of the
minimum (LOM) in 1840 (for references and history of
the Sprengel-Liebig LOM see [209]). The LOM states
that growth is controlled not by the total amount of
resources available, but by the scarcest resource. This is
a very important notion if we regard AHN for what it is:
a growth process. The LOM explains how a deficiency
in any essential growth or maturation factor cannot, by
definition (since being essential), be compensated by
another. Hence the lack of the respective behavioural or
environmental cues or other essential growth factors,
which limits the proliferation, growth or maturation of
new DG-neurons, must inevitably lead to a disturbed
AHN, with the consequences of cortisol hypersecretion,
depression and an increased risk of developing AD.
Epidemiological studies have identified many risk fac-
tors for AD as well as for major depression, and many
of those are limiting and essential factors for AHN ac-
cording to the LOM, and most if not all of them are be-
havioural and therefore modifiable (see also Fig. 1
“requirements” for, and Fig. 2 “deficits” inhibiting a
productive AHN). Since the dynamics of hippocampal
growth include the hippocampus’s potential to shrink,
each factor missing not only hinders a productive
AHN, but also leads to a reduced hippocampal size and
increased risk for depression and AD. One important
prediction emanates from the LOM when applied to a
potential multi-causal disease like AD, where individual
lifestyles usually lead to several deficiencies, interven-
tion trials, which arbitrarily try to eliminate one or only
a limited number of such deficits (i.e. risk factors), can
have only weak effects, because only a fraction of the
study population will have a deficit only (!) in this (or
these) particular factor(s) and therefore benefits from
the respective intervention. Following is a commented
list of requirements for a productive AHN, many of
which are usually in deficit in economically advanced
societies (see also Figs. 1 and 2):
Moderate but extended physical activity increases
brain volume even in aging humans [210]. This makes a
lot of sense from an evolutionary point of view: Physical
activity was a prerequisite for survival in pre-modern so-
cieties and hormonal signals from the working body are
used as a mechanism to enhance not only fitness but
and also autobiographic memory capacity (see below). In
a sense, being physically active signals to the brain that
new experiences are to be expected: The further one
walks the more one will experience and the larger one’s
hippocampal memory index has to grow. Nowadays, we
have the choice to run or not to run, and most of us
embrace effort-sparing technologies and lead sedentary
lifestyles. The rise of physical inactivity contributes
enormously to the overall quality of life by diminishing
strength, the ability to perform daily chores and social
interactions, mobility and cognitive performance.
In a well-controlled randomized study, 120 older
adults without dementia were randomly assigned either
to an aerobic exercise group (n = 60, average age 67,
6 years) or to a stretching control group (n = 60, average
age 65,5 years) [211]. The groups did not differ in hippo-
campal baseline volume as measured by MRI. Besides
being healthy, a prerequisite to be part of the program
was a sedentary lifestyle, defined as being physically ac-
tive for 30 min or less daily in the last 6 month before
the intervention. After an initial 6 weeks training phase,
the aerobic walking group reached a level of 40 min
walking daily with a target heart-rate zone of 60–75 of
the maximum heart rate reserve, the stretching and ton-
ing control group exercised with dumbbells or resistance
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 13 of 52
bands, trained to improve balance including a yoga
sequence. After the one-year intervention, the aerobic
exercise group showed an increase in hippocampal vol-
ume of about 2 %, counteracting the usual hippocampal
shrinkage in volume of 1–2 % annually in older adults
even without dementia [212]. Such a loss of volume in-
creases the risk for developing cognitive impairment as
outlined above. The stretching control group fitted this
pattern of age-related loss and demonstrated a 1.4 %
decline in volume over the one-year interval, indicating
that aerobic exercise is a requirement for brain health
at old age, and stretching is not sufficient. That long-
term mild aerobic exercise is superior in enhancing
AHN has also been shown in rodents [213]. In fact,
short bouts of even intense physical activity had no
positive effect on AHN [214].
Interestingly, the individual improvements in aerobic
fitness of members in the walking group strongly corre-
lated with the increase in hippocampal volume. Growth
occurred mainly in the anterior section, which includes
the DG. This is a significant finding as cells in the anter-
ior hippocampus mediates acquisition of spatial memory
as well as verbal memory performance [215] and is more
prone to age-related atrophy compared with the poster-
ior hippocampus [216]. Hence the positive effect was
directly and significantly related to improvements in
memory performance, indicating that increases in hippo-
campal volume due to aerobic exercise augments mem-
ory function even in late adulthood.
Changes in physical activity have also important con-
sequences for health in general and lifespan. In line with
the GMH, an unnatural sedentary behaviour in 70-year-
Fig. 1 “Natural mechanisms preserve lifelong mental health”. Our genetic program is well adapted to the lifestyle conditions that dominated for
the largest part of humans’ life history. Ancient lifestyle was marked by extensive and daily physical activity, alternated phases of fasting and a
nutrient-rich diet, sufficient sleep and eustress. Furthermore, survival was critically dependent on extended family bonds, hence went along with
a rich social life. The exceptional long postmenopausal period served the purpose of transgenerational generativity, which, according to the
grandmother hypothesis, provides the main current explanation for humans’ longevity. Therefore, under these natural conditions, all key
physiological systems (immune and cardiovascular function, energy metabolism etc.) positively interact and thereby support key mechanisms like
neuronal rejuvenation and adult hippocampal neurogenesis in order to allow the lifelong acquisition of knowledge and to preserve mental
health up to high age. For details, please refer to the main text
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old men was shown to reduce the probability of sur-
vival up to the age of 90 from 54 to 44 % [217]. Physical
inactivity leads to many so-called “lifestyle diseases”,
which are sometimes rather inappropriately named dis-
eases of longevity, as if age were the cause rather than a
chronically unhealthy lifestyle [218]. Declining levels of
expression of neurotrophic factors level such as BDNF,
nerve growth factor (NGF) and glial cell-derived neuro-
trophic factor (GDNF) are strongly implicated in aging
and AD [219]. But correlation with age does not equal
causality [220, 221]. Rather, all these hormonal factors
are positively regulated by exercise, explaining the ac-
celerated brain aging is rather caused by a sedentary
lifestyle in the elderly [222], and therefore appears to
have little to do with aging per se.
This direction of causality, i.e. from lifestyle to brain
“degeneration” over the years, was tested in animal ex-
periments. In one setting, downregulation of GDNF in
sedentary triple-transgenic AD mice was reversed by
voluntary exercise and improved synaptic functioning
[223]. This particular AD-model triple-transgenic model
(3 × Tg-AD) harbours the PS1M146V (a presenilin 1
Fig. 2 “AD is a deficiency disease”. Our genetic program is not adapted to the fast and very recent changes that define our modern lifestyle,
which connotes individual combinations of physical inactivity, an ad libitum eating pattern of a nutrient-poor diet, chronic distress emanating
from the demands of a highly competitive labour situation, which often goes along with a loss of extended family bonds. Furthermore and under
such conditions, the concept of retirement, a late invention in humans’ cultural history, counteracts the main purpose in late life from an
evolutionary point of view : A lack in transgenerational generativity leads to a devastating lack of purpose in life. Deficiencies in essential
requirements for mental health cannot, by definition, be compensated by our genetic program. Consequently, as defined by the law of the
minimum, individual deficits hamper neuronal rejuvenation, and in particular hinder productive AHN. As the neuronal correlate of depression, the
disturbed HPA axis regulation and cortisol hypersecretion as well as other pathophysiological consequences (neuroinflammation and breakdown of
the blood brain barrier, insulin resistance, hypertension and arteriosclerosis) emanate from these lifestyle-derived deficits and lead to an accumulation
neurotoxic Aβ, hippocampal shrinkage in particular, and brain atrophy in general, hence the well-known hallmarks of AD. Under these conditions of
behavioural deficiencies, environmental toxins, chronic infections and genetic predisposition accelerate AD progression. The indicated interactions
between the different pathological processes activate a multitude of vicious cycles that make the AD-process a runaway phenomenon, which
can only be stopped and reversed to the situation depicted in Fig. 1 by a systems biological approach, which is outlined in the main text and
schematically presented in Fig. 3
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mutant), APPSwe (a β-amyloid precursor protein mu-
tant), and tauP301L (a p-tau mutant) transgenes and
was specifically developed for evaluating the impact
potential AD therapeutics of both amyloid plaque and
p-tau tangle pathology on synaptic function [42]. In an-
other experiment, NGF was also up-regulated by phys-
ical exercise and shown to stimulate AHN [224].
Furthermore, BDNF was shown to promote differenti-
ation and maturation of adult-born DG-neurons [225]
and was being released from the hippocampus upon
exercise [226].
In the above outlined aerobic walking intervention
study, increased hippocampal volume in the exercise
group was also associated with increased levels of serum
BDNF, which were shown, at least in rats and pig, to
parallel hippocampal BDNF concentrations [227]. The
observation that BDNF secretion in the hippocampus
can be induced by exercise is an important finding as
this member of the nerve growth factor family was
found to be reduced in the hippocampus and the tem-
poral cortex of AD patients [228]. Another intervention
study in humans provided further evidence that hippo-
campal volume loss, which was significantly and dir-
ectly associated with poor memory performance, could
be counteracted by moderate-intensity exercise [229].
Interestingly, both exercise-induced erythropoietin
(EPO) and vascular endothelial growth factor (VEGF),
released in reaction to general or local decrease in oxy-
gen concentration, respectively, enhance AHN. VEGF
was even shown to be necessary for exercise-induced AHN
[230, 231]. EPO was found to enhance hippocampus-
dependent memory by modulating plasticity, synaptic
connectivity and activity of memory-related neuronal
networks [232]. It also activates AHN [233, 234] and
protects hippocampal neurons through increasing the
expression of BDNF [235].
The importance of physical activity in the prevention
of chronic diseases and in particular AD is also exem-
plified by BDNF’s ability to stimulate both, PGC-1α-
dependent mitochondrial biogenesis in hippocampal
neurons and promotion of synapse formation and
maintenance [236]. Activating PGC-1α through exer-
cise also plays a key role in inhibiting AD-driving neu-
roinflammation [237]. The significance of physical
exercise for the brain’s health is further substantiated
by the fact that evermore hormonal signalling pathways
are being identified, which ensure that physical activity
stimulates AHN and improves memory function. In
addition to BDNF, NGF, GDNF, EPO and VEGF, men-
tioned above, physical exercise was found to stimulate
AHN through dihydrotestosterone [238], which, not
surprisingly, mediates the well-known antidepressant
effects of physical activity [239]. Direct support of a
link between androgen activity and AD came from a
recent study that provided evidence that androgen-
deprivation as part of a prostate-cancer treatment dou-
bled the risk of developing AD [240].
GH [241] and IGF-1 [242] also respond to repeated
bouts of aerobic exercise, stimulate AHN and are neuro-
protective. Fibroblast growth factor 2 (FGF-2) is also in-
duced by physical exercise directly in the hippocampus
[243] and was shown to restoring hippocampal function
in murine models of AD [244]. FGF-2 is even discussed
as a potential treatment option for AD [245], although,
as the LOM predicts, single therapeutic measures have a
low probability to be successful in curing AD. Further-
more, the central release of serotonin is required for
physical activity-dependent AHN, where it also plays a
direct and acute regulatory role in young adult as well as
in aged mice [246]. This finding led to the conclusion
that the understanding of exercise-induced AHN might
offer preventive but also therapeutic opportunities in de-
pression and age-related cognitive decline. Similarly, fat-
cell secreted adiponectin appears to mediate physical
exercise-induced AHN [247], thereby acting as an anti-
depressant [248]. Interestingly, some hormones or cyto-
kines are secreted directly by the working muscle itself,
which therefore can be considered as an endocrine
organ [82]. The AHN-promoting hormones irisin [249]
and meteorin-like [250] appear to be released solely by
the active muscle.
Last but not least, the effects of physical activity on
health and memory are also mediated by moderate
levels of cortisol [251]. Whereas the positive effects of
physical exercise peak at upper-middle intensity levels
and thereby activating AHN, excessive cortisol levels
due to extreme physical workout are inhibiting AHN
[252]. One mechanism besides psychological stress that
often accompanies extreme physical activity might be
the increased release of pro-inflammatory cytokines like
IL-6 from strained muscles that activate adrenocortico-
tropic hormone (ACTH) secretion from the pituitary
gland, which, in turn, induces high levels of cortisol se-
cretion [253]. This cortisol hypersecretion was found to
aggravate neuroinflammation [254]. In contrast, regular
and moderate physical exercise reduces systemic in-
flammation [255]. Similarly, while moderate physical
activity enhances antioxidant defence mechanisms, in-
tense levels of physical activity deplete the antioxidant
reserve [256]. Therefore, extreme levels of physical ex-
ercise should be omitted as they are leading to adverse
neurological effects [257]. Hence in order to maintain
physical and mental health, a balanced life style with
frequent workouts at moderate intensity is ideal, while
physical inactivity (as well as over-activity) needs to be
omitted whenever possible.
Besides the insufficient activation of AHN [258] that
initiates the above outlined detrimental causal chain of
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events, physical inactivity directly increases the risk of
developing AD by reducing the clearance of excess Aβ.
A sedentary lifestyle was found to downregulate low
density lipoprotein receptor-related protein 1 (LRP1),
the major export protein for Aβ [259], located in the
BBB. Physical inactivity also inhibits the activation of
neprilysin, one of the main Aβ-degrading enzymes
[260]. In addition, being sedentary leads to persistent
sterile neuroinflammation [237], insulin-resistance, dia-
betes mellitus and visceral obesity. According to a re-
cent study, these conditions all add to individual risk
for developing AD [261].
Important for therapeutic considerations, becoming
physically active even helps when AD is already diag-
nosed. A recent pilot study investigated the effect of a
home-based physical activity intervention program on
AD-patients on the development of clinical symptoms
and functional abilities and the effects on family care-
giver burden after 12 and 24 weeks [262]. While the
(sedentary) control group experienced decreases in the
ability of daily living performances, the patients in the
(physically active) intervention group remained cogni-
tively stable. Analyses of executive function and lan-
guage ability revealed considerable positive effects for
semantic word fluency in the intervention group. In
fact, the physical active patients improved during the
intervention, whereas the controls revealed continuous
worsening. Consequently, caregiver burden remained
stable in the intervention group but worsened in the
control group.
AS the LOM tells us, physical exercise is not enough
to effectively prevent or cure AD. Nevertheless, in most
studies, the LOM was ignored and in some studies, in
addition, the amount of daily exercise of the intervention
group was very low, which led the researchers to devalue
exercise for the prevention of AD [263]. Unfortunately,
studies of this type, which are scientific standard (only
one variable should be altered), lead to misleading re-
sults and their popularisation potentially undermine the
public understanding regarding the importance of a
healthy lifestyle. But being physically active is just one
natural (and from an evolutionary perspective obvious)
requirement that needs to be fulfilled. Another is the
steady supply with essential nutrients.
Nutritional effects on AHN
There is a long list of nutrients that are essential
building blocks for (adult) neurogenesis and synapto-
genesis (for review, see [264]) and which are also im-
portant for NRJ. For instance, n-3 polyunsaturated
fatty acids (PUFAs), flavonoids, antioxidant-rich ber-
ries and resveratrol, a polyphenol found in red grapes
and other fruits, were all shown to stimulate AHN
[265]. In addition, they reduce oxidative stress and
down-regulate pro-inflammatory processes (for review,
see [266]); some even have potent anti-amyloidogenic
properties [267, 268].
In contrast, a typical WeDi with its high intake of red
and processed meats, animal fat, refined grains and
sweets is low in essential nutrients and when simulated
in animal studies, markedly reduces brain levels of neu-
rotrophins such as BDNF, hampers neuronal plasticity
and learning [269]. This type of modern diet also leads
to increased ROS levels and neuroinflammation, which
also hampers AHN and dysregulates the HPA axis by
chronic cortisol hypersecretion [270]. There is also con-
siderable evidence that advanced glycation end products
(AGEs) might play a role in AD [271]. Sugar, fructose,
corn syrup and generally food including beverages with
high glycemic load cause intermittent hyperglycaemic
episodes. This contributes to the endogenous generation
of AGEs. In addition, meat products, particularly from
industrial livestock farming, provide a large amount of
exogenous AGEs (for review, see [272]). AGE (not
age!)-induced neuroinflammatory processes are medi-
ated by inflammatory cytokines like interleukin-1 (Il-1)
[273], interleukin-6 (IL-6) [274] or tumour necrosis
factor-alpha (TNF-α) [275] and aggravate neurodegen-
erative processes and were shown to further decrease
productive AHN [276].
Intensifying the problem of chronic neuroinflamma-
tion caused by AGEs, is the high intake of omega-6
(n-6 PUFAs) in absolute, but also in relative quantities
to n-3 PUFAs, whose intake is typically low in a typical
WeDi [277]. In general, chemokines derived from the n-6
PUFA arachidonic acid (AA) are pro-inflammatory, while
those derived from n-3 PUFAs, like for instance docosa-
hexaenoic acid (DHA), have anti-inflammatory properties
[278]. Pro- and anti-inflammatory processes are essential
for wound repair and healing, respectively, but require a
balanced intake of both types of PUFAs. But with the ad-
vance of industrially produced food, there has been a dra-
matic change from an healthy (and “natural”) n-6 PUFA
to n-3 PUFA ratio of about 1 to 1 in pre-modern diet to
ratios up to 20 to 1 in current WeDi [279]. One reason
for this development is the widespread use of vegetable
oils with high a high concentration of n-6 PUFAs, i.e.
linoleic acid like e.g. sunflower oil (contains up to 70 %)
and corn oil (up to 60 %). The use of these polyunsatur-
ated oils was propagated by the food industry for their
serum cholesterol-lowering properties, but recent study
based on available evidence from randomized con-
trolled trials shows that replacement of saturated fat in
the diet with linoleic acid actually increased the risk of
death from coronary heart disease or all causes by 22 %
for each 30 mg/dL (0.78 mmol/L) reduction in serum
cholesterol [280]. A healthy alternative would be the
use of extra-virgin olive oil [281–283], as well as the
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moderate use of organically grown canola [284] or flax-
seed oil [285], with healthier n-6 PUFA to n-3 PUFA
ratios.
Another reason for the increase of n-6 PUFAs in our
modern diet results from the intense consumption of
meat and high fat milk products. The fact that those
products are derived from intensive animal farming ag-
gravates the negative effect on consumer’s health, since
the unnatural “way of life” of those animals negatively
impacts the n-6 PUFA to n-3 PUFA ratio in their prod-
ucts [286, 287]. Reason might be food for fattening, a
lack of exercise and stress of the farmed animals. Last
but not least, since the conversion of plant-derived n-3
PUFAs to DHA (or eicosapentaenoic acid (EPA), another
physiologically important n-3 PUFA product, is a very
inefficient metabolic process in humans, the low con-
sumption of fish (the major source of animal DHA and
EPA) in a WeDi leads to an absolute deficit in the supply
of these two n-3 PUFAs. In addition, the high intake of
n-6 PUFAs further compromises the already low meta-
bolic conversion rate of plant-derived n-3 PUFAs to
DHA and EPA [288]. The resulting serious imbalance of
n-6 to n-3 PUFAs drives premature aging, neuroinflam-
matory processes, depression and AD [289, 290].
This development is unfortunate, since high concen-
trations of DHA would inhibit lipid peroxidation [291],
and, together with EPA, would reduce brain inflamma-
tion and cognitive impairment [292]. Furthermore, many
different neuroprotecting cellular mediators derive from
DHA, EPA as well as another important n-3 PUFA,
docosapentaenoic acid (DPA) (for review see [293]).
For example, DHA-derived neuroprotectin D1 (NPD1)
induces signalling for homeostatic maintenance of cel-
lular integrity, and is neuroprotective due to its ability
to inactivate pro-apoptotic and pro-inflammatory sig-
nalling pathways [294, 295]. Furthermore, NPD1 is a
mediator with proven anti-amyloidogenic bioactivity
[296], which was originally ascribed to DHA [297].
DHA was shown to positively regulate BDNF [298]
and GDNF [299], thereby acting synergistically to en-
hance AHN and synaptic growth. In addition, PUFAs
like AA and DHA are essential building blocks for all
neuronal tissue, making up roughly 30 % of our brains
membrane lipids [300]. Taken together, a diet deficient
of DHA limits neurogenesis, making its supply critical
for healthy brain development and maintenance of
neural plasticity in later life [301]. Supporting these
observations is the recent finding, that lower intakes
of nutrient-dense foods and higher intakes of un-
healthy foods, typical for a WeDi, were each found to
independently being associated with smaller left hippo-
campal volume in humans [302]. In contrast, supplemen-
tation of about 1 g per day of a mixture with n-3 PUFAs
DHA and EPA significantly improved episodic memory
outcomes in older adults with mild memory complaints
[303].
It is reasonable to assume that at least for the hun-
dreds of thousand years of human evolution before the
advent of the so-called “modern life style” beginning in
the 19th century, mankind was used to a diet with suffi-
cient and roughly equal quantities of n-3 PUFAs to n-6
PUFAs (for review see [297]). It might be not only a
mere coincidence that the change to a marine food diet
which provided a stable and continuous supply of essen-
tial DHA (and EPA) sources appear to happen together
with advancements in human’s cultural development, as
exemplified by the bladelet stone tool technology and
other cultural advancements [304]. Indeed, there is also
now incontrovertible support from fossil evidence for
the hypothesis that steady access to the marine food web
must have played a critical role in human’s final steps in
evolution [305]. This might have allowed humans to
evolve big brains even without the ability to efficiently
convert plant-derived n-3 PUFAs into DHA and EPA.
Hence, humans are not at all adapted to the very recent
and rapid change in dietary habits that cause a detri-
mental deficit in DHA as well as EPA.
While a lack of essential n-3 PUFA is causing neuroin-
flammation and a disturbed AHN (wherefore supple-
ments containing EPA and DHA were shown to have a
positive effect on primary depression [306]), there is also
substantial convergence of research findings to date indi-
cating that seafood consumption reduces the risk of de-
mentia and AD [307].
However, not all researchers agree with this, since a
major breakthrough in AD prevention by adding fish to
patients’ diet has not been achieved (for a list of trials
see [289]) and many therefore argue for longer-term
human trials in hope for better success rates [308].
Notwithstanding, one should be aware that only those
participants of any cohort might benefit from DHA
treatment (or any other AHN-compromising deficit),
who actually have a deficit in DHA (or any other re-
spective deficit), and, according to the above outlined
LOM, have no deficit in any other essential require-
ments for a productive AHN and NRJ. Hence, even if
longer intervention trials might not raise the success
rates, as long as we do not rectify all concomitant defi-
cits. In any case, one should not conclude that provid-
ing sufficient DHA is not essential, simply because in
most published cases it has on its own not been effect-
ive in preventing or treating AD (or major depression).
One key question however remains: Where should a
steady world supply with DHA (and EPA) come from?
With regards to meeting the assumed global consump-
tion needs, there is a growing concern about the sustain-
ability of global fisheries. An economic and ecological
alternative to selectively consuming wild caught and
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organic farmed fish is to increase the supply of edible oil
rich in DHA and EPA derived from of organically grown
micro-algae [309]. This would also circumvent the prob-
lem of the contamination with methylmercury (MeHg)
in fish (see below).
Mediterranean diet (MeDi)
A healthy alternative to the standard WeDi is the MeDi
[310]. Since all Mediterranean countries have their own
type of cuisine, one has to be aware that what we call
MeDi is an artificial construct. Nevertheless, the princi-
pal aspects of this diet include proportionally high con-
sumption of olive oil, legumes, unrefined cereals, fruits
and nuts, and vegetables, moderate to high consumption
of fish, restrained consumption of dairy products, mod-
est red wine consumption, and low consumption of
non-fish meat and non-fish meat products [311]. Older
adults, adhering to a MeDi, have less brain atrophy, with
an effect similar to 5 years of aging, when compared to
those adhering to a WeDi, according to a recent study
[312]. Particularly higher fish and lower meat intake
might be the two key food elements that contributed to
the benefits of MeDi on brain structure, as the authors
of the study pointed out. Another study provided evi-
dence that such dietary interventions play a role in the
prevention of AD. Here, individuals without cognitive
deficits showing lower adherence to a MeDi had cortical
thinning in the same brain regions as clinical AD
patients, i.e. entorhinal cortex, orbito-frontal cortex, in-
ferior parietal lobule, inferior and middle temporal cor-
tex and posterior cingulate cortex, compared to those
showing higher adherence [57]. Interestingly, ApoE4-
subjects showing higher MeDi adherence had the great-
est benefit of all other subgroups, which is in line with
the aforementioned role of ApoE4 being primarily an ac-
celerator of the AD process under unhealthy lifestyle
conditions. A similar protective effect was found for the
traditional Japanese diet (for review see [313]), which
might explain at least partially the low AD prevalence
rates in the old Japan, as discussed above.
Importantly, the benefits of the MeDi, like for any diet
protecting against chronic disorders, should not only be
attributed to its products. They are also strongly influ-
enced by the food processing techniques and the style of
cooking. Mechanistic and epidemiological evidence pro-
vide convincing evidence that food processing impacts
on the quality of the inherent phytochemicals and this in
turn impacts on the protective properties of these foods
against chronic diseases associated with inflammation
(for review see [272]).
Vitamins
A WeDi is generally low in vital nutrients and leads to a
reduced intake of vitamins and essential trace elements.
In line with the LOM, each individual deficit inhibits
productive AHN and was shown to increase the risk of
AD, including deficits of vitamin A [314], all the B-
complex vitamins [315], vitamin B1 [316, 317], B3 [318,
319], B6, B9 and B12 (see below), C (for a comprehen-
sive review see [320]), D (see below and [321]), and the
E tocopherols [322]. As it is beyond the scope of this re-
view to detail the impact of each deficit on AHN and
resulting risk for depression and AD, I will provide only
two examples. Nevertheless, in AD prevention (and ther-
apy), each deficit needs to be addressed.
Example 1
Nutritional deficiencies in the either of the vitamins B6, B9
or B12 lead to an increased accumulation of homocysteine,
an intermediate product in the L-methionine and L-
cysteine amino acid metabolism, where these three vita-
mins are essential cofactors. An elevated homocysteine
blood level is a predictor of cognitive decline in AD [323].
Homocysteine induces oxidative stress through neuronal
nitric oxide synthase activation and free radical formation
[324], thus causing a significant increase in neuronal cell
death [325]. Furthermore, elevated homocysteine was
shown to be detrimental to AHN [326], where it inhibits
the proliferation of neuronal precursors by interfering with
several signalling pathways required for cell proliferation
[327]. A recent 10-year study based on post-mortem
neuropathological and MRI findings identified that ele-
vated homocysteine was related to Aβ accumulation and
brain atrophy. The highest homocysteine quartile had an
odds ratio of 3.78 for medial temporal atrophy and 4.69
for periventricular white matter hyperintensities [328].
Since all associations were independent of several potential
confounders, including common vascular risk factors, defi-
ciencies of either vitamin B6, B9 or B12 should therefore
be regarded as independent risk factors for AD due to
homocysteine elevation.
However, despite the fact that lowering homocysteine-
levels by supplementing B vitamins was shown to signifi-
cantly slow-down the rate of accelerated brain atrophy
in MCI (from 1.08 % per year in the placebo group to
0.76 % in the active treatment group) [329], no full pre-
vention nor cure of AD can be expected, according to
the LOM, as long as other essential risk factors are not
eliminated as well. Only a preventive and therapeutic
scheme that provides all essentials, as schematically out-
lined in Fig. 1, might be successful. Therefore, manage-
ment of potential micronutrients deficiencies can only
be one, albeit important, aspect of AD prevention and
treatment strategies (for review see [313, 330]).
Example 2
Vitamin D deficiency is known to decrease bone density
and increase the risk for many common forms of cancer
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[331] as well as cognitive impairment in older but also
younger adults [332]. The overall prevalence rate of vita-
min D deficiency is widespread. For instance, it averages
in the USA at about 41.6 %, with the highest rate seen in
blacks (82.1 %), followed by Hispanics (69.2 %), accord-
ing to a recent study [333]. Vitamin D deficiency causes
abnormal AHN [334]. While the results of a recent
meta-analysis analyses were consistent with the hypoth-
esis that low vitamin D concentration is associated with
depression (taken as a sentinel disease for an unpro-
ductive AHN), there is always the call for more rando-
mised controlled trials to find out for instance, if
vitamin D supplementation could indeed be useful for
the prevention and treatment of depression [335] or
cognitive decline [336]. I understand that there is a
strong scientific need to understand better how Vita-
min D insufficiency dysregulates certain nerve growth
factors and respective signalling pathways [337], but
waiting for more scientific understanding what goes
wrong when an essential vitamin is missing does not
help those who suffer right now under such a deficiency
and are prone to develop serious diseases. Furthermore
and again, such interventions do not help those in-
cluded in trials that have sufficient serum vitamin D at
baseline [338]. Second and as stated above, only those
participants benefit fully of vitamin D supplementation
when at the same time all other essential factors, that
are missing and which are required for a productive
AHN are provided as well. Since this is rarely done, a
weak or negative outcome regarding AD prevention
should not lead to the false conclusion that the deficit
in question is not casually linked to AD and should be
corrected.
Indeed, the results from a recent study confirm that
vitamin D deficiency is strongly associated with a sub-
stantially increased risk of all-cause dementia and AD
[339]. Conversely, higher dietary intake of vitamin D
was shown to be associated with a significant lower
risk of AD [340]. Furthermore, a recent study provided
evidence that serum 25-Hydroxyvitamin D levels of
70 nmol/L were associated with the lowest cardiovas-
cular disease mortality risk [341], close to the values
that showed an over two-fold reduced brain atrophy
(>50 nmol/L), when compared to insufficient vitamin
D levels [339]. In my opinion, all the results taken to-
gether warrants immediate action of primary care phy-
sicians but also policy makers to make the screening
for deficits in all essential nutrients, Vitamin D being
one of them, part of nationwide prevention programs.
Trace elements
The same logic in the prevention and treatment of AD
applies to deficiencies in essential trace elements, like
for example selenium, zinc or lithium.
Selenium deficiency plays an important role in AD
[342, 343], because selenium-dependent enzymes (sele-
noenzymes) are required to prevent and even reverse
oxidative damage throughout the body, and in particular
in the nervous system [344]. An optimal range of serum
selenium around 85 μg/L was associated with reduced
risk of depressive symptomatology in young adults [345].
Interestingly, inducing differentiation in primary neur-
onal stem cells (NSCs) was recently shown to result in
an immediate increase of total mitochondria number
and overall ROS production, suggesting oxidative stress
is generated as a result of routine adult neurogenesis
[346]. This metabolic adaptation process appears to be
common for all types of stem cell systems [347]. There-
fore, a deficiency of selenium seems to limit the buffer
capacity against an AHN-increased ROS production,
which might result in an non-productive AHN and
therefore a heightened risk of depression and AD.
Zinc is another main trace element required for AHN
[348, 349]. In patients with major depression, a low
zinc serum level was correlated with an increase in the
activation of markers of the immune system, leading to
impaired AHN. Moreover, a preliminary clinical study
demonstrated the benefit of zinc supplementation in
antidepressant therapy. In preclinical research, the anti-
depressant activity of zinc was observed in the majority
of rodent models of depression and revealed a causative
role for zinc deficiency in the induction of depressive-
like symptoms, the reduction of neurogenesis and neur-
onal survival or impaired learning and memory ability
(for review see [350]). In addition, zinc is critical for
the enzymatic non-amyloidogenic processing pathway
of the amyloid precursor protein (APP) and for enzym-
atic degradation of the Aβ [351].
Lithium is not yet generally recognized as a trace
element but several lines of evidence make it a strong
candidate [352]. For instance, long-term low-dose expos-
ure to lithium exerts anti-aging capabilities and unam-
biguously decreases mortality in animal models [353]. In
humans, epidemiological studies indicate an inverse cor-
relation between lithium concentration in drinking water
and mood, depression and suicide rates [354], amongst
other psychiatric conditions [355]. In a study that com-
pared elderly bipolar patients (who exhibit a higher risk
for dementia) who had received chronic lithium treat-
ment, with bipolar patients who had not received lith-
ium, it was shown that the prevalence of the treated
group was equivalent to the general, age-comparable
population, whereas the non-lithium-treated patients
had an incidence of dementia that was six times greater,
i.e. 5 % vs. 33 %, respectively [356]. In another study it
was shown that lithium treatment resulted in an increase
in volumes of the hippocampi in both hemispheres com-
pared to an unmedicated group, an effect that was
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apparent even after a brief treatment period of about
4 weeks on average [357]. Importantly, intake of lithium
not only in standard therapeutic but also in trace doses
reduces the risk for dementia, suicide, and other be-
havioural outcomes, suggesting an pharmacological
interference with key regulators of these pathological
processes [358]. So, lithium naturally regulates critical
cell signalling pathways and a lack of lithium in the
diet can therefore cause increased disease risk.
It has been shown that lithium modulates negatively
the activity of the two kinases GSK-3α and GSK-3β,
which might explain both the relative specificity and
sensitivity of the effects of low-dose lithium treatment
(see below) [359]. Since GSK-3β-activation by oligomeric
Aβ promotes neuroinflammation, phosphorylation of tau
and disturbance of AHN [360], all key mechanisms in
the AD process, in inhibition of GSK-3 by lithium re-
sults in reduced tauopathy and neurodegeneration in
vivo [361]. Likewise, lithium treatment was shown to im-
prove AHN, neuropathology and cognitive functions in a
mouse model of AD [362]. Furthermore, such “AD-
mice” treated from two months of age had decreased
numbers of senile plaques, no neuronal loss in cortex
and hippocampus and increased BDNF levels when
compared to non-treated transgenic mice [363]. In order
to achieve this effect, it was sufficient to give lithium at
about one per mill of the high standard-dose therapy in
bipolar disorder, a dose which can cause some significant
side effects. Hence the authors of the study believe that
their data support the use of (virtually side-effect free)
microdose lithium in the prevention and treatment of
Alzheimer’s disease.
Indeed, long-term lithium treatment already provided
preliminary evidence of its disease-modifying proper-
ties for amnestic MCI in a randomised controlled trial,
where the lithium-treated group had fewer conversions
from MCI to AD. [364]. Lithium treatment was associ-
ated with a significant decrease in cerebrospinal fluid
concentrations of hyperphosphorylated tau and better
performance on the cognitive subscale of the Alzhei-
mer’s Disease Assessment Scale and in attention tasks.
At a more advanced stage of AD, microdose treatment
with only 300 μg lithium administered once daily stabi-
lized the AD patients during the complete evaluation
phase of 15 months [365]. For instance, whereas the
treated group showed no decreased performance in the
mini-mental state examination (MMSE), lower scores
were observed for the control group during the same
period, with significant differences occurring after
three months, and increasing progressively.
Importantly, lithium, besides being required for effi-
cient AHN and blocking AD-specific pathological pro-
cesses, also impacts on cell-rejuvenating autophagy.
Lithium was found to inhibit the activity of inositol
monophosphatase (IMPase), which leads to a decrease
of myo-1, 4, 5-triphosphate (IP3). This reduction of IP3-
activity induces autophagy, independent of mTOR [366].
In this context it is important to note that lithium chlor-
ide extends the lifespan of the nematode Caenorhabditis
elegans [367], possibly by means of mitochondrial reju-
venation [368], which suggests that lithium exerts its ef-
fects on evolutionary highly conserved mechanisms.
Intake of drinking water with comparable low lithium
concentrations were found to be inversely correlated
with all-cause mortality in a large epidemiological study
in Japan [353]. Hence a lack of lithium is linking aging
and frailty (all increasing mortality) to disturbed au-
tophagy, and AD to impaired AHN, and, thus, might
represent another important and modifiable risk factor
in this neurodegenerative disease [369]. Traces of lith-
ium can be ingested in some geographic areas by
drinking local tap water or otherwise by consuming
commercially available, mineral-rich spring waters,
containing suitable concentrations of around 1 mg
lithium per litre. Hence microdose lithium intake by
means of one or two glasses of such water a day is not
only of potential therapeutic value (see below) but also
a safe preventive measure, by means of simply redu-
cing an intake-deficit of an important novel trace
element.
The importance of IMF for brain fuelling, AHN and
neuronal rejuvenation
Hunting and gathering are perilous enterprises. Hence
leaving the secure living area and going into the wild
was most certainly avoided by our ancestors as long as
their stomach was filled. As a consequence, mechanisms
must have evolved that allowed brains and bodies to
functioning well even when hungry. Particularly the epi-
sodic memory function of the hippocampus is import-
ant, since remembering well where food can be found
and predators are lurking was key to survival and there-
fore reproductive success. Linking IMF to hippocampal
growth was such a mechanism our ancestors could rely
on (see below). But whereas the need to acquire food
was a major day-to-day challenge during much of hom-
inid evolutionary history, for people in modern societies
a constant supply of food became the norm [66]. The
resulting ad libitum eating pattern also applies routinely
to laboratory animals. For example, transgenic AD
models kept in standard housing with ad libitum feeding
develop AD-like symptoms, and a high high-caloric diet
even accelerates memory impairment [370]. In contrast,
keeping such mice under a more natural IMF-diet im-
proved cognitive functions and brain structures not only
in wild-type mice [371]. One year of IMF prevented cog-
nitive decline even in a triple-transgenic mouse model of
AD, which expresses the human APPswe, PS1M146V,
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and tauP301L mutations [42], providing evidence that
not aging per se but rather long-term feeding patterns
have long-lasting effects on memory [43]. Interestingly,
the positive effects of IMF were independent of changes
in Aβ and tau pathology, hinting that IMF protects brain
cells by another mechanism, like for instance by activa-
tion of protein chaperones, antioxidant enzymes and by
the suppression of neuroinflammation [372–374] or by
activating NRJ [375], thereby promoting regeneration,
enhanced cognitive performance, and healthspan [376].
Furthermore, the “hunger hormone” acyl-ghrelin was
found to activate proneurogenic signalling pathways by
increasing levels of the neurogenic transcription factor
Egr-1 in DG-neurons [377]. IMF also induces FGF2 and
BDNF expression in the hippocampus [378], which pro-
motes the survival of newly generated neurons and
thereby contributes to the enhancement of AHN [379].
BDNF also protects DG-neurons against excitotoxicity,
energy deprivation and oxidative stress [380, 381].
Another hallmark of AD is increased neuronal insulin
resistance in the temporal lobe. The inability of insulin-
resistant hippocampal neuronal cells to take up glucose
is another driving force of the AD process [382]. Due to
“standard housing” in animal research and the “normal-
ity” of the Western lifestyle as observed in epidemio-
logical studies, the detrimental condition of neuronal
insulin resistance is similar to AD regarded as a pri-
mary consequence of aging, and rarely as result of a
sedentary lifestyle, obesity, a WeDi, high cortisol secre-
tion and the accumulation of toxic Aβ-levels caused by
increased production (impaired AHN) and disturbed
removal. Conversely, an experimental change to an
IMF-like dietary pattern as well as to more daily phys-
ical activity increases insulin sensitivity, fatty acid
mobilization and ketone body production (which cir-
cumvents the energy starvation of hippocampal neu-
rons in AD). Importantly, these lifestyle adaptations,
which take advantage of our genetic program, are not
only important for AD prevention but should also be
an indispensable part of any prevention and curative
treatment program for many chronic disorders [383].
Intriguingly, the ketone body βOHB is not only a
carrier of energy from the liver to peripheral tissues
like the brain during IMF or exercise, βOHB was also
found to be an important signalling metabolite [91].
For example, βOHB acts through the adipocyte recep-
tor HCAR2 (hydroxycarboxylic acid receptor 2), also
known as GPR109A, through which niacin (Vitamin
B3) stimulates the secretion of adiponectin [318],
known to induce AHN [247]. By activating HCAR2,
βOHB also negatively regulates its own production,
thereby preventing ketoacidosis and promoting effi-
cient use of fat stores. In addition, βOHB suppresses
the sympathetic nervous system (which leads to energy
conservation when fasting) by antagonizing FFAR3
(free fatty acid receptor 3), also known as GPR41,
which is most abundantly expressed in sympathetic
ganglia of mice and humans [384].
Furthermore, by inhibiting histone deacetylases (HDAC),
βOHB regulates via epigenetic reprogramming the expres-
sion of genes that support subcellular renewal and cellular
survival, like for instance autophagy and stress response
pathways, which leads to neuroprotection and longev-
ity. These genetic programs are highly conserved. For
instance, βOHB, by inhibiting HDACs, extends the life-
span of C. elegans by a multitude of mechanisms in-
cluding the activation of conserved stress response
pathways, increased thermotolerance, reduced glucose
toxicity and, in regard to AD, delayed toxicity of oligo-
meric Aβ [385]. Similarly, βOHB protects hippocampal
cultures from hypoxia and glutamate excitotoxicity
[386], as well as Aβ-toxicity (for review see [387, 388]).
In addition, βOHB counteracts neuroinflammation
[389], protects against insulin glycation (insulin-AGEs)
as a mechanism for neuronal insulin resistance, and in-
creases microglia viability by an anti-lipid peroxidation
effect [390]. βOHB also stimulates autophagy and pre-
vents neurodegeneration induced by glucose deprivation
in cultured cortical neurons [391]. Furthermore, βOHB-
induced upregulation of hypoxia inducible factor-1α, a
primary constituent associated with hypoxia-induced
angiogenesis and a regulator of neuroprotective responses,
leads to a reduction in neuronal loss in stroke models
[392]. And, as outlined above, increasing ketogenesis by
extensive physical activity or IMF leads to activation of
PGC-1α and inhibition of mTOR, and consequently lon-
gevity, at least on the neuronal level.
In this context it is important to note that the health
benefits of IMF do not require overall reduction in cal-
oric intake, like for instance CCR. For example, mice fed
only for 8 h a day (i.e. IMF for 16 h daily) are resistant
to high-fat diet-induced obesity [393], without altering
the overall calorie intake. The longer the ketosis on a
day to day basis the better for health outcome, which
even puts into question the widely held belief that break-
fast is the most important meal of the day [394]. Indeed,
it is reasonable to suppose that skipping breakfast could
be as metabolically beneficial as excluding late eating, as
long as an inter-meal interval is long enough to allow
sufficient ketogenesis to reduce the risk of obesity and of
co-morbidities like AD [395].
Taken together, the endogenous signalling metabolite
βOHB improves memory function not only by providing
brain fuel under conditions of neuronal insulin resist-
ance, but also by favourably changing our genetic and
epigenetic program. This is an indication that the princi-
ples of long-term brain health as they developed during
evolution still are valid today [396]. Besides IMF and
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prolonged physical activity, brain-protecting ketogenesis
remains active during the day if we omit the intake of
food with a high glycemic index that leads to a postpran-
dial secretion of insulin, as this “sugar-stress” hormone
most effacingly blocks lipolyses [397] and ketogenesis
[398]. Furthermore, there even exists a natural possibility
to increase ketogenesis when eating.
Ketogenic brain fuelling without fasting
The ingestion of medium-chain triglycerides (MCTGs),
like those being provided by virgin coconut oil, which
contains them at concentrations up to 60 %, leads to ele-
vated ketone body production. In contrast to ingested
long-chain triglycerides, MCTGs are water soluble and
therefore directly transported via the portal vein to the
liver where they are efficiently transformed into ketone
bodies [399]. And indeed, the acute administration of
MCTGs appears to improve somewhat memory per-
formance in AD patients [400, 401], whereby the degree
of memory improvement was found to being positively
correlated with plasma levels of generated βOHB. But
the benefits were only observed in less advanced stages
of the disease [402]. Furthermore, in all these studies,
besides the weakness of the overall beneficiary effect,
they were less pronounced in ApoE4-carriers. Both these
observations might indicate that using MCTGs like a
drug to increase βOHB-levels does not completely pro-
vide all possible health benefits generated by IMF or
prolonged physical activity. Hence as important as keto-
genesis for hippocampal metabolism, AHN and neuronal
rejuvenation might be, simply adding ketogenic MCTG
to the diet is not sufficient to prevent or treat AD.
Nevertheless, some researchers tend to base a complete
unified theory of AD simply on activation of ketogenic
energy metabolism [403].
Comparisons of the effects of energy restriction and
physical exercise on gene expression in various brain re-
gions support the notion that these two different envir-
onmental factors have both overlapping but also distinct
effects on brain cell plasticity [66]: While running exer-
cise primarily enhances the proliferation of neural stem
cells and secondarily the survival of newly generated
neurons, IMF, besides supporting basal stem cell prolif-
eration, first and foremost improves the chance of sur-
vival of newly generated neurons [379]. In this regard it
is obvious that exercise and energy restriction show
additive effects on AHN [404] as well as neuroplasticity:
Both running wheel exercise and daily energy restriction
resulted in increased dendritic spine density in hippo-
campal DG neurons when compared to mice that only
run or are only energy restricted [405]. From the evolu-
tionary perspective, these findings are consistent with
the notion that IMF and foraging result in structural and
functional improvements of neuronal circuits in the
brain that provide a survival advantage. These physio-
logical effects explain why human intervention studies
fail to show clear cut effects when they focus on only
one aspect (like only providing only coconut oil or
MCTG or advocating only IMF as a lifestyle choice). It
also explains, why a WeDi, where most individuals on a
daily basis consume large amounts of simple sugars and
unhealthy fats in large quantities become are chronically
ill. Under these conditions, a large number of people are
not only deprived of food with high nutrient value, also
efficient and therefore health-protecting ketogenesis
rarely occurs [406, 407].
Taken together, besides the importance of IMF and
physical exercise, also dietary MCTGs can be an at-
tractive (indirect) source of ketone bodies during the
non-fasting state. The intake of coconut oil as a healthy
source of MCTGs has additional positive effects on
neuronal insulin resistance, neuroinflammation as well
as Aβ-toxicity, improves the LDL/HDL-cholesterol
quotient by increasing HDL, and ameliorates several
others key progression factors of AD [408]. Hence the
use of virgin coconut oil is highly recommended as a
safe and healthy alternative for polyunsaturated oils for
frying and baking and butter and an important part of a
comprehensive strategy for the prevention and treat-
ment of AD.
Body composition and visceral fat
A lifestyle that encompasses 12+ hours IMF overnight, a
nutrient-rich, low-glycemic diet and regular physical ex-
ercise almost inevitably leads to a body composition
close to that of our foraging ancestors: lean and muscu-
lar. Unfortunately, the behavioural trend goes in the
other direction, where obesity and “age-related” muscle
loss is becoming a major health issue [409]. This trend
has negative consequences also on brain function, since
adipocytes produce adipokines (like muscle cells myo-
kines) with endocrine functions that affect the physi-
ology of essentially all organs, including the brain [410].
Both, the lack as well as the abundance of visceral fat
leads to an unhealthy regulation of these adipokines. In
particular, the epidemic visceral obesity causes a rise of
several disease risks for AD like the development of
chronic inflammation [411], insulin resistance [412],
hypertension [413], hypercholesterolemia [414], arterio-
sclerosis [415] and finally, the metabolic syndrome, a
condition composed of more or less all these AD-risk
factors cited above [416–418].
The dysregulation of certain adipokines have also dir-
ect effects on the proposed central mechanism of AD,
namely AHN. For instance, leptin is an adipokine well-
known for its hypothalamic regulation of food intake
and energy metabolism. But leptin has also remarkable
effects on AHN, axon growth, synaptogenesis, dendritic
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morphology, neuron excitability, neuroprotection and
even regulation of Aβ levels [419]. Due to these pleio-
tropic effects, leptin treatment was shown to reduce
brain pathology and to improve memory in transgenic
mouse models of AD [420]. Conversely, obesity induced
overexpression of leptin causes leptin resistance and
hence disturbed AHN and depression [421]. In a murine
model for obesity and diabetes, leptin resistance was
shown to promote AD-relevant tau pathology [422].
Conversely, the neuroprotective adiponectin, a promin-
ent activator of AHN, is down-regulated by central obes-
ity [423].
Taken together, adipokines impact directly and indir-
ectly on key brain functions, which adds central obesity
in midlife to the large list of causal risk factors for AD
[extensively reviewed in [424] and [425]. Hence any
causal AD prevention strategy should aim to reduce vis-
ceral fat depots by encouraging physical activity, over-
night IMF of at least 12 h, and a healthy diet (e.g.
MeDi).
Social engagement and purpose in life
Brains have for one central function: to overcome envir-
onmental challenges in order to improve the chances of
survival and successful reproduction. AHN in particular
is important as it allows the lifelong collection of essen-
tial life experiences. But cognitive capabilities are only
improved by cognitive challenges. Without new experi-
ences, newborn DG-neurons would not interconnect
with the existing DG-network. Without functional
synapses, neurons undergo apoptosis [426]. Hence for
a productive AHN to occur, the human brain continues
to require memorable activities even at high age. Since
social activities for beings like humans, whose survival
depend on social support, have high importance and
therefore a high emotional impact, they also generate
best memorable experience. In other words, mental
health is depending on social interactions. Neither
retirement at old age was part of human’s long life his-
tory nor the modern individualism that leads ever more
frequently to a breakdown of tight extended family
bonds where grandparents are less (or not) involved in
family support. The impoverishment in mental challenges
and social interactions has detrimental consequences,
since those individuals rating at a low score on the pur-
pose in life measure were found to be associated with a
2.4 times increased risk of AD when compared to those
rating themselves at a high score [427].
Since correlation in human studies does not a priori
equal causality and sometimes even reflects reverse
causality, animal models are important for distinguishing
between different causal possibilities and in case of a
causal correlation help to even possibly identify the
underlying molecular mechanism. In animal research,
experience of a complex challenging environment was
shown to enhance brain plasticity, improving both
structure and function. The effects of environmental
enrichment (EE) are of particular importance under
neuropathological conditions: Experience in a complex
(natural) environment rescues impaired AHN in trans-
genic mice harbouring a familial AD-linked transgene
[428]. Productive proliferation of hippocampal cells
improved significantly after EE. In addition, EE signifi-
cantly enhanced hippocampal LTP. Furthermore, en-
hanced AHN was accompanied by a significant
reduction in levels of p-tau and oligomeric Aβ in the
hippocampus and cortex of environmentally enriched
mice. In another animal model of AD, social inter-
action rescued memory deficits by means of increasing
BDNF-dependent AHN [429]. Prolonged enrichment
was even found to prevent LTP inhibition by synapto-
toxic Aβ-oligomers [153]. From these experiments one
can conclude that environmental modulation might be
able to rescue the impaired phenotype of the AD brain
and that induction of brain plasticity by increasing so-
cial and cognitive challenges (and not decreasing, as
often happens to patients diagnosed with early AD)
may represent a valuable therapeutic and preventive
avenue. Indeed, human studies revealed that higher
baseline social integration predicted slower memory
decline in a representative US sample of elderly adults
[430]. Memory among the least integrated patients de-
clined at twice the rate when compared with the most
integrated ones. Additionally, there was no evidence of
reverse causation in these study groups, i.e. cognitive
decline causing reduced social interaction.
On the other hand, while systematic cognitive training
and respective computer-based programs produce long-
term improvement in cognitive function and less diffi-
culty in performing activities of daily living, activities like
these do not simulate social (emotional) learning and
therefore might not as well improve AHN. i.e. the sur-
vival of newborn DG-neurons. Although computer-
based mental training has it benefits for the skills being
trained [431], it is therefore no surprise that cognitive
training was not found to be associated with a lower rate
of incidence in dementia [432]. From an evolutionary
perspective, human’s ability to stay mentally healthy up
to high age, based on a productive AHN, requires other
activities. In particular and in line with the GMH, being
and feeling generative by exhibiting concern and behav-
iour to benefit others (or at least kinship) is a very im-
portant developmental goal of midlife and beyond.
Therefore, a recent study examined whether participa-
tion in the intergenerational civic engagement program,
named Experience Corps (EC), would benefit older
adults’ self-perceptions of generativity (as outlined above,
generativity is meant in the psychosocial sense and refers
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to the concern for establishing and guiding the next gen-
eration). Participants randomized to the intervention
group were placed as volunteers within the Baltimore
public school system for 2 years. The results provided
the first-ever, large-scale experimental demonstration
that participation in an intergenerational civic engage-
ment program not only positively alters self-perceptions
of generativity in older adulthood [433], but also buff-
ered against brain atrophy. In particular, whereas men in
the control arm of the EC-program exhibited continued
hippocampal declines for 2 years, men in the socially ac-
tive arm showed a 0.7 to 1.6 % increase in brain volumes
[434]. These findings show that purposeful social activity
not only stops but even reverses the decline in brain vol-
ume in regions vulnerable to dementia, commonly ob-
served in the elderly population.
In contrast, unintended by the individual or even
forced social isolation is stressful and disrupts AHN,
as was recently shown in marmoset monkeys [435].
Moreover, traumatic events early in life result in HPA
axis dysregulation with deleterious consequences like
anxiety-like behaviours later in life, which in turn con-
tinue to disturb AHN. In animal models, sensoring of
circulating corticosteroid levels was shown to be im-
peded through epigenetic downregulation of the cor-
ticosteroid receptor (CR) in hippocampal neurons,
potentially leading to long-term HPA axis dysregula-
tion [436]. There is evidence that the same principles
work in humans: DNA methylation levels in the pro-
moter region of the GR gene were shown to be posi-
tively correlated in a cumulative manner with the
number of stressful life events as child or young adult
experiences (such as parental divorce, severe illness
etc.) [437]. Reduced cortisol sensing hinders HPA axis
negative feedback regulation, thereby increasing the
risk to develop major depression or AD. For example,
childhood abuse altered HPA stress responses and in-
creased risk of suicide, which was found to be closely
linked to epigenetic differences in a neuron-specific
GR promoter [438]. Correspondingly, a chronically
distressful life, like chronic problems at work or a
chronic disabling disease, divorce, or death of a close
family member, was shown to be inversely correlated
with hippocampal size, which was linked to cognitive
deficits in depressed patients [439]. According to a re-
cent 38-year longitudinal population study, such psy-
chosocial stressors in middle-aged women appear to
increase the risk of AD in later life [440]. But not
everybody who experiences stressful events becomes
depressed or develops AD. Indeed, those who are psy-
chological resilient and cope with such distressful
events, as a more detailed follow-up analyses of the
study data revealed, are less prone of developing AD
later in life. The researchers found that a higher degree
of “neuroticism” (characterized by anxiety, fear, moodi-
ness, worry, envy, frustration, jealousy, and loneliness) in
midlife was associated with long-standing distress and in-
creased risk of AD dementia. In particular, personalities
with high “neuroticism” and low extraversion scores
showed the highest risk of AD dementia [441]. Both traits,
“neuroticism” and introversion, are associated with HPA
axis dysregulation [442, 443]. The authors of the popula-
tion study conclude that midlife “neuroticism” is associ-
ated with increased risk of AD dementia, and that distress
mediates this association. Hence not stressful events but
our reaction to those stressors affect our mental health in
the long run. The results of these studies have therefore
implications for AD prevention as well as treatment of
early AD: In both cases, increasing psychological resilience
by reactivating a productive AHN must be a primary goal.
The required lifestyle changes reduce the risk of cogni-
tive decline, but are generally regarded as stressful, at
least in the beginning. But they also lead to rewarding
experiences (more physical and mental fitness, more so-
cial activities) and thereby buffer progenitor cells in the
DG from the negative effects of elevated stress hor-
mones [254]. Particularly oxytocin is a potent activator
of AHN even under stressful situations marked by high
cortisol levels [444], and was found to positively modu-
late the behavioural and physiological responses to
stressors [445]. In humans, oxytocin is released in the
hippocampus under conditions of social reward [446].
Besides oxytocin, in particular the activity of neuropep-
tide Y (NPY) in the neurogenic “niche” of the hippocam-
pus has been associated with behavioural resilience to
stressors [447], mediating the positive effects of certain
stressors/rewarding experiences on AHN [448]. Interest-
ingly, the NPY-ergic system was recently found to be a
key mediator of the EE-facilitated coping-with-stress re-
sponse and reduced anxiety in an animal model for post-
traumatic stress [449]. Since stress coping stimulates
AHN in adult non human primates [450], psychother-
apies designed to promote stress coping combined with
AHN-promoting behaviours, as outlined in this review,
should have similar beneficiary effects in humans [451].
In particular those subjects should profit from such an
intervention, who belong to high risk groups for devel-
oping major depression or AD. As a consequence, yoga
or mindfulness-based stress-reduction programs [452],
as well as psychotherapy to overcome stressful life ex-
periences of the past, thereby increasing psychological
resilience, should be part of any AD prevention and
treatment strategy [453].
The importance of sleep
Sleep deprivation harms hippocampal learning and
memory. As outlined above, AHN is particularly sensi-
tive to the consequences of sleep loss [454]. In particular,
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hippocampal subfield atrophy is observed in chronic
insomnia and sleep fragmentation leads to reduced
AHN as well as neuronal loss in the cornu ammonis
(CA) subfields, which renders patients with chronic
sleep disturbance particularly vulnerable to cognitive im-
pairment [455].
In addition to the manifold mechanisms by which
sleep disruption causes an increase in AD risk [456], a
lack of uninterrupted sleep disturbs melatonin’s function
on brain health. Melatonin is secreted at the onset of
darkness from the pineal gland to orchestrate deep sleep.
Melatonin was found to be a potent inhibitor of neuro-
inflammation [457]. In addition, it promotes dendritic
maturation of newly generated DG-neurons and sup-
ports their survival [458]. This proneurogenic hormonal
effect is supported by hormonal mediators like GH and
BDNF, which are being upregulated during sleep. Fur-
thermore and as importantly for a productive AHN,
during deep sleep, secretion of cortisol as well as the
expression of antineurogenic immune mediators like
IL-1, IL-6 and TNFα are being reduced. Importantly,
Aβ concentrations, which rise during wakefulness, fall
during sleep. If this Aβ diurnal pattern is compromised
by inadequate sleep, accumulation and oligomerization
of toxic Aβ occur [459]. Interestingly, Aβ deposition
even in the preclinical stage of AD causes disturbed
sleep quality [460], leading to a vicious circle that needs
to be addressed in any systemic therapeutic approach.
Recently, the breakdown of the BBB was suggested to
be a consequence of aging per se (similarly to neuroin-
flammation, type-2-diabetes or AD). The cause was
found to be the accumulation of oligomeric Aβ in the
hippocampus [11, 461]. Hence BBB dysfunction was
seen as a cause and consequence of AD [462]. But as
discussed, under natural condition, particular with suf-
ficient REM sleep, our brain is protected from these
putative effects of aging. Indeed, sleep restriction in
general [463] and REM sleep restriction in particular
was found to increase BBB permeability, but even brief
periods of deep sleep rapidly and effectively restored
even severe alterations of BBB function [464]. These
observation suggests that REM sleep not only regulates
the physical barrier properties of the BBB, but also that
neither Aβ-accumulation nor BBB-permeability might
not be an inevitable consequence of aging.
In this context it is noteworthy that sleep disruption
is also the most common consequence of traumatic
brain injury, which might explain the increased AD
risk following concussions of professional NF-players
(as discussed above). When frequently interrupted
sleep becomes a chronic condition, no matter what the
aetiology, it causes decreased cellular repair and neuroin-
flammation, compromised BBB function, altered neuro-
plasticity, neurodegeneration, a reduction of AHN and
hippocampal volume and impaired hippocampal plasticity
and function [142, 465]. Hence sleep inadequacy with in-
creased daytime sleepiness are both risk factors for de-
mentia, independent of demographic and clinical factors
[466].
Taken together, improving sleep quality must be an im-
portant aspect in any regimen aiming to prevent or treat
cognitive decline. Potential treatment options for restoring
the normal sleep cycle are improving sleep hygiene
(www.ncbi.nlm.nih.gov/pubmedhealth/PMH0072504),
mindfulness training [467] and cognitive behavioural ther-
apy, in particular when psycho-traumatic experiences
need to be overcome. Medications like melatonin [468],
analogues [469], or its precursor tryptophan (which is also
a precursor of serotonin and a provitamin of vitamin B3)
might help in acute situations until behavioural causes
have been identified and removed.
The complex mechanisms of lifelong brain health
Predicted from the GMH, human reproduction strategy
(and genetic selection) relies on the lifelong acquisition
of experience that increases the chance of survival of the
following generations. As depicted in Fig. 1 and from an
evolutionary view as outlined in the preceding text,
human’s genetic program appears to be exquisitely
adapted to a pre-modern lifestyle and optimized to pro-
vide the key requisite for transgenerational generativity
of the experienced elderly: i.e. mental health up to high
age. The daily supply with vitamins, essential PUFAs and
trace elements, sufficient physical activity, IMF, a rich
social life with a purpose up to high age as well as
enough time for regeneration (sleep) most likely charac-
terized environmental and behavioural “normality” for
the largest part of human evolution. There was for in-
stance no need for our ancestors to maintain genes that
encode an energy-costly vitamin C-producing machin-
ery, since sufficient vitamin C was always in the diet.
One important physiological function that depends on
the constant availability of all these disparate factors is
AHN. But according to the LOM, AHN, like any bio-
logical growth process, can only be productive if all es-
sential requirements are fulfilled. Adult-born DG-neurons
regulate HPA axis activity by registering novelty and com-
paring it with prior experiences. A productive AHN might
therefore lead to increased psychological resilience with
an enhanced interest in new challenges (novelty seeking).
This increases the likelihood of novel experiences, a pre-
requisite for neuronal maturation and long-term brain
health (for review see [470]). I term this natural
process, as indicated in Fig. 1, the “virtuous circle of
mental growth”. Most of the behavioural and environ-
mental factors that are required for a productive AHN
also influence other important physiological functions
of our organism like for instance insulin sensitivity,
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 26 of 52
blood pressure and microcirculation, immune and BBB
function or cellular rejuvenation, and thereby indirectly
influence neuronal survival up to high age. All these
behavioural factors optimize Aβ homeostasis, with Aβ-
production during wake, assuring synapto- and neuro-
protective concentrations, followed by Aβ-degradation
during sleep in order to efficiently acquire new experi-
ences by hippocampal learning. Taken together, under
the guidance of our genetic program, all these complex
environmental, social, behavioural, physiological and
molecular processes appear to be needed to sustain
lifelong mental health.
AD is driven by deficiencies and accelerated by
environmental toxins
In contrast and as shown in Fig. 2 (which contains all
major risk factors and deficiencies leading to AD), and
depending on each individual’s scheme of life, one or
several qualitative deficits combine in different quantities
and limit the efficient generation, maturation and/or of
integration of new DG-neurons by AHN. As outlined
above and depicted in Fig. 2, an ineffective AHN limits
memory capacity and starts the “vicious circle of depres-
sion”. The proposed model reconciles the three conflict-
ing models originally suggested by Sapolsky to explain
the physiological link between hippocampal shrinking
and depression [471], and it provides a logical basis for
the many different causes of depression besides chronic
or severe psychosocial stress. Direct causes are the afore-
mentioned deficiencies in essential requirements for pro-
ductive AHN (behavioural deficits) and the interference
with a productive AHN by environmental toxins, which
will be described below. Indirect causes are the behav-
ioural consequences of those deficiencies (or toxins) that
either disturb BBB-function, lead to neuronal insulin
resistance, obesity, hypertension, arteriosclerosis and re-
duced blood supply and aggravate the behavioural defi-
cits. None of them might therefore be caused by aging
per se since unhealthy lifestyle conditions might suffice.
Nevertheless, particularly neuroinflammatory processes,
which inhibit AHN and lead to increased Aβ accumula-
tion, are almost always regarded as a consequence of
aging [472]. But is neuroinflammation indeed caused by
aging per se, as often argued (for instance see [473]), or
is it rather a consequence of modifiable lifestyle factors
(and a misinterpretation of animal research under un-
natural housing conditions)? Results of a recent study
suggest the latter, as neuroinflammation was found to
be far less pronounced in older AD patients when
compared with younger AD patients [474]. If chronic
inflammation as the driving force of AD was indeed
age-induced, the opposite result should be expected.
Neuroinflammation is rather multi-causal, with the
same behavioural deficits and environmental factors
contributing, which were found to disturb productive
AHN (for review see [475]). In addition to the nutritional
factors outlined above, these modifiable factors range from
chronic stress [476], an amyloid-producing microbiome
that might act as seeds for Aβ-oligomerization in the brain
(for review see [477] as a consequence of inadequate nu-
trition, a sedentary lifestyle [478], poor sleep quality [479],
visceral obesity [480], poor dental hygiene (for review see
[481]) or other causes of chronic infections [482, 483].
Since depression and AD share not only a disturbed AHN
but also neuroinflammation as a potential causative fea-
ture, Berk et al. asked a question also relevant for the
UTAD, “So depression is an inflammatory disease, but
where does the inflammation come from?” Their answer:
Modifiable risk factors [484], which, in essence, can also
be argued for AD.
As further depicted in Fig. 2, HPA-activation and
therefore cortisol hypersecretion, a biomarker of MCI
and early AD [178], leads to Aβ overproduction. Insuffi-
cient sleep as well as a lack of physical or social activity
inhibit Aβ clearance via the BBB [259, 485]. Both, in-
creased production as well as decreased clearance lead
to an accumulation and formation of Aβ to neurotoxic
oligomers. Furthermore, extracellular matrix (ECM)
ecto-protein kinases and phosphatases [486] were
found to enhance the aggregation and toxicity of the
Aβ-species [487]. How this emerging field connects to
current behavioural deficiencies or environmental
toxins is not yet clear but it would be surprising if the
physiology of the ECM activities would not be as highly
regulated as all the other processes.
As indicated by the circular arrow in Fig. 2, toxic Aβ
promotes its own generation by at least two mechanism.
1) Aβ as well as tau protein, the capital agents for the se-
nile plaques and intracellular neurofibrillary tangles, are
also called ‘prionoids’ indicating that proteins exhibit
prion-like properties [488], which is characterized by
propagation of protein misfolding [489], hence they
share key biophysical and biochemical characteristics
with prion diseases. 2) Oligomeric Aβ enhances pro-
amylogenic cleavage of APP through the activation of
GSK-3β, which also causes detrimental phosphorylation
of tau [126]. All these pro-neurodegenerative processes
interact and promote hippocampal shrinkage as well as
cortical thinning. Additional vicious circles develop in
the early phases of AD-pathogenesis, making it often dif-
ficult to distinguish cause and effect. Nevertheless, once
vicious circles are initiated, they tend to accelerate the
detrimental process on many different levels. Besides the
viscous circle of depression (continuous black arrows),
Fig. 2 contains several others (dashed black arrows):
 Sleep disturbances, as discussed above, increase
toxic Aβ accumulation by different mechanisms.
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But toxic Aβ also impairs sleep [490], which at
least in the early phase of AD might be a significant
cause of memory deficits.
 Both arteriosclerosis and AD might be linked to
similar behavioural deficiencies, which might explain
the high degree of comorbidity [491]. In addition,
arteriosclerotic hypoperfusion leads to an activation
of pro-amylogenic APP-processing and reduced
Aβ clearance, hence an increase in Aβ build up in
the brain [492], whereas Aβ tends to accumulate
in the blood vessel walls, leading to oxidative stress,
inflammation and endothelial dysfunction, thereby
enhancing the arteriosclerotic process [493].
 Toxic Aβ disturbs the function of the BBB, making
a breakdown of this critical barrier both a
consequence as well as an intermediate link in the
causal chain of the pathogenic process [462], for
instance by allowing bacterial or viral infections to
enter the brain and accelerate disease progression
[494, 495].
 Both toxic Aβ and chronically elevated cortisol
concentrations enhance hippocampal (temporal lobe)
insulin resistance [496]. Neuronal insulin resistance
aggravates the impairment of AHN, which
compromises via the “vicious cycle of depression” the
patients’ ability to lifestyle alterations, which are
required to recover neuronal insulin sensitivity, like
engaging in physical and social activity or taking up a
nutrient-rich diet.
 Aβ-activated GSK-3β not only leads to more Aβ
but also phosphorylates tau, which also was shown
to behave like a prion [497], thereby driving
neurodegeneration. Neuronal damage and prionic
aggregates aggravate neuroinflammation, which
in turn enhances neurodegeneration [498].
Hyperphosphorylated tau also causes oxidative
stress, which in turn leads to tau-
hyperphosphorylation [129].
It is obvious, that any successful AD therapy needs
to interrupt all significant self-maintaining and
disease-accelerating vicious circles. How this can be
accomplished will be outlined in a therapeutic pro-
posal below. Such a scheme must include the re-
moval of any type of environmental toxin that might
inhibit AHN and entertain and aggravate the disease
process:
 Tobacco smoke diminishes AHN and promotes
gliogenesis in rats [499]. Hence, heavy smokers
(2 packs a day) have a 2.6 fold increased AD risk
[500]. But also electronic cigarettes, even if they
would only contain nicotine as an ingredient
(which they do not), are unhealthy and most likely
AD-promoting, as nicotine impairs neurogenesis
and plasticity of hippocampal neurons [501].
 Alcohol intake of two drinks or more per day
accelerates AD by about 2 to 3 years and, when
combined with heavy smoking (20 cigarettes per
day) by about 4 to 6 years. And for those, carrying
an ApoE4 allele, which aggravates the consequences
of unhealthy lifestyle choices (as detailed above),
the onset of AD is on average 10 years earlier [502].
High alcohol intake was shown to efficiently block
AHN in an non-human primate model, with the
effect lasted for 2 months even after alcohol
discontinuation [503]. The lasting alcohol-induced
reduction in AHN paralleled an increase in neural
degeneration by nonapoptotic mechanisms.
Interestingly, abstaining from alcohol was also
seen as a risk factor in the past [504], but this
finding has not been confirmed [505]. Hence,
drinking small amounts of alcohol might not be
statistically harmful, but most likely does not
decrease the risk of developing AD.
 Trans fatty acids (TFAs), either from processed
food (fried products and many fast-food sources)
or from whole-fat dairy and ruminant meat
products are implicated in AD [506]. Both sources
were shown to equally efficiently increase low
density lipoprotein (LDL)-cholesterol [507] and
cause negative health effects [508]. TFAs drive the
mortality risk from cardiovascular diseases [509]
and increase the rates of cognitive decline in the
elderly, again, irrespective of the source [510, 511].
Epidemiological studies starting with healthy
participants showed that TFAs raise insulin
resistance, blood pressure and cause also chronic
inflammation [508], all well accepted causal risk
factors for AD. Furthermore, TFAs inhibit the
conversion of n-3 PUFAs into DHA, limiting their
accumulation in the brain [512]. DHA depletion
has been shown to result in decreased BDNF levels
[513], in impeded productive AHN [514] and in
neuroinflammation [308]. A recent in-vitro study
provided convincing evidence that TFAs increase
amyloidogenic processing of the amyloid precursor
protein (APP), resulting in an overproduction of
Aβ [515]. Moreover, TFAs were shown to enhance
the oligomerization and aggregation of Aβ. Taken
together, high intake of TFAs, independent of
the source, might increase the AD risk by many
avenues, also causing an earlier onset of the disease.
 Nitrosamines cause deficits in motor function and
spatial learning, as well as neurodegeneration
characterized by lipid peroxidation, increased levels
of Aβ and p-tau, neuroinflammation and neuronal
insulin resistance [516]. Nitrosamines are found in
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tobacco smoke. Significant levels of nitrosamines
are also produced from nitrites and secondary
amines found in many products, like processed
meat and cheese preserved with nitrite pickling salt.
This is another reason to avoid (mass produced)
meat or cheese products.
 Bisphenol A (BPA) leads to unwanted hormonal
activity and was shown to impair AHN, spatial
learning and memory [517]. BPA is found in a
variety of common consumer goods like water
bottles. Epoxy resins containing BPA are used to
line water pipes and for coatings on the inside of
many food and beverage cans. Exposure to other
bisphenols (B-Z) that are used as replacements
(in order to advertise BPA-free products) show
similar detrimental effects [518]. Hence BPA-free
products are not necessarily safer and support the
removal of all bisphenols from consumer merchan-
dise [519].
 Pesticides: Roundup (a glyphosate-based herbicide)
was recently shown to increase the lipid-
peroxidation, glutamate excitotoxicity and oxidative
damage in the hippocampus [520]. The widely used
pyrethroid pesticide deltamethrin induces apoptotic
signalling in the hippocampus and impairs AHN
[521]. Similar effects were observed for Carbofuran,
a carbamate pesticide [522]. These neurotoxic effect
of widely used chemicals in conventional agriculture
argues for the use of organic produced products for
the prevention and the treatment of AD [4].
 Aluminium might act as an accelerator of the
progression of [523]. Aluminium enhances
pro-apoptotic signalling, reduces BDNF in the
hippocampus and negatively affects spatial learning
in animal models. In fact, every biochemical function
in brain cells appears to be affected by aluminium
(reviewed in [2]). In addition, aluminium may play
crucial roles as a cross-linker in Aβ oligomerization
[524]. Taken together, aluminium exposure should be
avoided in prevention and treatment of AD.
 Methylmercury (MeHg) competes with selenium
for its enzymatic binding sites and acts as a highly
specific and irreversible inhibitor of selenoenzymes,
which are required to prevent and even reverse
oxidative damage throughout the body, in particular
the nervous system. Inhibition of selenoenzymes
appears to be the proximal cause of the pathological
effects known to accompany MeHg toxicity [525].
Dietary selenium intake is inversely related to
vulnerability to methylmercury (MeHg) toxicity,
which explains why maternal ingestion of foods that
contain MeHg in molar excess of Se has adverse
child outcomes, whereas eating MeHg-containing
but selenium-rich ocean fish results in improved
child IQs [526]. Similarly, MeHg intake impairs
hippocampal development and AHN [527] and is
associated with delay in cognitive development [528]
and AD [529]. Nevertheless, a recent study showed
seafood consumption was associated with less AD
neuropathology despite the increased mercury
levels [58]. This controversial result might be
explained by the fact that both DHA and selenium
are contained in high concentration in seafood.
Interestingly, in this study, ApoE4 carriers profited
most of high seafood intake, or conversely, ApoE4
carriers are more harmed by a deficit in DHA and/
or selenium consumption. Taken together, a diet low
in MeHg is advised, but at least as important is a
diet that keeps selenium and n-3 PUFAs
(DHA and EPA) levels sufficiently high.
 Iron is essential for many metabolic processes, but,
when left unregulated, is implicated as a potent
catalyst of reactive oxygen species generation.
Iron complexes with ferritin, the major cellular
storage of this transition metal [530]. As outlined
above, increased ferritin levels in the cerebrospinal
fluid (CSF) are negatively associated with cognitive
performance and predicted speed of MCI conversion
to AD. Since ApoE4 (in contrast to ApoE2 and
ApoE3) enhances iron uptake into the brain [59],
carriers who consume large amounts of iron-rich
animal products are particularly susceptible to
elevated brain iron, enhanced ROS production and
AD progression. This might be one of the reasons,
why a diet low in animal products reduces AD risk;
and pesco-vegetarians have the lowest mortality
when compared to other common diets [531].
Individuals with MCI and high CSF-ferritin levels
might delay conversion to AD by as much as 3 years
by taking a chelating drug like deferiprone [532],
according to the authors of the above mentioned
CSF-ferritin-study. An alternative option with less
side effects is treatment with α-lipoic acid (ALA)
[533], which was shown to be highly effective in
reversing oxidative stress arising from iron
overload [534]. Due to the multitude of additional
useful properties of ALA for the treatment of AD,
ALA will be part of a therapeutic scheme
suggested below.
 Copper like iron is an essential element for human
growth and development. And likewise, excessive
intake which leads to free copper contributes to
neurotoxicity and impaired spatial memory by
specific changes in the expression of synaptic
proteins and hippocampal signalling pathways,
which causes oxidative stress and neuronal apoptosis
[535]. Inorganic copper from drinking water can be
directly absorbed and elevate the serum free copper
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pool, thereby attributing to AD progression [536].
In case of high free copper levels, three regimens
are advised: (1) Avoiding water contaminated with
copper and supplements, (2) restoring normal zinc
levels, as it was shown that elevating zinc levels
significantly reduced serum free copper in AD
patients [3] and (3) treatment with free copper-
lowering ALA [537], as will be discussed in more
detail below.
 Medications: Use of gastric acid inhibitor was
significantly associated with the presence of vitamin
B12 deficiency [538], a risk factor for AD.
Meanwhile, it was found that these drugs increase
the levels of Aβ in the brains of mice and are
association with an increased risk of dementia in
humans [539]. Increases in incident dementia are
associated with long-term use (over three years)
of anticholinergic drugs like for example the
tricyclic antidepressant doxepin, the antihistamines
chlorpheniramine and diphenhydramine, and
bladder control drugs like for instance oxybutynin
[540]. A case–control study showed an association
between the use of benzodiazepines (used for sleep
and anxiety control) and the risk of AD [541].
A recent study provided evidence that memory
and hippocampal architecture of WeDi-treated
rats was particularly vulnerable to short-term
treatment with the benzodiazepine midazolam [542].
Again, this short number of examples must suffice
to show that there is always the chance that artificial
chemicals like many commonly used drugs might
interfere with the complex pathomechanisms
outlined by the UTAD, thereby increasing AD risk.
AD prevention strategy
The UTAD provided a framework for the understand-
ing that cognitive decline and Alzheimer’s (like any
other culture-born) disease depend largely on modifi-
able risk factors. The top part of Fig. 3 schematically
depicts the key areas where behavioural deficits can
lead an increased AD risk. As indicated by the green
lines, different behaviours impact AHN and other key
physiological functions that are required for long-term
brain health. But as predicted by the LOM, not a single
one can completely replace or compensate for another
that is lacking (although there might be some func-
tional overlap between physical and intense social, i.e.
oxytocin-inducing activities in respect to stimulating
AHN). The essentiality of each factor in biological pro-
cesses explains, why intervention trials that focus only
on one aspect like physical activity [263] or solely on
supplementation with n-3 PUFAs [543] lower AD risk
only minimally or not at all.
One of the most comprehensive experiment in chan-
ging the lifestyle of an elderly population is the Finnish
Geriatric Intervention Study to Prevent Cognitive Im-
pairment (FINGER) [17]. The participants of the inter-
vention group received dietary guidance and cognitive
training and engaged in a social and physical activity
program, whereas the control group received solely
general health advise. According to the authors of the
study, comprehensive outcome measurements sug-
gested beneficial effects on both global cognition and
cognitive domains highly relevant for everyday activities
(e.g., executive functioning, processing speed, and com-
plex memory tasks). Nevertheless, according to the pro-
posed UTAD, even FINGER does not take into account
a couple of important requirements for long-term brain
health. According to the specifics of FINGER (http://
www.alzheimersprevention.org/downloadables/FINGER
-study-report-by-ARPF.pdf ), it entailed for instance no
specific program for stress-reduction or improving
sleep quality, no instructions regarding the benefit of
IMF or ketogenesis, and no monitoring (and therefore
correction) of potential vitamin deficiencies (e.g. no
homocysteine measurement). According to the recent
study results, even the recommended daily dose of
400–800 units vitamin D is most likely is not sufficient
to prevent AD [339]. In addition, no monitoring and
correction of potential deficiency in essential trace ele-
ments was implemented.
But according to the UTAD, a program efficient in
preventing cognitive decline needs to be individualized
and comprehensive. It requires besides standard med-
ical checkups a complete measurement of vitamins,
essential trace elements as well as an analysis for the
potential accumulation of environmental toxins out-
lined above. In case of high blood levels with toxic
metals, ALA-treatment as an intervention-measure is
advised. If, after a change in lifestyle, deficits remain
(e.g., too low selenium concentrations in food produced
in European countries caused by low amounts of selen-
ium in the soil, or low vitamin D production in the skin
when people live far in the north or in winter when
simply not sufficient ultraviolet light reaches the skin
[544], or insufficient lithium intake due to low concen-
tration in tap water), specific dietary supplementation
becomes an important part of a prevention strategy.
Causal AD therapy
The pathogenesis of AD is progressive and therapeutic
intervention should start as early as possible. AD ad-
vanced in stages from stage 1 or subjective cognitive de-
cline (SCD) (for a detailed classification, see [545]), to
stage 2 or MCI [546], to stage 3 or mild/early AD; stage
4 or middle/moderate AD, to stage 5 or late/severe AD.
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A causal therapy according to the UTAD aims to elim-
inate all causal factors, identical to the AD prevention
scheme outlined above. Due to the behavioural impair-
ment of AHN, patients will present either with overt
depression or at least exhibit cortisol hypersecretion.
Therefore the cortisol status needs to be analyzed as
well and regularly monitored during the therapy. Be-
sides a guided return to a healthy lifestyle, the thera-
peutic regimen aims at interrupting the vicious cycles
outlined above, which maintain and even accelerate the
disease process. Once this is established, at least pa-
tients in stage 1 to stage 3 might fully recover episodic
memory capability, as up to these early stages of AD,
episodic memory deficits prevail and the patients do
not yet suffer from AD-driven cognitive decline. This
assumption is in line with the results from a recent
study conducted by Dale Bredesen where 8 of the 10
patients that represented with stage 1 (3 patients),
stage 2 (2 patients) and stage 3 (3 patients) recovered
their episodic memory after adhering to a similar
therapeutic scheme as it results from the UTAD (see
below) [547]. The single stage 4 patient maintained his
status and the one stage 5 patient was not treatable. As
these results are rather case-based, they require con-
firmation by larger trials. But the success following the
removal of individual deficits is fully in line with the
UTAD proposed in this paper and its resulting implica-
tions for prevention and therapy. Similar improve-
ments in cognition and episodic memory function in
particular are meanwhile observed in the first three
stage 3 AD-patients in a private practice (personal
communication by W. Karner & B. Karner, Freiburg,
Fig. 3 “A systems biological program for prevention and therapy of AD”. In order to support our genetic programs’ “interest” in maintaining
lifelong mental health, the primary measures to prevent AD consist of a rich social life, daily new challenges which provide eustress and
memorable experiences, physical activity and sufficient deep sleep, and adequate amounts of essential nutrients. As indicated by the green
lines (and outlined in the main text), each of these measures have positive impacts, directly or indirectly, on key physiological systems or
processes required for the preservation of mental health. In the case of an AD-diagnosis, these systems are not only compromised but, as
outlined in Fig. 2 and detailed in the main text, lead to runaway phenomena. Hence, in addition to the implementation of the preventive
measures and the correction of lifestyle-caused deficiencies, the proposed therapeutic interventions consist of a systemic combination of
active components that were shown to interrupt the various vicious cycles that drive and accelerate the AD process. Each one was selected
by its ability to interfere with a particular key pathophysiological process. But as indicated by the red lines and as outlined in detail in the
main text, all of the suggested active components help to reactivate a variety of functions that are disturbed by the AD process
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Germany), which have started to implemented the
treatment plan outlined herein.
I estimate that the therapeutic program takes about
6 months to complete. The calculation is based on sev-
eral assumptions: First, it takes several weeks to imple-
ment the lifestyle changes, particularly if the unhealthy
lifestyle is very comprehensive and deeply engrained.
Second, AHN, once reactivated, requires several months
to fully integrate new, adult-born DG-neurons. Further-
more, the timeframe is not much different from major
depression treatment, where similarly an unproductive
AHN needs to be targeted. In addition, in Bredesen’s
pilot study, most patients were reported to show signifi-
cant improvements and reversal of cognitive decline)
after about 4–6 months. Similar observations are now
being made in Freiburg, Germany (personal communica-
tion by W. Karner & B. Karner).
Besides reinitiating a productive AHN, the proposed
therapy aims to reactivate the neuronal rejuvenation
program and to interrupt the vicious cycles of AD that
have been outlined above and are shown in Fig. 2. Fur-
thermore, any lingering or overt infection should be
treated, which includes dental care and treatment with
probiotics to improve microbiome composition in order
to reduce the acceleration of the AD process (see above).
In addition to the individual preventive measures out-
lined above (upper part of Fig. 3), the following thera-
peutic measures are suggested (bottom part of Fig. 3):
Hypericum perforatum extract (HPE)
As proposed by the UTAD, cortisol hypersecretion due
to impaired AHN is a major link in the causal chain
leading to AD. It not only drives the disease process, it
also might reduce the patient’s compliance with the re-
quired therapeutic measures, in particular the openness
and adherence to lifestyle changes. One way to over-
come this depression-like predicament could be treat-
ment with standard antidepressants like the SSRI-class,
as they are also known to increase AHN as a key mech-
anism of action [548]. For example, one study showed
that maturation and functional properties of young
neurons are necessary for the anxiolytic/antidepressant
activity of the chronically administered SSRI-type drug
fluoxetine and thus explained the well-known delayed
onset of therapeutic efficacy [549]. In another study, an
SSRI-type antidepressant significantly reduced Aβ pro-
duction in transgenic AD mice as well as in healthy
humans [550]. In contrast to the slow process of hippo-
campal neurogenesis, the mechanism regulating Aβ
production was found to be much faster. Apparently,
stimulation of serotonin receptors quickly activates the
extracellular-signal regulated kinase (ERK) signalling
cascade, which was shown to be required for serotonin-
dependent suppression of Aβ [551]. Activation of ERK
signalling by an SSRI-type antidepressant increases
non-amylogenic α-secretase activity [552] and reduces γ-
secretase activity [553], both leading to lower Aβ levels.
An alternative to an SSRI-type antidepressant are ex-
tracts from Hypericum perforatum (HPE), which is also
known as St. John’s wort. Based on a large meta-analysis
of 29 clinical trials, a report of the Centre for Comple-
mentary Medicine Research in Munich, Germany, came
to the following conclusion [554]: The available evidence
suggests that HPE tested in the included trials a) are su-
perior to placebo in patients with major depression; b)
are similarly effective as standard antidepressants; c) and
have fewer side effects than standard antidepressants.
Meanwhile, the German S3 patient care guideline for
unipolar depression published in 2015 regarded the
evidence-based effect of 900 mg HPE as therapeutically
equivalent to the lead SSRI Citalopram (20 mg/d) for the
treatment of moderate major depression (http://www.lei-
tlinien.de/mdb/downloads/nvl/depression/depression-2aufl
-vers3-lang.pdf), whereby HPE is characterised by a
superior tolerability. Similarly, another meta-analysis
concluded that HPE does not differ from SSRIs by its
efficacy but by its advantage in the management of
major depressive disorder and by its higher patient
compliance due to less adverse events [555].
HPE has many anti-AD-specific effects: (1) HPE effi-
ciently reverses the anxiety/depressive-like state due
to chronic corticosterone treatment [554]; (2) counter-
acts the reduced proliferation of progenitor cells in
the murine hippocampus under chronic corticosterone
treatment; (3) decreases the corticosterone-induced
prevention in hippocampal stem cell proliferation in
long-term; (4) and ameliorates corticosterone-reduced
spine density (5). Tetrahydrohyperforin (THH), a syn-
thetic derivative of hyperforin, one biologically potent
constituent of HPE, (6) activates AHN both in wild-
type mice and AD models [556]. (7) HPE treatment
significantly decreases intracerebral Aβ42 levels (8),
rescues neocortical neurons from toxic Aβ, (9) restores
cognition to normal levels, and (10) and activates micro-
glia in vitro and in vivo [557]. Mechanistically, the re-
duction of soluble Aβ42 species was shown to be a
consequence of increased activity of the ABCC1-
transporter, a member of the superfamily of ATP-
binding cassette (ABC) transporters located in the BBB,
which were found to play a fundamental role in Aβ ex-
cretion into the bloodstream. Likewise, HPE treatment
reduced Aβ-accumulation in a double transgenic AD-
model by activating ABCB1, another ABC transporter
involved in Aβ export [558]. (11) In addition, THH was
found to inhibit the amylogenic processing of APP
[559]. By this mode of action, (12) THH prevented tau
phosphorylation and synaptotoxicity in a murine AD
model [560]. (13) And last but not least, mice treated
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with HPE showed increased levels of adiponectin in
white adipose tissue and an insulin-sensitizing effect
[561].
Taken together and as shown in Fig. 3 (red lines), HPE
acts against multiple AD specific processes and vicious
cycles. Nevertheless, although HPE is generally safe and
in the USA even available without prescription, it should
only be taken under the guidance of an experienced
physician, as HPE is known for its significant induction
of the detoxifying liver enzyme CYP 3A4 [562]. The
therapeutic administration of a standard dose of about
1 g per day HPE may therefore result in diminished clin-
ical effectiveness and increased dosage requirements for
all CYP 3A4 substrates, which represent at least 50 % of
all commercially available medications.
α-lipoic acid (ALA)
ALA is an enzymatic cofactor, which is essential for aer-
obic mitochondrial energy production [563]. Though de
novo synthesis in all animal cells appears to supply all
the necessary ALA needed for its role in intermediary
metabolism, ALA can also be efficiently absorbed from
the diet. Only the (R)-(+)-enantiomer exists in nature
and is superior in its biological activity [564]. The (S)-
(−)-enantiomer as a by-product in chemical synthesis
and many over-the-counter ALA-products might even
block important biological activities of the natural form,
like for instance ALA ability to reduce insulin resistance
[565]. Hence when I further discuss ALA, I refer to the
(R)-(+)-enantiomer.
Dietary ALA is safe in moderate doses and elicits a
surprising array of metabolic and clinical effects that
are of high interest in treating AD and related demen-
tias (for review see [566]): (1) ALA and its reduced
form dihydrolipoic acid (DHLA), which readily forms
in the human organism, are highly efficient in chelating
redox-active transition metals that might accelerate the
AD process, as outlined above. Elimination of stock-
piled toxins from the body by ALA may diminish their
adverse impact on human biology and allow restoration
of physiological function (for review see [567]). Import-
antly, neither ALA nor DHLA is capable of removing
iron from aconites or copper from superoxide dismut-
ase, implying that ALA supplementation modulates
only the labile pool of redox active transition metals
without causing metal depletion [568]. (2) Both ALA
and DHLA are ideal antioxidants because they can eas-
ily quench radicals, scavenge ROS and lipid peroxida-
tion products and inhibit the formation of hydrogen
peroxide and hydroxyl radicals. For instance, ALA was
shown to reduce glutamate- and oxidant-induced cell
death by decreasing oxidative damage, increasing antioxi-
dant defence and improving mitochondrial function [569].
(3) ALA regenerates other antioxidants, for example by
increasing the level of reduced glutathione. (4) ALA also
induces the enzymes of glutathione synthesis and other
antioxidant protective enzymes. This mode of mitochon-
drial protection attenuates inflammation-induced impair-
ment of AHN [570]. (5) ALA downregulates inflammatory
processes and attenuates the release of free radicals and
cytotoxic cytokines. As mentioned above, (6) ALA sen-
sitizes the insulin receptor pathway [571], which leads
to an increased glucose uptake in aged animals [572].
(7) ALA increases PGC-1α expression and activates a
compromised cerebral blood flow, thereby protecting
against focal ischemia [573]. Stimulating mitochondrial
biogenesis is one of the important mechanisms for
ALA to ameliorate cognitive dysfunction in aging and
AD [574]. By activating PGC-1α, the effects of ALA are
not organelle-limited, but reside on the functional and
effective coordination of mitochondria-cytosol-nucleus
communication that restores age-associated impair-
ment of brain energy metabolism [572]. This might ex-
plain why ALA treatment in a stroke model was
recently shown to be neuro-restorative and promoting
functional recovery [575]. (8) ALA protects neurons
from harmful effects of oligomeric Aβ, excess iron and
other neurotoxins [576]. (9) ALA was also shown to
stabilize the BBB [577]. Last but not least, (10) ALA in-
creases acetylcholine (ACh) production, known to be
reduced in AD brains [578].
This is of particular interest, as a recent study eluci-
dated that endogenous ACh-signalling through α7-
containing nicotinic receptors (α7-nAChRs) promotes
maturation and integration of adult-born DG-neurons
in the hippocampus. It indicates a profound role for the
ACH/alpha7-nAChRs-system in AHN and conversely
shows that α7-nAChR loss will cause progressive im-
pairment in hippocampal circuitry and function over
time as fewer neurons are added to the DG and those
that are added integrate to a lesser extent [579]. In fact,
increased release of ACh in the hippocampus due to
physical activity might contribute to the stimulatory ef-
fect of exercise on AHN [580]. Hence physiological
and/or pharmacological cholinergic stimulation(s) ame-
liorates cognitive decline even in aged animals, most
likely by supporting AHN. By activation of choline ace-
tyltransferase [581], ALA raises brain ACH-levels and
thereby as well supports AHN. As summarized by Holm-
quist et al. [566]: ALA provides a prime rationale for
symptomatic improvement of cholinergic cognitive dys-
function via stimulation of the ACh synthesis pathway.
One should be aware of the fact that ALA’s mode of
action is much different from acetylcholinesterase inhib-
itors (AChEI) like donecepil [582], which raises ACH by
inhibiting its degradation. This might explain ALA’s
comparably much lower unwanted side effect profile.
Due to the multiple additional functionalities (i.e., anti-
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inflammatory, antioxidant, carbonyl scavenging, metal-
chelating, pro-energetic and neuroprotective properties)
treatment with ALA promises to slow down the progres-
sion of AD. This is in contrast to AChEI in MCI, which,
according to systematic review of randomised controlled
trials was not associated with any delay in the onset of
AD or dementia. Moreover, the safety profile showed,
that the risks associated with AChEIs are not negligible
[583]. Another, more recent meta-analyses conducted in
2015 provided evidence that treatment of MCI with
AChEIs provides no benefit when compared with a con-
trol group. A small cognitive benefit was observed using
behavioural therapies when compared with the control
group, which might be used justify their current use.
However, the authors conclude that the clinical signifi-
cance of this small benefit remains uncertain and that
current evidence does not support the use of AChEIs for
treating MCI [584].
Treatment with 600 mg ALA daily improved MMSE
scores in mild to moderate AD patients particularly if
there was a comorbidity with type-2-diabetes [585],
perhaps due to the additional capability of ALA of im-
proving insulin sensitivity. In a study over 48 months,
600 mg ALA daily stabilized the cognitive functions in
patients with mild dementia, with the disease progres-
sing extremely slowly (MMSE: −0.6 points/year) [586].
Also in patients with moderate dementia, the rate of
progression was dramatically lower than data reported
for untreated patients or patients on AChEIs in the sec-
ond year. Hence they conclude that despite the fact that
their study was not double-blinded, placebo-controlled
and randomized, treatment with ALA might be a prom-
ising “neuroprotective” therapy option for AD. Import-
antly, one has again to be aware that all these studies
were carried out under the deficiency conditions, dis-
cussed above. Embedded in a therapeutic scheme that
entails the preventive measures outlined in this review,
the effect might be even better than merely stabilizing
cognitive decline.
Although ALA is available as an over-the-counter nu-
tritional supplement in many countries, most prepara-
tions contain the two possible enantiomers (R)-(+)-lipoic
acid and (S)-(−)-lipoic acid as a racemic mixture. Pa-
tients should only be given (R)-(+)-lipoic acid under the
supervision of an experienced physician, due to ALAs
insulin-sensitizing ability. In this respect it is important
to note that metal chelators like ALA might interfere
with vitamin B12’s uptake mechanism from the GI tract
[587]. Although this has not directly been shown for
ALA, vitamin B12 should be monitored during long-
term treatment since its deficiency might offset the ben-
efits of ALA. Similarly, high doses of ALA might lead to
a biotin deficiency, which requires for patients under
ALA treatment to be supplemented with biotin [588].
Nevertheless, ALA in daily dosage of 600 mg is a safe
multimodal drug for the treatment of AD particularly
when applied under a comprehensive therapeutic plan.
Extracts of Ginkgo biloba leaves (EGbs)
As outlined above, a disturbed microcirculation might
be cause and effect of AD, forming a vicious circle be-
tween these two disease processes. Hence EGbs’ ability
(1) to increase microcirculation and (2) to significantly
improve the radical scavenging capacity even in elderly
patients is of great therapeutic utility in AD [589].
These effects might be attributed to a multitude of po-
tent pharmacologically active ingredients. For example,
the standardized EGb-761 contains approximately 24 %
flavonoid glycosides (for instance quercetin, kaemp-
ferol, isorhamnetin), 6 % terpenoids (of which 3.1 % are
ginkgolides A, B, C, and J and 2.9 % is bilobalide), and
5–10 % organic acids (for review see [590]). Each of its
constituents has different effects on the pathological
mechanisms of AD (for review see [591]): In addition
to the two effects mentioned above, (3) EGb-761 is able
to reduce Aβ42-induced cell apoptosis [592], (4) Aβ-
toxicity [593] and even (5) Aβ-production [594]; (6)
EGbs positively modulate tau-metabolism [595]; (7) re-
duce oxidative stress and improve mitochondrial respir-
ation. Particularly flavonoids, bilobalide and some of
the ginkgolides (B and J) show a high neuroprotective
capacity (for review see [596]). In diet-induced obese
rats, (8) EGbs improve insulin signalling, dyslipidemia,
and body adiposity, hence support dysfunctional energy
metabolism [597]; (9) EGb-761 protected in ovariecto-
mized rats as models of post-menopause against the de-
crease of cytochrome c oxidase activity, mitochondrial
adenosine-5′-triphosphate and glutathione content in
both platelets and the hippocampus, suggesting its po-
tential role as a protective agent against central neurode-
generation in post-menopausal women [598]; (10) EGbs
applied in a colitis-model dose-dependently inhibited the
upregulation of TNF-α and IL-6, both inflammatory cyto-
kines are involved in neuroinflammation [599]; (11) Last
but not least, EGbs treatment showed a beneficial role on
AHN even in aged mice with a significant increase in new-
born DG-neurons with well-developed tertiary dendrites
compared to controls [600].
Two recent meta-analyses concluded that treatment
with EGb-761 at 240 mg/day over half a year stabilizes
or slows decline in cognition, function, behaviour, and
global change in cognitive impairment and dementia
[601, 602]. Consequently, in January 2016, a group of
AD experts presented the German S3 patient care
guideline for dementia, where for the first time the use of
EGBs (specifically EGb-761) was suggested for the treatment
of patients with mild to moderate AD (http://www.dgn.org/
images/red_leitlinien/LL_2016/PDFs_Download/038013_
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 34 of 52
LL_Demenzen_2016.pdf ). However, caution should be
taken, when combining EGb with medicines metabo-
lized by CYP3A4, as EGbs induce the expression of the
gene [603].
Taken together, EGbs’ multiple modes of action rele-
vant for AD, their potential to interrupt vicious cycles
that are already active in the early phase of AD patho-
genesis, and the fact, that EGbs like EGb-761 are gener-
ally very well tolerated at dosages of up to 240 mg/day
even in aged patients taking multiple medications, ren-
ders them useful in a systemic therapeutic scheme as
outlined in Fig. 3.
Pyrroloquinoline quinone (PQQ)
PQQ was first discovered as a bacterial redox cofactor
[604]. Since PQQ is also a potent plant growth factor, it
is also part in the animal food chain. PQQ is reported
to participate in a range of biological functions with ap-
parent survival benefits (for example, improved neo-
natal growth and reproductive performance) [605].
There are also benefits from PQQ supplementation re-
lated to cognitive, immune, and antioxidant functions,
as well as protection from cardiac and neurological is-
chemic events (for review see [606]). For instance, mice
deprived of PQQ by a chemically defined diet show
functional defects in connective tissue metabolism, are
growth retarded and infertile [607], which suggests that
PQQ plays a fundamental role as a growth factor.
PQQ-deficient animals also show low cellular mito-
chondrial content, which is reversed when as little as
200–300 μg of PQQ/kg of diet are added [608]. Due to
its nutritional importance, its inherent free-radical
scavenging and redox modulator properties, and its co-
enzyme function in mammalian tissue [609], PQQ was
proposed as a potential new B-vitamin [610]. Since
PQQ showed neuroprotective effects in a cerebral is-
chemia model [611], it attracted pharmacological inter-
est for the treatment of neurodegenerative diseases.
Surprisingly, PQQ was found to inhibit the neurotoxic
oligomerization of α-Synuclein, a causative link in the
chain of events leading to Parkinson’s disease [612].
The anti-fibril-forming function of PQQ was soon ex-
tended to mouse prion protein and Aβ-42 [613]. More-
over, PQQ was shown to protect neuronal cells against
Aβ-induced neurotoxicity [614].
Since diseases like AD are associated with mitochon-
drial dysfunction, PQQ supplementation may be of
additional benefit since it efficiently stimulates mito-
chondrogenesis via activation of both, cAMP response
element-binding protein (CREB) and PGC-1α [615]. As
part of the proposed therapeutic scheme for AD, PQQ-
supplementation would support the above outlined
AD-preventing measures, namely IMF and physical ac-
tivity, in activating mitochondrial biogenesis and NRJ.
Indeed, dietary PQQ was shown to alter indicators of
inflammation and mitochondrial-related metabolism in
human subjects [616]. Furthermore, in a small clinical
trial, 20 mg of PQQ daily for 8 weeks was shown to
improve significantly measures of vigour, fatigue,
tension-anxiety, depression, anger-hostility and confu-
sion, as well as those for quality of life, appetite, sleep,
obsession and pain [617]. In a double-blind, placebo-
controlled comparative study, the mental status of
middle-aged and elderly persons consuming foods
containing PQQ for 12 weeks enhanced some of high-
level cerebral functions including attention and dis-
criminating and processing abilities [618]. Particularly
in combination with microdosed lithium, PQQ might
exert useful therapeutic effects in AD (see below).
Lithium
As schematically shown in Fig. 3 and discussed above,
daily intake of low amounts of lithium is an important
preventive measure for maintaining brain health. Due to
the interference of lithium in several self-maintaining
signalling pathways in AD, daily intake of microdosed
lithium (at least 300 μg with lithium-containing drinking
water) is also of high therapeutic relevance: Lithium re-
duces toxic Aβ and p-tau generation, positively impacts
mitochondrial rejuvenation and thereby energy metab-
olism. In addition, it appears to be important for pro-
ductive AHN. Interestingly and in line with the
therapeutic proposal in this work, Lazzara and Kim re-
cently commented on the multimodal activity and
therapeutic potential of lithium in neurodegenerative
diseases [369]. They pointed out that high-dose
lithium-only treatment may not be a suitable thera-
peutic option for neurodegenerative diseases due to
inconsistent efficacy and potential side-effects. But
low-dose lithium in combination with other potential
or existing therapeutic compounds may be a promis-
ing approach to reduce symptoms and disease pro-
gression in neurodegenerative diseases.
Indeed, evidence for a powerful synergistic effect of
low-dose lithium and PQQ supplementation was re-
cently shown in a murine double transgenic AD model.
The results showed that the combination at relative low
dose exhibited more powerful effects in restoring im-
paired learning and memory, facilitating hippocampal
LTP, and reducing cerebral Aβ deposition and p-tau level
when compared to lithium alone. According to the au-
thors, their study demonstrated the efficacy of a novel
AD therapeutic strategy in targeting multiple disease-
causing mechanisms through the synergistic effects of
microdose lithium and PQQ [619].
Similarly, according to the UTAD the daily intake of
sufficient amounts of essential trace elements like sel-
enium and zinc, essential n-3 PUFAs DHA and EPA,
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vitamins etc. as part of a healthy diet is part of the
therapeutic scheme. Nevertheless, in the initial phase of
the therapy, all potential deficits need to be evaluated
and treated immediately by supplementation until a
change in diet eliminates the occurrence of those
deficits.
Summary and discussion
Over 50 thousand AD researchers worldwide continue
to build an ever-growing amount of scientific data, each
one being another piece of an unsolved puzzle. It ap-
pears that analytically dividing the puzzle in evermore
pieces does not bring us closer to a complete picture. In
order to find a path through the wealth of data and con-
tradicting hypotheses, I made a basic assumption: I took
for granted that the evolutionary theory is correct and
therefore should serve as a firm foundation as well as a
guide to reconcile conflicting interpretations. And in-
deed, the interpretation of AD as a modern epidemic
started to make sense from this perspective and led to
the UTAD, which delivers a logical explanation for the
behavioural causes of AD, all known risk factors as well
as an understanding of how AD might be overcome.
Nevertheless, the search term “Alzheimer” retrieved far
more than 80 thousand publications at the National
Centre for Biotechnology Information (NCBI). It was
therefore impossible to check each one for consistency
with the herewith proposed UTAD as a behavioural defi-
ciency disease. It was not even possible to discuss each
one that I have studied. But whenever I found discrepan-
cies, they were either explained by the design of the
study or the (mis) interpretation of the results. Very
often, these were a consequence of the false assumption
that correlation equals causality, or normality equals nat-
uralness (for instance, that aging of animals kept under
unnatural conditions reflects natural aging or a natural
course of AD; the same goes for human intervention or
epidemiological studies).
The UTAD explains the evolutionary logic that led to
human’s exceptional longevity and why our genetic pro-
gram should protect us from ailments like AD or other
mind-incapacitating diseases. This program like any
other works best under the conditions to which it was
tailored. Since modernization changed our way of living
faster than our genetic program could adapt to it, and
because productive AHN is particularly vulnerable to
many culture-born deficiencies, the LOM as an import-
ant part of the UTAD easily explains why AD can be
caused by a multitude of different individual deficiencies.
Furthermore, the UTAD helps to understand the current
epidemic of AD (as well as of major depression) in mod-
ern societies and the steady rise of its incidence and
prevalence rates in emerging economies, which parallels
the economic growth rate. But it also explains, why
intervention trials in AD often fail or show only limited
success. Instead of correcting all individual disease-
causing deficits in their intervention group, they offer
one for all solutions with a limited set of corrective mea-
sures. It is not surprising that usually no or only mar-
ginal success can be reported [16], since only those few
individuals in an intervention group will benefit from
the correction of a deficit who suffer from this (and only
this!) particular deficit. If we want to win the fight
against dementia, only an aggressive correction of all (!)
individual risk factors (deficiencies) might, according to
the UTAD, turn out to be a successful strategy.
In 2006, Brinton and Wang discussed that the causes
of age-associated decline in AHN remain to be fully
determined, but that loss in growth factors like FGF-2,
IGF-1 and VEGF, in the microenvironment of the sub-
granular zone (SGZ) are prime contributors to the re-
duced neurogenic potential hypothesis [620]. What
they were not aware of is that the neurogenic potential
even at higher age is still there, following the results
from a landmark study published in 2013 [150]. Proof
of the persistence of the neurogenic potential up to
higher age is even provided by analysis of post-
mortem brains in late-stage AD [621]. Interestingly,
some argue that this observed upregulation in AD-
brains is evidence against the assumption that disease-
related loss of AHN might be a key causal contributor
to cognitive impairment in AD [622]. Hence, reactiva-
tion of AHN by removing AHN-impairing behavioural
deficits, as proposed in this review, might not be a
therapeutic option. But is this a valid objection? There
is general consensus in the field that the generation of
fully mature and functional neurons is impaired in AD
[623], although both increases, decreases, no changes,
and changes dependent on the stage of the disease
have been described in AD patients and animal models
(for review see [624]). Indeed, Aβ signalling through
p-tau drives ectopic neuronal cell cycle re-entry in
AD, causing neurodegeneration of the hippocampus
by aberrant and non-productive neurogenesis [625].
As was shown, the resulting increase in proliferation
of neural progenitor cells (NPCs) does neither in-
crease the number of migratory neuroblasts nor that
of differentiated neurons [626]. All these pathogenic ef-
fects are most likely attributed to the AHN-inhibiting neu-
roinflammatory microenvironment prevailing in AD, as
well as an unchanged lifestyle that continues to de-
prive the hippocampus from behavioural stimuli and
essential nutrients required for a productive AHN. For
instance, the unproductive proliferation of NPC in AD
might also be driven by the combined action of immu-
nomodulators particularly acting in the late stage of
the disease, like for instance transforming growth fac-
tor β1 (TGFβ1).
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TGFβ1-signalling under physiological conditions pro-
tects neurons from potential Aβ-toxicity [627] and
enhances AHN [628], primarily by upregulating the
proliferation of NPCs and promoting the survival of
newly generated neurons by supporting their functional
differentiation, while, at the same time, maintaining the
neurogenic stem cells (NSC) in a quiescent stage [629].
In contrast, under pathological conditions like chronic
neuroinflammation (caused by the multiple behavioural
deficiencies, as has been discussed above), chronically
elevated levels of TGFβ1 contribute to disease progres-
sion [630, 631]. For example, chronic exposure to TGFβ
lengthens the G1 phase of the cell cycle in activated
stem cells, thereby impairing cell cycle progression of
neural progenitors [632]. At the same time, high corti-
sol and toxic levels of Aβ and many other pathogenetic
effects due to inflammation harm the maturation and
integration of the adult-born neurons in the DG-
network.
The assumption that AHN could be of great thera-
peutic potential is not new and raised the hope that
transplanting NSC might one day cure AD [68, 633].
The optimism generated a flurry of studies in which the
effects of stem cell transplantation on cognitive decline
in animal models of AD were investigated [634]. Some
experiments provided the unexpected evidence that pro-
liferating stem cells injected in the murine hippocampus
even ameliorated Aβ-induced neurotoxicity and cogni-
tive decline by inhibiting apoptotic cell death and oxida-
tive stress [635]. While this was certainly encouraging
news, one fundamental question remains: Why would
we want to inject exogenous NSC in the hippocampus,
if patients, at least in the early stages of AD, could bene-
fit from reactivated “endogenous” AHN in the subventri-
cular zone of the hippocampus? Of course, since AHN is
restricted to the formation of mostly granule cells and
some interneurons in the DG [205], activation of pro-
ductive AHN by lifestyle intervention in already heavily
compromised late stage of AD-patients is less likely to
be disease modifying (large parts of the brain being irre-
versibly affected) and practically difficult (compliance
compromised). This is the main reason why I am argu-
ing for early diagnosis.
Meanwhile, more and more experts in the field de-
mand pleiotropic interventions to prevent or even cure
AD [636, 637]. They realize that monotherapy targeting
early single steps in the complicated cascade with
agents that solely inhibit production, clearance, or ag-
gregation of Aβ is not sufficient. But without a UTAD,
as I propose it in this review, their arguments are less
convincing to a research community, where the major-
ity is still driven by the hope of finding the “magic bullet”,
a therapy that does not require any changes in lifestyle. In
particular, since most proposals for intervention lack a
comprehensive explanation for all the complex processes
that run more or less simultaneously in AD, the question
which molecular targets and/or behavioural deficits need
to be addressed and what therapeutic interventions are re-
quired has so far been answered rather arbitrarily. But this
is detrimental, as every researcher usually favours his or
her own concept of AD, which leads to many conflicting
hypotheses. So, the public receives a steady flow of infor-
mation about the pros and cons of such partial explana-
tions, which (in line with the LOM) might never be the
basis for fully preventing or curing AD.
Fighting AD does not mean fighting human nature.
Claiming that AD is mainly and fatally caused by aging
per se unjustifiably frightens the public. Furthermore,
who would be willing to change his way of living if re-
searchers belittle the effects. Therefore we should ra-
ther encourage a change to a healthy lifestyle and offer
early diagnostic services in order to correct AD-causing
deficiencies as early as possible.
Conclusion
The proposed Unified Theory of Alzheimer’s Disease
(UTAD) defines AD as a behavioural deficiency disease,
emanating from a discrepancy between the natural re-
quirements, which are explained by long-lasting humans
natural life history, and our modern lifestyle, which is
explained by humans’ very recent cultural (technological,
social and economic) history. These deficiencies inter-
fere with neuronal rejuvenation and adult hippocampal
neurogenesis, both being required to maintain mental
health, as well as with many other physiological pro-
cesses and systems, which aggravate and accelerate
mental decline. The UTAD provides an encompassing
explanation of how the multiple well-known risk fac-
tors (including environmental and genetic) interact to
cause AD and clarifies their impact on the aetiology
and pathogenesis of AD. Furthermore, the UTAD makes
clear why prevention strategies based on the correction of
only one or a few risk factors fail or show only limited suc-
cess, and similarly, why treatment strategies, which ignore
the primary pathological causes and their correction
might continue to be ineffective. Conversely, the UTAD
argues for a systemic biological approach based on the law
of the minimum governing essential processes required
for lifelong mental health in order to prevent sporadic
AD with high probability. In addition, the logical
framework provided by the UTAD allows the develop-
ment of a curative regimen, which is based on the indi-
vidualized correction of detrimental deficits and a
multi-pronged, systems-biological approach with the
aim to interrupt key pathological processes in AD.
Hence this review based on my theoretical findings ar-
gues that current prevention strategies need to be
reconsidered and fundamentally changed. Furthermore,
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monotherapeutic treatment strategies that ignore the
primary causes and deficiencies should be replaced by
a systems-biological approach that is to be initiated as
early as possible in the course of disease aiming at elimin-
ating all disease-causing factors in order to give the pa-
tient a fighting chance to reverse cognitive decline.
Abbreviations
AA, arachidonic acid; Aβ, amyloid beta; AcAc, acetoacetate; ACh, acetylcholine;
AChEI, acetylcholinesterase inhibitor; ACTH, adrenocorticotropic hormone; AD,
Alzheimer’s Disease; AGEs, advanced glycation end products; AHN, adult
hippocampal neurogenesis; ALA, α-lipoic acid; alpha7-nAChRs, alpha7-
containing nicotinic receptors; ALS, amyotrophic lateral sclerosis; BBB,
blood brain barrier; BDNF, brain-derived neurotrophic factor; βOHB,
D-β-hydroxybutyrate; CA, cornu ammonis; CSF, cerebrospinal fluid; CCR,
chronic caloric restriction; CR, corticosteroid receptor; CRF, corticotropin
releasing factor; DG, dentate gyrus; DHA, docosahexaenoic acid; DHLA,
dihydrolipoic acid; DPA, docosapentaenoic acid; EE, enriched environment;
EGbs, extracts from Ginkgo biloba leaves; EPA, eicosapentaenoic acid; EPO,
erythropoietin; ERK, extracellular-signal regulated kinase; FDG-PET/CT,
2-deoxy-2-[fluorine-18] fluoro- D-glucose integrated with computed
tomography; FGF-2, fibroblast growth factor 2; GDNF, glial cell-derived
neurotrophic factor; GH, growth hormone; GMH, grandmother hypothesis;
GSK-3α, glycogen synthase kinase-3α; GSK-3β, glycogen synthase kinase-3β; HC,
hippocampus complex; HCAR2, hydroxycarboxylic acid receptor 2; HDAC,
histone deacetylases; HMIT, hippocampal memory index theory; HPA axis,
hypothalamic–pituitary–adrenal axis; HPE, Hypericum perforatum extract;
IGF-1, insulin-like growth factor 1; Il-1, interleukin-1; IL-6, interleukin-6; IMF,
intermittent fasting; LDL, low density lipoprotein; LEC, lateral entorhinal
cortex; LTP, long-term potentiation; LOM, law of the minimum; LRP1, low
density lipoprotein receptor-related protein 1; MCTGs, medium-chain
triglycerides; MEC, medial entorhinal cortex; MeDi, Mediterranean diet;
MeHg, methylmercury; MCI, mild cognitive impairment; MMSE, mini–mental
state examination; MRI, magnetic resonance imaging; mTOR, mammalian target
of rapamycin; NFL, national football league; NGF, nerve growth factor; NPD1,
neuroprotectin D1; NPY, neuropeptide Y; n-3 PUFA, omega-3 polyunsaturated
fatty acid; n-6 PUFA, omega-6 polyunsaturated fatty acid; NRJ, neuronal
rejuvenation; PGC-1α, peroxisome proliferator-activated receptor γ coactivator
1α; PRH, perirhinal cortex; PUFAs, polyunsaturated fatty acids; REM, rapid
eye movement; ROS, reactive oxygen species; SCD, subjective cognitive
decline; SSRI, selective serotonin reuptake inhibitor; SWS, slow-wave sleep;
TFAs, trans fatty acids; THH, Tetrahydrohyperforin; TNF-α, tumour necrosis
factor-alpha; UTAD, unified theory of AD; VEGF, vascular endothelial




The author is an independent researcher and funds himself. There is no
funding body influencing the design of this review, the analysis of the
publicly available data, interpretation of the data and writing the manuscript.
Availability of data and materials
All data (and materials) used in this review are publicly available and
referenced in the “References” section below.
Authors’ contributions
Only Michael Nehls, as the sole author contributed, conceived and wrote the
complete manuscript.
Authors’ information
MN is an independent researcher with a long scientifically successful career
both in academia and industry.
Competing interests
The author is an independent researcher; he declares he has no financial or
non-financial competing interests.
Consent for publication
“Not applicable”, this manuscript does not contain any individual person’s
data in any form (including and individual details, images or videos).
Ethics approval and consent to participate
“Not applicable”, the manuscript does not report on or involve the use of
any animal or human data or tissue.
Received: 4 May 2016 Accepted: 3 July 2016
References
1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress
and problems on the road to therapeutics. Science. 2002;297(5580):353–6. 19.
2. Kawahara M, Kato-Negishi M. Link between aluminum and the
pathogenesis of Alzheimer’s disease: the integration of the aluminum and
amyloid cascade hypotheses. Int J Alzheimers Dis. 2011;2011:276393. doi:10.
4061/2011/276393.
3. Brewer GJ. Alzheimer’s disease causation by copper toxicity and treatment
with zinc. Front Aging Neurosci. 2014;6:92. doi:10.3389/fnagi.2014.00092.
4. Yegambaram M, Manivannan B, Beach TG, Halden RU. Role of
environmental contaminants in the etiology of Alzheimer’s disease: a
review. Curr Alzheimer Res. 2015;12(2):116–46.
5. Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as
drivers of cognitive decline: new experimental models adopting a broader
paradigm in dementia research. Alzheimers Res Ther. 2015;7(1):33. doi:10.
1186/s13195-015-0117-2.
6. Wu Z, Nakanishi H. Connection between periodontitis and Alzheimer’s
disease: possible roles of microglia and leptomeningeal cells. J Pharmacol
Sci. 2014;126(1):8–13.
7. Miklossy J. Alzheimer’s disease - a neurospirochetosis. Analysis of the
evidence following Koch’s and Hill’s criteria. J Neuroinflammation. 2011;8:90.
doi:10.1186/1742-2094-8-90.
8. Hill JM, Lukiw WJ. Microbial-generated amyloids and Alzheimer’s disease
(AD). Front Aging Neurosci. 2015;7:9. doi:10.3389/fnagi.2015.00009.
9. Hölscher C. Diabetes as a risk factor for Alzheimer’s disease: insulin
signalling impairment in the brain as an alternative model of Alzheimer’s
disease. Biochem Soc Trans. 2011;39(4):891–7. doi:10.1042/BST0390891.
10. de la Monte SM, Wands JR. Alzheimer’s disease is type 3 diabetes-evidence
reviewed. J Diabetes Sci Technol. 2008;2(6):1101–13.
11. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al.
Blood–brain barrier breakdown in the aging human hippocampus. Neuron.
2015;85(2):296–302. doi:10.1016/j.neuron.2014.12.032.
12. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide
across the blood–brain barrier: implication for therapies in Alzheimer’s
disease. CNS Neurol Disord Drug Targets. 2009;8(1):16–30.
13. Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines
released from microglia in Alzheimer’s disease. Ann Transl Med. 2015;3(10):
136. doi:10.3978/j.issn.2305-5839.2015.03.49.
14. Talboom JS, Velazquez JS, Salvatore O. The mammalian target of rapamycin
at the crossroad between cognitive aging and Alzheimer’s disease. npj
Aging and Mechanisms of Disease 1. 2015; Article number: 15008. doi:10.
1038/npjamd.2015.8.
15. Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science. 2002;298(5594):
789–91.
16. Korczyn AD. Why have we failed to cure Alzheimer’s disease? J Alzheimers
Dis. 2012;29(2):275–82. doi:10.3233/JAD-2011-110359.
17. Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R,
et al. A 2 year multidomain intervention of diet, exercise, cognitive training,
and vascular risk monitoring versus control to prevent cognitive decline in
at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;
385(9984):2255–63. doi:10.1016/S0140-6736(15)60461-5.
18. Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H. Future directions in
Alzheimer’s disease from risk factors to prevention. Biochem Pharmacol.
2014;88(4):661–70. doi:10.1016/j.bcp.2014.01.003.
19. Perani D, et al. A survey of FDG- and amyloid-PET imaging in dementia and
GRADE analysis. Biomed Res Int. 2014;2014:785039. doi:10.1155/2014/785039.
20. O’Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al.
18 F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy
body dementias. J Nucl Med. 2014;55(12):1959–65. doi:10.2967/jnumed.114.
143347.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 38 of 52
21. Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, et al.
Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and
epidemiological human studies. Acta Neuropathol. 2011;121(5):571–87.
doi:10.1007/s00401-011-0826-y.
22. Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M. The
presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ
deposition in the brain. Acta Neuropathol. 2012;123(1):31–7. doi:10.1007/
s00401-011-0912-1.
23. Gowers WR. A manual of diseases of the nervous system. Philadelphia: P
Blakiston, Son and Co; 1888.
24. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozess der
Hirnrinde. Neurologisches Centralblatt. 1906;23:1129–36.
25. Boyd W. A textbook of pathology: an introduction to medicine, Lea and
febiger. 1938.
26. Grant WB. Trends in diet and Alzheimer’s disease during the nutrition
transition in Japan and developing countries. J Alzheimers Dis. 2014;38(3):
611–20. doi:10.3233/JAD-130719.
27. Islami F. Torre LA1, Jemal A. Global trends of lung cancer mortality and
smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327–38. doi:10.3978/j.
issn.2218-6751.2015.08.04.
28. Rise In Alzheimer’s Disease Incidence Due To Western Diet - October 03,
2013. Asian Scientist Magazine | Science, Technology and Medicine News
Updates From Asia - http://www.asianscientist.com
29. Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST,
Ganguli M. Incidence of Alzheimer’s disease in a rural community in India:
the Indo-US study. Neurology. 2001;57(6):985–9.
30. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global
prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):
2112–7.
31. Ogunniyi A, Baiyewu O, Gureje O, Hall KS, Unverzagt F, Siu SH, et al.
Epidemiology of dementia in Nigeria: results from the Indianapolis-Ibadan
study. Eur J Neurol. 2000;7(5):485–90.
32. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW,
et al. Prevalence of Alzheimer’s disease and dementia in two communities:
Nigerian Africans and African Americans. Am J Psychiatry. 1995;152(10):
1485–92.
33. Graves AB, Rajaram L, Bowen JD, McCormick WC, McCurry SM, Larson EB.
Cognitive decline and Japanese culture in a cohort of older Japanese
Americans in king county, WA: the kame project. J Gerontol B Psychol Sci
Soc Sci. 1999;54(3):S154–61.
34. Martin GM, Kukull WA. Do cultural differences affect Alzheimer disease?
JAMA. 1996;276(12):993–5.
35. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S.
Incidence of dementia over three decades in the Framingham heart study.
N Engl J Med. 2016;374(6):523–32. doi:10.1056/NEJMoa1504327.
36. Wang H, Schumacher AE, Levitz CE, Mokdad AH, Murray CJ. Left behind:
widening disparities for males and females in US county life expectancy,
1985–2010. Popul Health Metr. 2013;11(1):8. doi:10.1186/1478-7954-11-8.
37. Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, Brayne C.
Dementia in Western Europe: epidemiological evidence and implications for
policy making. Lancet Neurol. 2016;15(1):116–24. doi:10.1016/S1474-
4422(15)00092-7.
38. Toth LA, Kregel K, Leon L, Musch TI. Environmental enrichment of
laboratory rodents: the answer depends on the question. Comp Med. 2011;
61(4):314–21.
39. Kempermann G, Gast D, Gage FH. Neuroplasticity in old age: sustained
fivefold induction of hippocampal neurogenesis by long-term
environmental enrichment. Ann Neurol. 2002;52(2):135–43.
40. Simpson J, Kelly JP. The impact of environmental enrichment in laboratory
rats - behavioural and neurochemical aspects. Behav Brain Res. 2011;222(1):
246–64. doi:10.1016/j.bbr.2011.04.002.
41. Frick KM, Stearns NA, Pan JY, Berger-Sweeney J. Effects of environmental
enrichment on spatial memory and neurochemistry in middle-aged mice.
Learn Mem. 2003;10(3):187–98.
42. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al.
Triple-transgenic model of Alzheimer’s disease with plaques and tangles:
intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409–21.
43. Halagappa VK, Guo Z, Pearson M, Matsuoka Y, Cutler RG, Laferla FM,
Mattson MP. Intermittent fasting and caloric restriction ameliorate age-
related behavioral deficits in the triple-transgenic mouse model of
Alzheimer’s disease. Neurobiol Dis. 2007;26(1):212–20.
44. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J.
Risk score for the prediction of dementia risk in 20 years among middle
aged people: a longitudinal, population-based study. Lancet Neurol. 2006;
5(9):735–41.
45. Guskiewicz KM, Marshall SW, Bailes J, McCrea M, Harding Jr HP, Matthews A,
Mihalik JR, Cantu RC. Recurrent concussion and risk of depression in retired
professional football players. Med Sci Sports Exerc. 2007;39(6):903–9.
46. Fralick M, Thiruchelvam D, Tien HC, Redelmeier DA. Risk of suicide after a
concussion. CMAJ. 2016.
47. Lehman EJ. Epidemiology of neurodegeneration in American-style
professional football players. Alzheimers Res Ther. 2013;5(4):34. doi:10.1186/
alzrt188.
48. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein
E controls cerebrovascular integrity via cyclophilin A. Nature. 2012;485(7399):
512–6. doi:10.1038/nature11087.
49. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer’s
disease and other neurological disorders. Lancet Neurol. 2011;10(3):241–52.
doi:10.1016/S1474-4422(10)70325-2.
50. Raichlen DA, Alexander GE. Exercise, APOE genotype, and the evolution of
the human lifespan. Trends Neurosci. 2014;37(5):247–55. doi:10.1016/j.tins.
2014.03.001.
51. Tuminello ER, Han SD. The apolipoprotein e antagonistic pleiotropy
hypothesis: review and recommendations. Int J Alzheimers Dis. 2011;2011:
726197. doi:10.4061/2011/726197.
52. Jasienska G, Ellison PT, Galbarczyk A, Jasienski M, Kalemba-Drozdz M,
Kapiszewska M, et al. Apolipoprotein E (ApoE) polymorphism is related to
differences in potential fertility in women: a case of antagonistic pleiotropy?
Proc Biol Sci. 2015;282(1803):20142395. doi:10.1098/rspb.2014.2395.
53. Mondadori CR, de Quervain DJ, Buchmann A, Mustovic H, Wollmer MA,
Schmidt CF, et al. Better memory and neural efficiency in young
apolipoprotein E epsilon4 carriers. Cereb Cortex. 2007;17(8):1934–47.
54. O’Dwyer L, Lamberton F, Matura S, Tanner C, Scheibe M, Miller J, et al.
Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI
study. PLoS One. 2012;7(11):e48895. doi:10.1371/journal.pone.0048895.
55. Woodard JL, Sugarman MA, Nielson KA, Smith JC, Seidenberg M, Durgerian
S, et al. Lifestyle and genetic contributions to cognitive decline and
hippocampal structure and function in healthy aging. Curr Alzheimer Res.
2012;9(4):436–46.
56. Perna L, Mons U, Rujescu D, Kliegel M, Brenner H. Apolipoprotein E e4 and
Cognitive Function: A Modifiable Association? Results from Two Independent
Cohort Studies. Dement Geriatr Cogn Disord. 2015;41(1–2):35–45.
57. Mosconi L, Murray J, Tsui WH, Li Y, Davies M, Williams S, et al.
Mediterranean Diet and Magnetic Resonance Imaging-Assessed Brain
Atrophy in Cognitively Normal Individuals at Risk for Alzheimer’s Disease. J
Prev Alzheimers Dis. 2014;1(1):23–32.
58. Morris MC, Brockman J, Schneider JA, Wang Y, Bennett DA, Tangney CC,
van de Rest O. Association of seafood consumption, brain mercury level,
and APOE ε4 status with brain neuropathology in older adults. JAMA. 2016;
315(5):489–97. doi:10.1001/jama.2015.19451.
59. Ayton S, Faux NG, Bush AI. Alzheimer’s disease neuroimaging initiative.
Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease
outcomes and are regulated by APOE. Nat Commun. 2015;6:6760. doi:10.
1038/ncomms7760.
60. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small
GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of
Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–3.
61. Lahdenperä M, Lummaa V, Helle S, Tremblay M, Russell AF. Fitness benefits of
prolonged post-reproductive lifespan in women. Nature. 2004;428(6979):178–81.
62. O’connell JF, Hawkes K, Blurton Jones NG. Grandmothering and the
evolution of homo erectus. J Hum Evol. 1999;36(5):461–85.
63. Hawkes K. Colloquium paper: how grandmother effects plus individual
variation in frailty shape fertility and mortality: guidance from human-
chimpanzee comparisons. Proc Natl Acad Sci U S A. 2010;107(2):8977–84.
64. Gurven M, Kaplan H. Longevity among hunter-gatherers: a cross-cultural
examination. Population and Development Review. 2007;33:321–65.
65. Brent LJ, Franks DW, Foster EA, Balcomb KC, Cant MA, Croft DP. Ecological
knowledge, leadership, and the evolution of menopause in killer whales.
Curr Biol. 2015;25(6):746–50. doi:10.1016/j.cub.2015.01.037.
66. Mattson MP. Lifelong brain health is a lifelong challenge: from evolutionary
principles to empirical evidence. Ageing Res Rev. 2015;20:37–45. doi:10.
1016/j.arr.2014.12.011.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 39 of 52
67. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M,
et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders.
Prog Neurobiol. 2014;112:24–49. doi:10.1016/j.pneurobio.2013.10.004.
68. Rodríguez JJ, Verkhratsky A. Neurogenesis in Alzheimer’s disease. J Anat.
2011;219(1):78–89. doi:10.1111/j.1469-7580.2011.01343.x.
69. Kotiadis VN, Duchen MR, Osellame LD. Mitochondrial quality control and
communications with the nucleus are important in maintaining
mitochondrial function and cell health. Biochim Biophys Acta. 2014;1840(4):
1254–65. doi:10.1016/j.bbagen.2013.10.041.
70. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen
species. Mol Cell. 2012;48(2):158–67. doi:10.1016/j.molcel.2012.09.025.
71. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-
inflammation-cell death axis in organismal aging. Science. 2011;333(6046):
1109–12. doi:10.1126/science.1201940.
72. Hamacher-Brady A, Brady NR. Mitophagy programs: mechanisms and
physiological implications of mitochondrial targeting by autophagy. Cell
Mol Life Sci. 2016;73(4):775–95. doi:10.1007/s00018-015-2087-8.
73. Larsen KE, Sulzer D. Autophagy in neurons: a review. Histol Histopathol.
2002;17(3):897–908.
74. Mammucari C, Rizzuto R. Signaling pathways in mitochondrial dysfunction
and aging. Mech Ageing Dev. 2010;131(7–8):536–43. doi:10.1016/j.mad.2010.
07.003.
75. Baloyannis SJ. Mitochondrial alterations in Alzheimer’s disease. J Alzheimers
Dis. 2006;9(2):119–26.
76. Barnett A, Brewer GJ. Autophagy in aging and Alzheimer’s disease:
pathologic or protective? J Alzheimers Dis. 2011;25(3):385–94. doi:10.3233/
JAD-2011-101989.
77. Green DR, Galluzzi L, Kroemer G. Cell biology. Metabolic control of cell
death. Science. 2014;345(6203):1250256. doi:10.1126/science.1250256.
78. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, et al. Nutrient-
dependent mTORC1 association with the ULK1-Atg13-FIP200 complex
required for autophagy. Mol Biol Cell. 2009;20(7):1981–91. doi:10.1091/mbc.
E08-12-1248.
79. Ehninger D. From genes to cognition in tuberous sclerosis: implications for
mTOR inhibitor-based treatment approaches. Neuropharmacology. 2013;68:
97–105. doi:10.1016/j.neuropharm.2012.05.015.
80. Balgi AD, Fonseca BD, Donohue E, Tsang TC, Lajoie P, Proud CG, et al.
Screen for chemical modulators of autophagy reveals novel therapeutic
inhibitors of mTORC1 signaling. PLoS One. 2009;4(9):e7124. doi:10.1371/
journal.pone.0007124.
81. Ehninger D, Neff F, Xie K. Longevity, aging and rapamycin. Cell Mol Life Sci.
2014;71(22):4325–46.
82. Schnyder S, Handschin C. Skeletal muscle as an endocrine organ: PGC-1α,
myokines and exercise. Bone. 2015;80:115–25. doi:10.1016/j.bone.2015.02.008.
83. Lindholm D, Eriksson O, Mäkelä J, Belluardo N, Korhonen L. PGC-1α: a
master gene that is hard to master. Cell Mol Life Sci. 2012;69(15):2465–8.
doi:10.1007/s00018-012-1043-0.
84. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian
target of rapamycin (mTOR) may determine robustness in young male mice
at the cost of accelerated aging. Aging (Albany NY). 2012;4(12):899–916.
85. He C, Sumpter Jr R, Levine B. Exercise induces autophagy in peripheral tissues
and in the brain. Autophagy. 2012;8(10):1548–51. doi:10.4161/auto.21327.
86. Fontana L, Partridge L, Longo VD. Extending healthy life span–from yeast to
humans. Science. 2010;328(5976):321–6. doi:10.1126/science.1172539.
87. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of
ageing and age-related disease. Nature. 2013;493(7432):338–45. doi:10.1038/
nature11861.
88. Blagosklonny MV. Calorie restriction: decelerating mTOR-driven aging from
cells to organisms (including humans). Cell Cycle. 2010;9(4):683–8.
89. Dong W, Wang R, Ma LN, Xu BL, Zhang JS, Zhao ZW, et al. Autophagy
involving age-related cognitive behavior and hippocampus injury is
modulated by different caloric intake in mice. Int J Clin Exp Med. 2015;8(7):
11843–53.
90. Dogan S, Johannsen AC, Grande JP, Cleary MP. Effects of intermittent and
chronic calorie restriction on mammalian target of rapamycin (mTOR) and
IGF-I signaling pathways in mammary fat pad tissues and mammary tumors.
Nutr Cancer. 2011;63(3):389–401. doi:10.1080/01635581.2011.535968.
91. Newman JC, Verdin E. Ketone bodies as signaling metabolites. Trends
Endocrinol Metab. 2014;25(1):42–52. doi:10.1016/j.tem.2013.09.002.
92. Robinson AM, Williamson DH. Physiological roles of ketone bodies as
substrates and signals in mammalian tissues. Physiol Rev. 1980;60(1):143–87.
93. Laffel L. Ketone bodies: a review of physiology, pathophysiology and application
of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15(6):412–26.
94. Cahill Jr GF. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1–22.
95. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill Jr GF. Brain
metabolism during fasting. J Clin Invest. 1967;46(10):1589–95.
96. Koeslag JH, Noakes TD, Sloan AW. Post-exercise ketosis. J Physiol. 1980;301:
79–90.
97. Féry F, Balasse EO. Response of ketone body metabolism to exercise during
transition from postabsorptive to fasted state. Am J Physiol. 1986;250(5 Pt 1):
E495–501.
98. McCue MD. Starvation physiology: reviewing the different strategies animals
use to survive a common challenge. Comp Biochem Physiol A Mol Integr
Physiol. 2010;156(1):1–18. doi:10.1016/j.cbpa.2010.01.002.
99. London ED, Margolin RA, Duara R, Holloway HW, Robertson-Tchabo EA,
Cutler NR, Rapoport SI. Effects of fasting on ketone body concentrations in
healthy men of different ages. J Gerontol. 1986;41(5):599–604.
100. Freemantle E, Vandal M, Tremblay Mercier J, Plourde M, Poirier J, Cunnane
SC. Metabolic response to a ketogenic breakfast in the healthy elderly. J
Nutr Health Aging. 2009;13(4):293–8.
101. Meijer WH, van der Klei IJ, Veenhuis M, Kiel JA. ATG genes involved in non-
selective autophagy are conserved from yeast to man, but the selective Cvt
and pexophagy pathways also require organism-specific genes. Autophagy.
2007;3(2):106–16.
102. Watson K, Baar K. mTOR and the health benefits of exercise. Semin Cell Dev
Biol. 2014;36:130–9. doi:10.1016/j.semcdb.2014.08.013.
103. Richardson A, Galvan V, Lin AL, Oddo S. How longevity research can lead to
therapies for Alzheimer’s disease: The rapamycin story. Exp Gerontol. 2015;
68:51–8. doi:10.1016/j.exger.2014.12.002.
104. Austin S, St-Pierre J. PGC1α and mitochondrial metabolism–emerging
concepts and relevance in ageing and neurodegenerative disorders. J Cell
Sci. 2012;125(Pt 21):4963–71. doi:10.1242/jcs.113662.
105. Sczelecki S, Besse-Patin A, Abboud A, Kleiner S, Laznik-Bogoslavski D, Wrann
CD, et al. Loss of Pgc-1α expression in aging mouse muscle potentiates
glucose intolerance and systemic inflammation. Am J Physiol Endocrinol
Metab. 2014;306(2):E157–67. doi:10.1152/ajpendo.00578.2013.
106. Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment–a
review of the evidence and causal mechanisms. Ageing Res Rev. 2013;12(4):
840–51. doi:10.1016/j.arr.2013.06.004.
107. Crimmins EM, Beltrán-Sánchez H. Mortality and morbidity trends: is there
compression of morbidity? J Gerontol B Psychol Sci Soc Sci. 2011;66(1):75–86.
doi:10.1093/geronb/gbq088.
108. Ryan L, Nadel L, Keil K, Putnam K, Schnyer D, Trouard T, Moscovitch M.
Hippocampal complex and retrieval of recent and very remote
autobiographical memories: evidence from functional magnetic resonance
imaging in neurologically intact people. Hippocampus. 2001;11(6):707–14.
109. Rasch B, Born J. About sleep’s role in memory. Physiol Rev. 2013;93(2):681–766.
doi:10.1152/physrev.00032.2012.
110. Stickgold R. How do I remember? Let me count the ways. Sleep Med Rev.
2009;13(5):305–8. doi:10.1016/j.smrv.2009.05.004.
111. Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L. A physiological
role for amyloid-beta protein: enhancement of learning and memory. J
Alzheimers Dis. 2010;19(2):441–9. doi:10.3233/JAD-2009-1230.
112. Gu L, Guo Z. Alzheimer’s Aβ42 and Aβ40 peptides form interlaced amyloid
fibrils. J Neurochem. 2013;126(3):305–11. doi:10.1111/jnc.12202.
113. Gessel MM, Bernstein S, Kemper M, Teplow DB, Bowers MT. Familial Alzheimer’s
disease mutations differentially alter amyloid β-protein oligomerization. ACS
Chem Neurosci. 2012;3(11):909–18. doi:10.1021/cn300050d.
114. Hayden EY, Teplow DB. Amyloid β-protein oligomers and Alzheimer’s
disease. Alzheimers Res Ther. 2013;5(6):60. doi:10.1186/alzrt226.
115. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid beta-protein
assembly and Alzheimer disease. J Biol Chem. 2009;284(8):4749–53. doi:10.
1074/jbc.R800036200.
116. Puzzo D, Privitera L, Leznik E, Fà M, Staniszewski A, Palmeri A, Arancio O.
Picomolar amyloid-beta positively modulates synaptic plasticity and
memory in hippocampus. J Neurosci. 2008;28(53):14537–45. doi:10.1523/
JNEUROSCI.2692-08.2008.
117. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-beta
as a positive endogenous regulator of release probability at hippocampal
synapses. Nat Neurosci. 2009;12(12):1567–76. doi:10.1038/nn.2433.
118. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al.
APP processing and synaptic function. Neuron. 2003;37(6):925–37.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 40 of 52
119. Mura E, Zappettini S, Preda S, Biundo F, Lanni C, Grilli M, et al. Dual effect of
beta-amyloid on α7 and α4β2 nicotinic receptors controlling the release of
glutamate, aspartate and GABA in rat hippocampus. PLoS One. 2012;7(1):
e29661. doi:10.1371/journal.pone.0029661.
120. Puzzo D, Arancio O. Amyloid-β peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers
Dis. 2013;33 Suppl 1:S111–20.
121. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al.
High-level neuronal expression of abeta 1–42 in wild-type human amyloid
protein precursor transgenic mice: synaptotoxicity without plaque
formation. J Neurosci. 2000;20(11):4050–8.
122. Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R,
et al. Mild cognitive impairment with suspected nonamyloid pathology
(SNAP): Prediction of progression. Neurology. 2015;84(5):508–15. doi:10.
1212/WNL.0000000000001209.
123. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, et al.
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly
associated with Alzheimer-type dementia. Brain. 2010;133(Pt 5):1328–41.
doi:10.1093/brain/awq065.
124. Nimmrich V, Ebert U. Is Alzheimer’s disease a result of presynaptic failure?
Synaptic dysfunctions induced by oligomeric beta-amyloid. Rev Neurosci.
2009;20(1):1–12.
125. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, et al.
Glycogen synthase kinase-3beta, or a link between amyloid and tau
pathology? Genes Brain Behav. 2008;7 Suppl 1:57–66. doi:10.1111/j.1601-
183X.2007.00376.x.
126. Llorens-Martín M, Jurado J, Hernández F, Avila J. GSK-3β, a pivotal kinase in
Alzheimer disease. Front Mol Neurosci. 2014;7:46. doi:10.3389/fnmol.2014.
00046.
127. Avila J, León-Espinosa G, García E, García-Escudero V, Hernández F, Defelipe
J. Tau Phosphorylation by GSK3 in Different Conditions. Int J Alzheimers Dis.
2012;2012:578373. doi:10.1155/2012/578373.
128. Lloret A, Badia MC, Giraldo E, Ermak G, Alonso MD, Pallardó FV, et al.
Amyloid-β toxicity and tau hyperphosphorylation are linked via RCAN1 in
Alzheimer’s disease. J Alzheimers Dis. 2011;27(4):701–9. doi:10.3233/JAD-
2011-110890.
129. Naini SM, Soussi-Yanicostas N. Tau hyperphosphorylation and oxidative
stress, a critical vicious circle in neurodegenerative tauopathies? Oxid Med
Cell Longev. 2015;2015:151979. doi:10.1155/2015/151979.
130. Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, et al.
Inducible expression of Tau repeat domain in cell models of tauopathy:
aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol
Chem. 2006;281(2):1205–14.
131. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP,
et al. Tangle and neuron numbers, but not amyloid load, predict cognitive
status in Alzheimer’s disease. Neurology. 2003;60(9):1495–500.
132. DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T,
Serenó L, et al. Brain oligomeric β-amyloid but not total amyloid plaque
burden correlates with neuronal loss and astrocyte inflammatory response
in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp
Neurol. 2011;70(5):360–76. doi:10.1097/NEN.0b013e318217a118.
133. Puzzo D, Gulisano W, Arancio O, Palmeri A. The keystone of Alzheimer
pathogenesis might be sought in Aβ physiology. Neuroscience. 2015;307:
26–36. doi:10.1016/j.neuroscience.2015.08.039.
134. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M,
et al. Decreased amyloid-β and increased neuronal hyperactivity by
immunotherapy in Alzheimer’s models. Nat Neurosci. 2015;18(12):1725–7.
doi:10.1038/nn.4163.
135. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two
phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N
Engl J Med. 2014;370(4):322–33. doi:10.1056/NEJMoa1304839.
136. Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat
Neurosci. 2015;18(6):794–9. doi:10.1038/nn.4017.
137. Tononi G, Cirelli C. Sleep and the price of plasticity: from synaptic and
cellular homeostasis to memory consolidation and integration. Neuron.
2014;81(1):12–34. doi:10.1016/j.neuron.2013.12.025.
138. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives
metabolite clearance from the adult brain. Science. 2013;342(6156):373–7.
doi:10.1126/science.1241224.
139. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Aβ-induced synaptic
dysfunction in Alzheimer’s disease. Mol Neurodegener. 2014;9:48.
doi:10.1186/1750-1326-9-48.
140. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1
night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in
healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;
71(8):971–7. doi:10.1001/jamaneurol.2014.1173.
141. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-
beta dynamics are regulated by orexin and the sleep-wake cycle. Science.
2009;326(5955):1005–7. doi:10.1126/science.1180962.
142. Fernandes C, Rocha NB, Rocha S, Herrera-Solís A, Salas-Pacheco J, García-
García F, et al. Detrimental role of prolonged sleep deprivation on adult
neurogenesis. Front Cell Neurosci. 2015;9:140. doi:10.3389/fncel.2015.00140.
143. Becker S. A computational principle for hippocampal learning and
neurogenesis. Hippocampus. 2005;15(6):722–38.
144. Arruda-Carvalho M, Sakaguchi M, Akers KG, Josselyn SA, Frankland PW.
Posttraining ablation of adult-generated neurons degrades previously
acquired memories. J Neurosci. 2011;31(42):15113–27. doi:10.1523/
JNEUROSCI.3432-11.2011.
145. McAvoy K, Besnard A, Sahay A. Adult hippocampal neurogenesis and
pattern separation in DG: a role for feedback inhibition in modulating
sparseness to govern population-based coding. Front Syst Neurosci. 2015;9:
120. doi:10.3389/fnsys.2015.00120.
146. Wiskott L, Rasch MJ, Kempermann G. A functional hypothesis for adult
hippocampal neurogenesis: avoidance of catastrophic interference in the
dentate gyrus. Hippocampus. 2006;16(3):329–43.
147. Kropff E, Yang SM, Schinder AF. Dynamic role of adult-born dentate granule
cells in memory processing. Curr Opin Neurobiol. 2015;35:21–6. doi:10.1016/
j.conb.2015.06.002.
148. Teyler TJ, Rudy JW. The hippocampal indexing theory and episodic
memory: updating the index. Hippocampus. 2007;17(12):1158–69.
149. Wiltgen BJ, Zhou M, Cai Y, Balaji J, Karlsson MG, Parivash SN, et al. The
hippocampus plays a selective role in the retrieval of detailed contextual
memories. Curr Biol. 2010;20(15):1336–44. doi:10.1016/j.cub.2010.06.068.
150. Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB,
et al. Dynamics of hippocampal neurogenesis in adult humans. Cell. 2013;
153(6):1219–27. doi:10.1016/j.cell.2013.05.002.
151. Besnard A, Sahay A. Adult Hippocampal Neurogenesis, Fear Generalization,
and Stress. Neuropsychopharmacology. 2016;41(1):24–44. doi:10.1038/npp.
2015.167.
152. Roy DS, Arons A, Mitchell TI, Pignatelli M, Ryan TJ, Tonegawa S. Memory
retrieval by activating engram cells in mouse models of early Alzheimer’s
disease. 2016; doi:10.1038/nature17172.
153. Li S, Jin M, Zhang D, Yang T, Koeglsperger T, Fu H, Selkoe DJ. Environmental
novelty activates β2-adrenergic signaling to prevent the impairment of
hippocampal LTP by Aβ oligomers. Neuron. 2013;77(5):929–41. doi:10.1016/j.
neuron.2012.12.040.
154. Akers KG, Martinez-Canabal A, Restivo L, Yiu AP, De Cristofaro A, Hsiang HL,
et al. Hippocampal neurogenesis regulates forgetting during adulthood and
infancy. Science. 2014;344(6184):598–602. doi:10.1126/science.1248903.
155. Aimone JB, Deng W, Gage FH. Resolving new memories: a critical look at
the dentate gyrus, adult neurogenesis, and pattern separation. Neuron.
2011;70(4):58–96. doi:10.1016/j.neuron.2011.05.010.
156. Ikrar T, Guo N, He K, Besnard A, Levinson S, Hill A, et al. Adult neurogenesis
modifies excitability of the dentate gyrus. Front Neural Circuits. 2013;7:204.
doi:10.3389/fncir.2013.00204.
157. Eadie BD, Redila VA, Christie BR. Voluntary exercise alters the
cytoarchitecture of the adult dentate gyrus by increasing cellular
proliferation, dendritic complexity, and spine density. J Comp Neurol. 2005;
486(1):39–47.
158. Konefal S, Elliot M, Crespi B. The adaptive significance of adult neurogenesis:
an integrative approach. Front Neuroanat. 2013;7:21. doi:10.3389/fnana.2013.
00021.
159. Kheirbek MA, Hen R. (Radio)active neurogenesis in the human
hippocampus. Cell. 2013;153(6):1183–4. doi:10.1016/j.cell.2013.05.033.
160. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease:
cell-specific pathology isolates the hippocampal formation. Science. 1984;
225(4667):1168–70.
161. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathol. 1991;82(4):239–59.
162. Vivar C, van Praag H. Functional circuits of new neurons in the dentate
gyrus. Front Neural Circuits. 2013;7:15. doi:10.3389/fncir.2013.00015.
163. Leutgeb JK, Leutgeb S, Moser MB, Moser EI. Pattern separation in the
dentate gyrus and CA3 of the hippocampus. Science. 2007;315(5814):961–6.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 41 of 52
164. Lisman J. Formation of the non-functional and functional pools of granule
cells in the dentate gyrus: role of neurogenesis, LTP and LTD. J Physiol.
2011;589(Pt 8):1905–9. doi:10.1113/jphysiol.2010.201137.
165. Jack Jr CR, Petersen RC, O’Brien PC, Tangalos EG. MR-based hippocampal
volumetry in the diagnosis of Alzheimer’s disease. Neurol. 1992;42(1):183–8.
166. Braak H, Braak E. Evolution of the neuropathology of Alzheimer’s disease.
Acta Neurol Scand Suppl. 1996;165:3–12.
167. Eckerström C, Olsson E, Klasson N, Bjerke M, Göthlin M, Jonsson M, et al.
High white matter lesion load is associated with hippocampal atrophy in
mild cognitive impairment. Dement Geriatr Cogn Disord. 2011;31(2):132–8.
doi:10.1159/000323014.
168. Marín-Burgin A, Schinder AF. Requirement of adult-born neurons for
hippocampus-dependent learning. Behav Brain Res. 2012;227(2):391–9.
doi:10.1016/j.bbr.2011.07.001.
169. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal
neurogenesis buffers stress responses and depressive behaviour. Nature.
2011;476(7361):458–61. doi:10.1038/nature10287.
170. Tannenholz L, Jimenez JC, Kheirbek MA. Local and regional heterogeneity
underlying hippocampal modulation of cognition and mood. Front Behav
Neurosci. 2014;8:147. doi:10.3389/fnbeh.2014.00147.
171. Hill AS, Sahay A, Hen R. Increasing Adult Hippocampal Neurogenesis is
Sufficient to Reduce Anxiety and Depression-Like Behaviors.
Neuropsychopharmacol. 2015;40(10):2368–78. doi:10.1038/npp.2015.85.
172. Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C, et al.
Antidepressants recruit new neurons to improve stress response regulation.
Mol Psychiatry. 2011;16(12):1177–88. doi:10.1038/mp.2011.48.
173. Perera TD, Dwork AJ, Keegan KA, Thirumangalakudi L, Lipira CM, Joyce N,
et al. Necessity of hippocampal neurogenesis for the therapeutic action of
antidepressants in adult nonhuman primates. PLoS One. 2011;6(4):e17600.
doi:10.1371/journal.pone.0017600.
174. Frodl T, Jäger M, Smajstrlova I, Born C, Bottlender R, Palladino T, et al. Effect
of hippocampal and amygdala volumes on clinical outcomes in major
depression: a 3-year prospective magnetic resonance imaging study. J
Psychiatry Neurosci. 2008;33(5):423–30.
175. Lee MM, Reif A, Schmitt AG. Major depression: a role for hippocampal
neurogenesis? Curr Top Behav Neurosci. 2013;14:153–79. doi:10.1007/7854_
2012_226.
176. Vilalta-Franch J, López-Pousa S, Llinàs-Reglà J, Calvó-Perxas L, Merino-
Aguado J, Garre-Olmo J. Depression subtypes and 5-year risk of dementia
and Alzheimer disease in patients aged 70 years. Int J Geriatr Psychiatry.
2013;28(4):341–50. doi:10.1002/gps.3826.
177. Gao Y, Huang C, Zhao K, Ma L, Qiu X, Zhang L, et al. Depression as a risk factor
for dementia and mild cognitive impairment: a meta-analysis of longitudinal
studies. Int J Geriatr Psychiatry. 2013;28(5):441–9. doi:10.1002/gps.3845.
178. Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, et al.
Cerebrospinal fluid cortisol and clinical disease progression in MCI and
dementia of Alzheimer’s type. Neurobiol Aging. 2015;36(2):601–7. doi:10.
1016/j.neurobiolaging.2014.10.031.
179. Saczynski JS, Beiser A, Seshadri S, Auerbach S, Wolf PA, Au R. Depressive
symptoms and risk of dementia: the Framingham Heart Study. Neurology.
2010;75(1):35–41. doi:10.1212/WNL.0b013e3181e62138.
180. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris
JC. Plasma cortisol and progression of dementia in subjects with Alzheimer-
type dementia. Am J Psychiatry. 2006;163(12):2164–9.
181. Du X, Pang TY. Is Dysregulation of the HPA-Axis a Core Pathophysiology
Mediating Co-Morbid Depression in Neurodegenerative Diseases? Front
Psychiatry. 2015;6:32. doi:10.3389/fpsyt.2015.00032.
182. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-
based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol.
2012;69(10):1318–25.
183. Jack Jr CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain
beta-amyloid measures and magnetic resonance imaging atrophy both
predict time-to-progression from mild cognitive impairment to Alzheimer’s
disease. Brain. 2010;133(11):3336–48. doi:10.1093/brain/awq277.
184. Zahodne LB, Stern Y, Manly JJ. Depressive symptoms precede memory
decline, but not vice versa, in non-demented older adults. J Am Geriatr Soc.
2014;62(1):130–4. doi:10.1111/jgs.12600.
185. Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M.
Increased neurofibrillary tangles in patients with Alzheimer disease with
comorbid depression. Am J Geriatr Psychiatry. 2008;16(2):168–74. doi:10.
1097/JGP.0b013e31816029ec.
186. Spalletta G, Caltagirone C, Girardi P, Gianni W, Casini AR, Palmer K. The role
of persistent and incident major depression on rate of cognitive
deterioration in newly diagnosed Alzheimer’s disease patients. Psychiatry
Res. 2012;198(2):263–8. doi:10.1016/j.psychres.2011.11.018.
187. Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and
their relevance to pathogenesis of neurodegenerative diseases. Acta
Pharmacol Sin. 2009;30(4):379–87. doi:10.1038/aps.2009.24.
188. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and
neurodegeneration. Pflugers Arch. 2010;460(2):525–42. doi:10.1007/s00424-
010-0809-1.
189. Dong H, Csernansky JG. Effects of stress and stress hormones on amyloid-
beta protein and plaque deposition. J Alzheimers Dis. 2009;18(2):459–69.
doi:10.3233/JAD-2009-1152.
190. Giuffrida ML, Caraci F, Pignataro B, Cataldo S, De Bona P, Bruno V, et al.
Beta-amyloid monomers are neuroprotective. J Neurosci. 2009;29(34):10582–7.
doi:10.1523/JNEUROSCI.1736-09.2009.
191. Giuffrida ML, Tomasello MF, Pandini G, Caraci F, Battaglia G, Busceti C, et al.
Monomeric ß-amyloid interacts with type-1 insulin-like growth factor
receptors to provide energy supply to neurons. Front Cell Neurosci. 2015;9:
297. doi:10.3389/fncel.2015.00297.
192. Bishop GM, Robinson SR. Physiological roles of amyloid-beta and implications
for its removal in Alzheimer’s disease. Drugs Aging. 2004;21(10):621–30.
193. Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E,
Copani A. The monomer state of beta-amyloid: where the Alzheimer’s
disease protein meets physiology. Rev Neurosci. 2010;21(2):83–93.
194. Park HJ, Ran Y, Jung JI, Holmes O, Price AR, Smithson L, et al. The stress
response neuropeptide CRF increases amyloid-β production by regulating γ-
secretase activity. EMBO J. 2015;34(12):1674–86. doi:10.15252/embj.201488795.
195. Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER,
Wilkinson CW, et al. Effects of chronic glucocorticoid administration on
insulin-degrading enzyme and amyloid-beta peptide in the aged macaque.
J Neuropathol Exp Neurol. 2005;64(2):139–46.
196. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM.
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model
of Alzheimer’s disease. J Neurosci. 2006;26(35):9047–56.
197. Wu KY, Hsiao IT, Chen CS, Chen CH, Hsieh CJ, Wai YY, et al. Increased brain
amyloid deposition in patients with a lifetime history of major depression:
evidenced on 18 F-florbetapir (AV-45/Amyvid) positron emission
tomography. Eur J Nucl Med Mol Imaging. 2014;41(4):714–22.
198. Drew LJ, Fusi S, Hen R. Adult neurogenesis in the mammalian
hippocampus: why the dentate gyrus? Learn Mem. 2013;20(12):710–29.
doi:10.1101/lm.026542.112.
199. Braun SM, Jessberger S. Adult neurogenesis: mechanisms and functional
significance. Development. 2014;141(10):1983–6. doi:10.1242/dev.104596.
200. Sherry DF, Hoshooley JS. Seasonal hippocampal plasticity in food-storing
birds. Philos Trans R Soc Lond B Biol Sci. 2010;365(1542):933–43. doi:10.
1098/rstb.2009.0220.
201. Wilbrecht L, Kirn JR. Neuron addition and loss in the song system:
regulation and function. Ann N Y Acad Sci. 2004;1016:659–83.
202. Barnea A, Pravosudov V. Birds as a model to study adult neurogenesis:
bridging evolutionary, comparative and neuroethological approaches. Eur J
Neurosci. 2011;34(6):884–907. doi:10.1111/j.1460-9568.2011.07851.x.
203. Jacobs LF, Spencer WD. Natural space-use patterns and hippocampal size in
kangaroo rats. Brain Behav Evol. 1994;44(3):125–32.
204. Walton JC, Aubrecht TG, Weil ZM, Leuner B, Nelson RJ. Photoperiodic regulation
of hippocampal neurogenesis in adult male white-footed mice (Peromyscus
leucopus). Eur J Neurosci. 2014;40(4):2674–9. doi:10.1111/ejn.12626.
205. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult
neurogenesis. Cell. 2008;132(4):645–60. doi:10.1016/j.cell.2008.01.033.
206. Sierra A, Encinas JM, Deudero JJ, Chancey JH, Enikolopov G, Overstreet-
Wadiche LS, et al. Microglia shape adult hippocampal neurogenesis through
apoptosis-coupled phagocytosis. Cell Stem Cell. 2010;7(4):483–95. doi:10.
1016/j.stem.2010.08.014.
207. Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant
answers and significant questions. Neuron. 2011;70(4):687–702. doi:10.1016/j.
neuron.2011.05.001.
208. Sprengel PC. Von der Substanz der Ackerkrume und des Untergrundes.
Leipzig: Journal für Technische und Ökonomische Chemie; 1828.
209. van der Ploeg RR, Böhm W, Kirkham MB. On the origin of the theory of
mineral nutrition of plants and the Law of the minimum. Soil Sci Soc Am J.
1999;63:1055–62. doi:10.2136/sssaj1999.6351055x.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 42 of 52
210. Colcombe SJ, Erickson KI, Scalf PE, Kim JS, Prakash R, McAuley E, et al.
Aerobic exercise training increases brain volume in aging humans. J
Gerontol A Biol Sci Med Sci. 2006;61(11):1166–70.
211. Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, et al.
Exercise training increases size of hippocampus and improves memory. Proc
Natl Acad Sci U S A. 2011;108(7):3017–22. doi:10.1073/pnas.1015950108.
212. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A,
et al. Regional brain changes in aging healthy adults: general trends,
individual differences and modifiers. Cereb Cortex. 2005;15(11):1676–89.
213. Inoue K, Okamoto M, Shibato J, Lee MC, Matsui T, Rakwal R, Soya H. Long-
term mild, rather than intense, exercise enhances adult hippocampal
neurogenesis and greatly changes the transcriptomic profile of the
hippocampus. PLoS One. 2015;10(6):e0128720. doi:10.1371/journal.pone.
0128720.
214. Nokia MS, Lensu S, Ahtiainen JP, Johansson PP, Koch LG, Britton SL,
Kainulainen H. Physical exercise increases adult hippocampal neurogenesis
in male rats provided it is aerobic and sustained. J Physiol. 2016. doi: 10.
1113/JP271552.
215. Hackert VH, den Heijer T, Oudkerk M, Koudstaal PJ, Hofman A, Breteler MM.
Hippocampal head size associated with verbal memory performance in
nondemented elderly. Neuroimage. 2002;17(3):1365–72.
216. Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer
disease, and brain structure. Neurology. 2009;73(22):1899–905. doi:10.1212/
WNL.0b013e3181c3f293.
217. Yates LB, Djoussé L, Kurth T, Buring JE, Gaziano JM. Exceptional longevity in
men: modifiable factors associated with survival and function to age
90 years. Arch Intern Med. 2008;168(3):284–90. doi:10.1001/archinternmed.
2007.77.
218. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic
diseases. Compr Physiol. 2012;2(2):1143–211. doi:10.1002/cphy.c110025.
219. Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI. The involvement
of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging Dis. 2015;
6(5):331–41. doi:10.14336/AD.2015.0825.
220. Rovio S, Kåreholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, et al.
Leisure-time physical activity at midlife and the risk of dementia and
Alzheimer’s disease. Lancet Neurol. 2005;4(11):705–11.
221. Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily
physical activity and the risk of AD and cognitive decline in older adults.
Neurology. 2012;78(17):1323–9. doi:10.1212/WNL.0b013e3182535d35.
222. Hollmann W, Strüder HK, Tagarakis CV, King G. Physical activity and the
elderly. Eur J Cardiovasc Prev Rehabil. 2007;14(6):730–9.
223. Revilla S, Suñol C, García-Mesa Y, Giménez-Llort L, Sanfeliu C, Cristòfol R.
Physical exercise improves synaptic dysfunction and recovers the loss of
survival factors in 3xTg-AD mouse brain. Neuropharmacol. 2014;81:55–63.
doi:10.1016/j.neuropharm.2014.01.037.
224. Chae CH, Lee HC, Jung SL, Kim TW, Kim JH, Kim NJ, Kim HT. Swimming
exercise increases the level of nerve growth factor and stimulates
neurogenesis in adult rat hippocampus. Neuroscience. 2012;212:30–7.
doi:10.1016/j.neuroscience.2012.03.030.
225. Waterhouse EG, An JJ, Orefice LL, Baydyuk M, Liao GY, Zheng K, Lu B, Xu B.
BDNF promotes differentiation and maturation of adult-born neurons
through GABAergic transmission. J Neurosci. 2012;32(41):14318–30. doi:10.
1523/JNEUROSCI.0709-12.2012.
226. Rasmussen P, Brassard P, Adser H, Pedersen MV, Leick L, Hart E, et al.
Evidence for a release of brain-derived neurotrophic factor from the brain
during exercise. Exp Physiol. 2009;94(10):1062–9. doi:10.1113/expphysiol.
2009.048512.
227. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al.
Blood BDNF concentrations reflect brain-tissue BDNF levels across species.
Int J Neuropsychopharmacol. 2011;14(3):347–53. doi:10.1017/
S1461145710000738.
228. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived
neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain
Res. 1997;49(1–2):71–81.
229. Makizako H, Liu-Ambrose T, Shimada H, Doi T, Park H, Tsutsumimoto K, et al.
Moderate-intensity physical activity, hippocampal volume, and memory in
older adults with mild cognitive impairment. J Gerontol A Biol Sci Med Sci.
2015;70(4):480–6. doi:10.1093/gerona/glu136.
230. Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N, et al. VEGF is
necessary for exercise-induced adult hippocampal neurogenesis. Eur J
Neurosci. 2003;18(10):2803–12.
231. Han J, Calvo CF, Kang TH, Baker KL, Park JH, Parras C, et al. Vascular endothelial
growth factor receptor 3 controls neural stem cell activation in mice and
humans. Cell Rep. 2015;10(7):1158–72. doi:10.1016/j.celrep.2015.01.049.
232. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, et al.
Erythropoietin enhances hippocampal long-term potentiation and memory.
BMC Biol. 2008;6:37. doi:10.1186/1741-7007-6-37.
233. Ransome MI, Turnley AM. Systemically delivered Erythropoietin transiently
enhances adult hippocampal neurogenesis. J Neurochem. 2007;102(6):1953–65.
234. Kaneko N, Kako E, Sawamoto K. Enhancement of ventricular-subventricular
zone-derived neurogenesis and oligodendrogenesis by erythropoietin and
its derivatives. Front Cell Neurosci. 2013;7:235. doi:10.3389/fncel.2013.00235.
235. Viviani B, Bartesaghi S, Corsini E, Villa P, Ghezzi P, Garau A, et al. Erythropoietin
protects primary hippocampal neurons increasing the expression of brain-
derived neurotrophic factor. J Neurochem. 2005;93(2):412–21.
236. Cheng A, Wan R, Yang JL, Kamimura N, Son TG, Ouyang X, et al.
Involvement of PGC-1α in the formation and maintenance of neuronal
dendritic spines. Nat Commun. 2012;3:1250. doi:10.1038/ncomms2238.
237. Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in
inflammation and chronic disease. Nature. 2008;454(7203):463–9.
doi:10.1038/nature07206.
238. Okamoto M, Hojo Y, Inoue K, Matsui T, Kawato S, McEwen BS, Soya H. Mild
exercise increases dihydrotestosterone in hippocampus providing evidence
for androgenic mediation of neurogenesis. Proc Natl Acad Sci U S A. 2012;
109(32):13100–5. doi:10.1073/pnas.1210023109.
239. Carrier N, Kabbaj M. Extracellular signal-regulated kinase 2 signaling in the
hippocampal dentate gyrus mediates the antidepressant effects of
testosterone. Biol Psychiatry. 2012;71(7):642–51. doi:10.1016/j.biopsych.2011.
11.028.
240. Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ,
Shah NH. Androgen Deprivation Therapy and Future Alzheimer’s Disease
Risk. J Clin Oncol. 2015
241. Kanaley JA, Weltman JY, Veldhuis JD, Rogol AD, Hartman ML, Weltman A.
Human growth hormone response to repeated bouts of aerobic exercise. J
Appl Physiol. 1997;83(5):1756–61.
242. Trejo JL, Carro E, Torres-Aleman I. Circulating insulin-like growth factor I
mediates exercise-induced increases in the number of new neurons in the
adult hippocampus. J Neurosci. 2001;21(5):1628–34.
243. Gómez-Pinilla F, Dao L, So V. Physical exercise induces FGF-2 and its mRNA
in the hippocampus. Brain Res. 1997;764(1–2):1–8.
244. Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T. FGF2 gene transfer
restores hippocampal functions in mouse models of Alzheimer’s disease
and has therapeutic implications for neurocognitive disorders. Proc Natl
Acad Sci U S A. 2011;108(49):E1339–48. doi:10.1073/pnas.1102349108.
245. Novelle MG, Contreras C, Romero-Picó A, López M, Diéguez C. Irisin, two
years later. Int J Endocrinol. 2013;2013:746281. doi:10.1155/2013/746281.
246. Klempin F, Beis D, Mosienko V, Kempermann G, Bader M, Alenina N.
Serotonin is required for exercise-induced adult hippocampal neurogenesis.
J Neurosci. 2013;33(19):8270–5. doi:10.1523/JNEUROSCI.5855-12.2013.
247. Yau SY, Li A, Xu A, So KF. Fat cell-secreted adiponectin mediates physical
exercise-induced hippocampal neurogenesis: an alternative anti-
depressive treatment? Neural Regen Res. 2015;10(1):7–9. doi:10.4103/1673-
5374.150637.
248. Yau SY, Li A, Hoo RL, Ching YP, Christie BR, Lee TM, et al. Physical exercise-
induced hippocampal neurogenesis and antidepressant effects are
mediated by the adipocyte hormone adiponectin. Proc Natl Acad Sci U S A.
2014;111(44):15810–5. doi:10.1073/pnas.1415219111.
249. Moon HS, Dincer F, Mantzoros CS. Pharmacological concentrations of irisin
increase cell proliferation without influencing markers of neurite outgrowth
and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism.
2013;62(8):1131–6. doi:10.1016/j.metabol.2013.04.007.
250. Jørgensen JR, Fjord-Larsen L, Wahlberg LU, Andrade NGM, Johansen TE.
Therapeutic use of a growth factor. METRNL US-patent. 2012;8334264:B2.
251. Soya H, Okamoto M, Matsui T, Lee M, Inoue K, Nishikawa S, et al. Brain
activation via exercise: exercise conditions leading to neuronal activation
and hippocampal neurogenesis. J Exerc Nutr Biochem. 2011;15:1–10.
252. Anacker C, Cattaneo A, Luoni A, Musaelyan K, Zunszain PA, Milanesi E, et al.
Glucocorticoid-related molecular signaling pathways regulating
hippocampal neurogenesis. Neuropsychopharmacol. 2013;38(5):872–83.
doi:10.1038/npp.2012.253.
253. Mastorakos G, Pavlatou M, Diamanti-Kandarakis E, Chrousos GP. Exercise and
the stress system. Hormones (Athens). 2005;4(2):73–89.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 43 of 52
254. Schoenfeld TJ, Gould E. Differential effects of stress and glucocorticoids on
adult neurogenesis. Curr Top Behav Neurosci. 2013;15:139–64. doi:10.1007/
7854_2012_233.
255. Gleeson M. Immune function in sport and exercise. J Appl Physiol. 2007;
103(2):693––9.
256. Gomez-Cabrera MC, Domenech E, Viña J. Moderate exercise is an
antioxidant: upregulation of antioxidant genes by training. Free Radic Biol
Med. 2008;44(2):126–31. doi:10.1016/j.freeradbiomed.2007.02.001.
257. Taverniers J, Van Ruysseveldt J, Smeets T, von Grumbkow J. High-intensity
stress elicits robust cortisol increases, and impairs working memory and
visuo-spatial declarative memory in Special Forces candidates: A field
experiment. Stress. 2010;13(4):323–33. doi:10.3109/10253891003642394.
258. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is
detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A.
2003;100(23):13632–7.
259. Lin TW, Shih YH, Chen SJ, Lien CH, Chang CY, Huang TY, et al. Running
exercise delays neurodegeneration in amygdala and hippocampus of
Alzheimer’s disease (APP/PS1) transgenic mice. Neurobiol Learn Mem. 2015;
118:189–97. doi:10.1016/j.nlm.2014.12.005.
260. Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Hayashida N, et al.
Exercise is more effective than diet control in preventing high fat diet-
induced β-amyloid deposition and memory deficit in amyloid precursor
protein transgenic mice. J Biol Chem. 2012;287(27):23024–33. doi:10.1074/
jbc.M112.367011.
261. Østergaard SD, Mukherjee S, Sharp SJ, Proitsi P, Lotta LA, Day F, et al.
Associations between Potentially Modifiable Risk Factors and Alzheimer
Disease: A Mendelian Randomization Study. PLoS Med. 2015;12(6):e1001841.
doi:10.1371/journal.pmed.1001841. discussion e1001841.
262. Holthoff VA, Marschner K, Scharf M, Steding J, Meyer S, Koch R, Donix M.
Effects of physical activity training in patients with Alzheimer’s dementia:
results of a pilot RCT study. PLoS One. 2015;10(4):e0121478. doi:10.1371/
journal.pone.0121478.
263. Sink KM, Espeland MA, Castro CM, Church T, Cohen R, Dodson JA, et al.
Effect of a 24-Month Physical Activity Intervention vs Health Education on
Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial.
JAMA. 2015;314(8):781–90. doi:10.1001/jama.2015.9617.
264. Zainuddin MS, Thuret S. Nutrition, adult hippocampal neurogenesis and
mental health. Br Med Bull. 2012;103(1):89–114. doi:10.1093/bmb/lds021.
265. Valente T, Hidalgo J, Bolea I, Ramirez B, Anglés N, Reguant J, et al. A diet
enriched in polyphenols and polyunsaturated fatty acids, LMN diet, induces
neurogenesis in the subventricular zone and hippocampus of adult mouse
brain. J Alzheimers Dis. 2009;18(4):849. doi:10.3233/JAD-2009-1188.
266. Dias GP, Cavegn N, Nix A, do Nascimento Bevilaqua MC, Stangl D,
Zainuddin MS, et al. The role of dietary polyphenols on adult hippocampal
neurogenesis: molecular mechanisms and behavioural effects on depression
and anxiety. Oxid Med Cell Longev. 2012;2012:541971. doi:10.1155/2012/
541971.
267. Stefani M, Rigacci S. Protein folding and aggregation into amyloid: the
interference by natural phenolic compounds. Int J Mol Sci. 2013;14(6):
12411–57. doi:10.3390/ijms140612411.
268. Porzoor A, Alford B, Hügel HM, Grando D, Caine J, Macreadie I. Anti-
amyloidogenic properties of some phenolic compounds. Biomolecules.
2015;5(2):505–27. doi:10.3390/biom5020505.
269. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gómez-Pinilla F. A high-fat,
refined sugar diet reduces hippocampal brain-derived neurotrophic factor,
neuronal plasticity, and learning. Neuroscience. 2002;112(4):803–14.
270. Martire SI, Maniam J, South T, Holmes N, Westbrook RF, Morris MJ. Extended
exposure to a palatable cafeteria diet alters gene expression in brain
regions implicated in reward, and withdrawal from this diet alters gene
expression in brain regions associated with stress. Behav Brain Res. 2014;
265:132–41. doi:10.1016/j.bbr.2014.02.027.
271. Perrone L, Grant WB. Observational and ecological studies of dietary
advanced glycation end products in national diets and Alzheimer’s disease
incidence and prevalence. J Alzheimers Dis. 2015;45(3):965–79. doi:10.3233/
JAD-140720.
272. Hoffman R, Gerber M. Food Processing and the Mediterranean Diet.
Nutrients. 2015;7(9):7925–64. doi:10.3390/nu7095371.
273. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur
T, Yirmiya R. Brain interleukin-1 mediates chronic stress-induced depression
in mice via adrenocortical activation and hippocampal neurogenesis
suppression. Mol Psychiatry. 2008;13(7):717–28.
274. Bowen KK, Dempsey RJ, Vemuganti R. Adult interleukin-6 knockout mice
show compromised neurogenesis. Neuroreport. 2011;22(3):126–30. doi:10.
1097/WNR.0b013e3283430a44.
275. Iosif RE, Ekdahl CT, Ahlenius H, Pronk CJ, Bonde S, Kokaia Z, et al. Tumor
necrosis factor receptor 1 is a negative regulator of progenitor proliferation
in adult hippocampal neurogenesis. J Neurosci. 2006;26(38):9703–12.
276. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult
hippocampal neurogenesis. Science. 2003;302(5651):1760–5.
277. Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, et al.
Polyunsaturated fatty acids in the food chain in the United States. Am J Clin
Nutr. 2000;71(1 Suppl):179S–88S.
278. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. Health implications of
high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:
539426. doi:10.1155/2012/539426.
279. Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and
the brain. Mol Neurobiol. 2011;44(2):203–15. doi:10.1007/s12035-010-8162-0.
280. Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP,
et al. Re-evaluation of the traditional diet-heart hypothesis: analysis of
recovered data from Minnesota Coronary Experiment (1968–73). BMJ. 2016;
353:i1246. doi:10.1136/bmj.i1246.
281. Rigacci S. Olive Oil Phenols as Promising Multi-targeting Agents Against
Alzheimer’s Disease. Adv Exp Med Biol. 2015;863:1–20. doi:10.1007/978-3-
319-18365-7_1.
282. Farr SA, Price TO, Dominguez LJ, Motisi A, Saiano F, Niehoff ML, et al. Extra
virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers
Dis. 2012;28(1):81–92. doi:10.3233/JAD-2011-110662.
283. Qosa H, Mohamed LA, Batarseh YS, Alqahtani S, Ibrahim B, LeVine 3rd H,
et al. Extra-virgin olive oil attenuates amyloid-β and tau pathologies in the
brains of TgSwDI mice. J Nutr Biochem. 2015;26(12):1479–90. doi:10.1016/j.
jnutbio.2015.07.022.
284. Lin L, Allemekinders H, Dansby A, Campbell L, Durance-Tod S, Berger A, Jones
PJ. Evidence of health benefits of canola oil. Nutr Rev. 2013;71(6):370–85.
doi:10.1111/nure.12033.
285. Rodriguez-Leyva D, Dupasquier CM, McCullough R, Pierce GN. The
cardiovascular effects of flaxseed and its omega-3 fatty acid, alpha-linolenic
acid. Can J Cardiol. 2010;26(9):489–96.
286. Garcia PT, Pensel NA, Sancho AM, Latimori NJ, Kloster AM, Amigone MA,
Casal JJ. Beef lipids in relation to animal breed and nutrition in Argentina.
Meat Sci. 2008;79(3):500–8. doi:10.1016/j.meatsci.2007.10.019.
287. Daley CA, Abbott A, Doyle PS, Nader GA, Larson S. A review of fatty acid
profiles and antioxidant content in grass-fed and grain-fed beef. Nutr J.
2010;9:10. doi:10.1186/1475-2891-9-10.
288. Gibson RA, Muhlhausler B, Makrides M. Conversion of linoleic acid and
alpha-linolenic acid to long-chain polyunsaturated fatty acids (LCPUFAs),
with a focus on pregnancy, lactation and the first 2 years of life. Matern
Child Nutr. 2011;7 Suppl 2:17–26. doi:10.1111/j.1740-8709.2011.00299.x.
289. Janssen CI, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from
genesis to senescence: the influence of LCPUFA on neural development,
aging, and neurodegeneration. Prog Lipid Res. 2014;53:1–17. doi:10.1016/j.
plipres.2013.10.002.
290. Liu JJ, Green P, John Mann J, Rapoport SI, Sublette ME. Pathways of
polyunsaturated fatty acid utilization: implications for brain function in
neuropsychiatric health and disease. Brain Res. 2015;1597:220–46. doi:10.
1016/j.brainres.2014.11.059.
291. Shichiri M, Adkins Y, Ishida N, Umeno A, Shigeri Y, Yoshida Y, et al. DHA
concentration of red blood cells is inversely associated with markers of lipid
peroxidation in men taking DHA supplement. J Clin Biochem Nutr. 2014;
55(3):196–202. doi:10.3164/jcbn.14-22.
292. Labrousse VF, Nadjar A, Joffre C, Costes L, Aubert A, Grégoire S, et al. Short-
term long chain omega3 diet protects from neuroinflammatory processes
and memory impairment in aged mice. PLoS One. 2012;7(5):e36861. doi:10.
1371/journal.pone.0036861.
293. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the
independent and shared effects of EPA, DPA and DHA. Front Aging
Neurosci. 2015;7:52. doi:10.3389/fnagi.2015.00052.
294. Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids. Prog
Lipid Res. 2008;47(2):147–55. doi:10.1016/j.plipres.2007.12.004.
295. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG.
Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival
via secretase- and PPARγ-mediated mechanisms in Alzheimer’s disease
models. PLoS One. 2011;6(1):e15816. doi:10.1371/journal.pone.0015816.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 44 of 52
296. Bazan NG, Molina MF, Gordon WC. Docosahexaenoic acid signalolipidomics
in nutrition: significance in aging, neuroinflammation, macular
degeneration, Alzheimer’s, and other neurodegenerative diseases. Annu Rev
Nutr. 2011;31:321–51. doi:10.1146/annurev.nutr.012809.104635.
297. Cole GM, Frautschy SA. Docosahexaenoic acid protects from amyloid and
dendritic pathology in an Alzheimer’s disease mouse model. Nutr Health.
2006;18(3):249–59.
298. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation
enhances the effects of exercise on synaptic plasticity and cognition. Neurosci.
2008;155(3):751–9. doi:10.1016/j.neuroscience.2008.05.061.
299. Tanriover G, Seval-Celik Y, Ozsoy O, Akkoyunlu G, Savcioglu F, Hacioglu G,
et al. The effects of docosahexaenoic acid on glial derived neurotrophic
factor and neurturin in bilateral rat model of Parkinson’s disease. Folia
Histochem Cytobiol. 2010;48(3):434–41. doi:10.2478/v10042-010-0047-6.
300. Luchtman DW, Song C. Cognitive enhancement by omega-3 fatty acids
from child-hood to old age: findings from animal and clinical studies.
Neuropharmacol. 2013;64:550–65. doi:10.1016/j.neuropharm.2012.07.019.
301. Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes
neurogenesis in vitro and in vivo. Neuroscience. 2006;139(3):991–7.
302. Jacka FN, Cherbuin N, Anstey KJ, Sachdev P, Butterworth P. Western diet is
associated with a smaller hippocampus: a longitudinal investigation. BMC
Med. 2015;13:215. doi:10.1186/s12916-015-0461-x.
303. Yurko-Mauro K, Alexander DD, Van Elswyk ME. Docosahexaenoic acid and
adult memory: a systematic review and meta-analysis. PLoS One. 2015;10(3):
e0120391. doi:10.1371/journal.pone.0120391.
304. Marean CW, Bar-Matthews M, Bernatchez J, Fisher E, Goldberg P, Herries AI,
et al. Early human use of marine resources and pigment in South Africa
during the Middle Pleistocene. Nature. 2007;449(7164):905–8.
305. Crawford MA, Broadhurst CL. The role of docosahexaenoic and the marine
food web as determinants of evolution and hominid brain development:
the challenge for human sustainability. Nutr Health. 2012;21(1):17–39.
doi:10.1177/0260106012437550.
306. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of
eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry.
2011;72(12):1577–84. doi:10.4088/JCP.10m06634.
307. Newton W, McManus A. Consumption of fish and Alzheimer’s disease. J
Nutr Health Aging. 2011;15(7):551–4552.
308. Thomas J, Thomas CJ, Radcliffe J, Itsiopoulos C. Omega-3 Fatty Acids in Early
Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer’s
Disease. Biomed Res Int. 2015;2015:172801. doi:10.1155/2015/172801.
309. Ros E, Martínez-González MA, Estruch R, Salas-Salvadó J, Fitó M, Martínez JA,
Corella D. Mediterranean diet and cardiovascular health: Teachings of the
PREDIMED study. Adv Nutr. 2014;5(3):330S–6S. doi:10.3945/an.113.005389.
310. Lane K, Derbyshire E, Li W, Brennan C. Bioavailability and potential uses of
vegetarian sources of omega-3 fatty acids: a review of the literature. Crit Rev
Food Sci Nutr. 2014;54(5):572–9. doi:10.1080/10408398.2011.596292.
311. Dernini S, Berry EM. Mediterranean Diet: From a Healthy Diet to a
Sustainable Dietary Pattern. Front Nutr. 2015;2:15. doi:10.3389/fnut.2015.
00015.
312. Gu Y, Brickman AM, Stern Y, Habeck CG, Razlighi QR, Luchsinger JA, et al.
Mediterranean diet and brain structure in a multiethnic elderly cohort.
Neurology. 2015;85(20):1744–51. doi:10.1212/WNL.0000000000002121.
313. Mosconi L, McHugh PF. Let Food Be Thy Medicine: Diet, Nutrition, and
Biomarkers’ Risk of Alzheimer’s Disease. Curr Nutr Rep. 2015;4(2):126–35.
314. Bonnet E, Touyarot K, Alfos S, Pallet V, Higueret P, Abrous DN. Retinoic acid
restores adult hippocampal neurogenesis and reverses spatial memory
deficit in vitamin A deprived rats. PLoS One. 2008;3(10):e3487. doi:10.1371/
journal.pone.0003487.
315. Morris MC, Schneider JA, Tangney CC. Thoughts on B-vitamins and
dementia. J Alzheimers Dis. 2006;9(4):429–33.
316. Zhao N, Zhong C, Wang Y, Zhao Y, Gong N, Zhou G, et al. Impaired
hippocampal neurogenesis is involved in cognitive dysfunction induced by
thiamine deficiency at early pre-pathological lesion stage. Neurobiol Dis.
2008;29(2):176–85.
317. Kv L’o’n, Nguyen LT. Role of thiamine in Alzheimer’s disease. Am J
Alzheimers Dis Other Demen. 2011;26(8):588–98. doi:10.1177/
1533317511432736.
318. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin
stimulates adiponectin secretion through the GPR109A receptor. Am J
Physiol Endocrinol Metab. 2009;296(3):E549–58. doi:10.1152/ajpendo.91004.
2008.
319. Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, et al.
Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive
decline. J Neurol Neurosurg Psychiatry. 2004;75(8):1093–9.
320. Oyarce K, Bongarzone ER, Nualart F. Unconventional Neurogenic Niches and
Neurogenesis Modulation by Vitamins. J Stem Cell Res Ther. 2014;4(3):184.
321. Banerjee A, Khemka VK, Ganguly A, Roy D, Ganguly U, Chakrabarti S. Vitamin
D and Alzheimer’s Disease: Neurocognition to Therapeutics. Int J Alzheimers
Dis. 2015;2015:192747. doi:10.1155/2015/192747.
322. Cuppini R, Ciaroni S, Cecchini T, Ambrogini P, Ferri P, Cuppini C, et al.
Tocopherols enhance neurogenesis in dentate gyrus of adult rats. Int J
Vitam Nutr Res. 2002;72(3):170–6.
323. Oulhaj A, Refsum H, Beaumont H, Williams J, King E, Jacoby R, Smith AD.
Homocysteine as a predictor of cognitive decline in Alzheimer’s disease. J
Geriatr Psychiatry. 2010;25(1):82–90. doi:10.1002/gps.2303.
324. Jara-Prado A, Ortega-Vazquez A, Martinez-Ruano L, Rios C, Santamaria A.
Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor
blockade, antioxidant treatment, and nitric oxide synthase inhibition.
Neurotox Res. 2003;5(4):237–43.
325. Poddar R, Paul S. Homocysteine-NMDA receptor-mediated activation of
extracellular signal-regulated kinase leads to neuronal cell death. J
Neurochem. 2009;110(3):1095–106. doi:10.1111/j.1471-4159.2009.06207.x.
326. Shin JY, Ahn YH, Paik MJ, Park HJ, Sohn YH, Lee PH. Elevated homocysteine
by levodopa is detrimental to neurogenesis in parkinsonian model. PLoS
One. 2012;7(11):e50496. doi:10.1371/journal.pone.0050496.
327. Rabaneda LG, Carrasco M, López-Toledano MA, Murillo-Carretero M, Ruiz FA,
Estrada C, Castro C. Homocysteine inhibits proliferation of neuronal
precursors in the mouse adult brain by impairing the basic fibroblast
growth factor signaling cascade and reducing extracellular regulated kinase
1/2-dependent cyclin E expression. FASEB J. 2008;22(11):3823–35. doi:10.
1096/fj.08-109306.
328. Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L,
Erkinjuntti T, et al. Plasma homocysteine, Alzheimer and cerebrovascular
pathology: a population-based autopsy study. Brain. 2013;136(Pt 9):2707–16.
doi:10.1093/brain/awt206.
329. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G,
et al. Homocysteine-lowering by B vitamins slows the rate of accelerated
brain atrophy in mild cognitive impairment: a randomized controlled trial.
PLoS One. 2010;5(9):e12244. doi:10.1371/journal.pone.0012244.
330. Cardoso BR, Cominetti C, Cozzolino SM. Importance and management of
micronutrient deficiencies in patients with Alzheimer’s disease. Clin Interv
Aging. 2013;8:531–42. doi:10.2147/CIA.S27983.
331. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer
prevention: global perspective. Ann Epidemiol. 2009;19(7):468–83. doi:10.
1016/j.annepidem.2009.03.021.
332. Darwish H, Zeinoun P, Ghusn H, Khoury B, Tamim H, Khoury SJ. Serum 25-
hydroxyvitamin D predicts cognitive performance in adults. Neuropsychiatr
Dis Treat. 2015;11:2217–23. doi:10.2147/NDT.S87014.
333. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency
in US adults. Nutr Res. 2011;31(1):48–54. doi:10.1016/j.nutres.2010.12.001.
334. Zhu Y, Zhou R, Yang R, Zhang Z, Bai Y, Chang F, et al. Abnormal
neurogenesis in the dentate gyrus of adult mice lacking 1,25-dihydroxy
vitamin D3 (1,25-(OH)2 D3). Hippocampus. 2012;22(3):421–33. doi:10.1002/
hipo.20908.
335. Anglin RE, Samaan Z, Walter SD, McDonald SD. Vitamin D deficiency and
depression in adults: systematic review and meta-analysis. Br J Psychiatry.
2013;202:100–7. doi:10.1192/bjp.bp.111.106666.
336. Wilson VK, Houston DK, Kilpatrick L, Lovato J, Yaffe K, Cauley JA, et al.
Relationship between 25-hydroxyvitamin D and cognitive function in older
adults: the Health, Aging and Body Composition Study. J Am Geriatr Soc.
2014;62(4):636–41. doi:10.1111/jgs.12765.
337. Lardner AL. Vitamin D, and hippocampal development-the story so far.
Front Mol Neurosci. 2015;8:58. doi:10.3389/fnmol.2015.00058.
338. Gowda U, Mutowo MP, Smith BJ, Wluka AE, Renzaho AM. Vitamin D
supplementation to reduce depression in adults: meta-analysis of
randomized controlled trials. Nutrition. 2015;31(3):421–9. doi:10.1016/j.nut.
2014.06.017.
339. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH,
et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology.
2014;83(10):920–8. doi:10.1212/WNL.0000000000000755.
340. Annweiler C, Rolland Y, Schott AM, Blain H, Vellas B, Herrmann FR, Beauchet
O. Higher vitamin D dietary intake is associated with lower risk of
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 45 of 52
alzheimer’s disease: a 7-year follow-up. J Gerontol A Biol Sci Med Sci. 2012;
67(11):1205–11. doi:10.1093/gerona/gls107.
341. Durup D, Jørgensen HL, Christensen J, Tjønneland A, Olsen A, Halkjær J,
et al. A Reverse J-Shaped Association Between Serum 25-Hydroxyvitamin D
and Cardiovascular Disease Mortality: The CopD Study. J Clin Endocrinol
Metab. 2015;100(6):2339–46. doi:10.1210/jc.2014-4551.
342. Loef M, Schrauzer GN, Walach H. Selenium and Alzheimer’s disease: a
systematic review. J Alzheimers Dis. 2011;26(1):81–104. doi:10.3233/JAD-
2011-110414.
343. Santos JR, Gois AM, Mendonça DM, Freire MA. Nutritional status, oxidative
stress and dementia: the role of selenium in Alzheimer’s disease. Front
Aging Neurosci. 2014;6:206. doi:10.3389/fnagi.2014.00206.
344. Raymond LJ, Deth RC, Ralston NV. Potential Role of Selenoenzymes and
Antioxidant Metabolism in relation to Autism Etiology and Pathology.
Autism Res Treat. 2014;2014:164938. doi:10.1155/2014/164938.
345. Conner TS, Richardson AC, Miller JC. Optimal serum selenium
concentrations are associated with lower depressive symptoms and
negative mood among young adults. J Nutr. 2015;145(1):59–65. doi:10.3945/
jn.114.198010.
346. Walton NM, Shin R, Tajinda K, Heusner CL, Kogan JH, Miyake S, et al. Adult
neurogenesis transiently generates oxidative stress. PLoS One. 2012;7(4):
e35264. doi:10.1371/journal.pone.0035264.
347. Wanet A, Arnould T, Najimi M, Renard P. Connecting mitochondria,
metabolism, and stem cell fate. Stem Cells Dev. 2015;24(17):1957–71.
doi:10.1089/scd.2015.0117.
348. Suh SW, Won SJ, Hamby AM, Yoo BH, Fan Y, Sheline CT, et al. Decreased
brain zinc availability reduces hippocampal neurogenesis in mice and rats. J
Cereb Blood Flow Metab. 2009;29(9):1579–88. doi:10.1038/jcbfm.2009.80.
349. Levenson CW, Morris D. Zinc and neurogenesis: making new neurons from
development to adulthood. Adv Nutr. 2011;2(2):96–100. doi:10.3945/an.110.
000174.
350. Szewczyk B, Kubera M, Nowak G. The role of zinc in neurodegenerative
inflammatory pathways in depression. Prog Neuropsychopharmacol Biol
Psychiatry. 2011;35(3):693–701. doi:10.1016/j.pnpbp.2010.02.010.
351. Watt NT, Whitehouse IJ, Hooper NM. The role of zinc in Alzheimer’s disease.
Int J Alzheimers Dis. 2010;2011:971021. doi:10.4061/2011/971021.
352. Terao T. Is lithium potentially a trace element? World J Psychiatry. 2015;5(1):
1–3. doi:10.5498/wjp.v5.i1.1.
353. Zarse K, Terao T, Tian J, Iwata N, Ishii N, Ristow M. Low-dose lithium uptake
promotes longevity in humans and metazoans. Eur J Nutr. 2011;50(5):387–9.
doi:10.1007/s00394-011-0171-x.
354. Ishii N, Terao T, Araki Y, Kohno K, Mizokami Y, Shiotsuki I, et al. Low risk of
male suicide and lithium in drinking water. J Clin Psychiatry. 2015;76(3):319–26.
doi:10.4088/JCP.14m09218.
355. Schrauzer GN, Shrestha KP. Lithium in drinking water and the incidences of
crimes, suicides, and arrests related to drug addictions. Biol Trace Elem Res.
1990;25(2):105–13.
356. Nunes PV, Forlenza OV, Gattaz WF. Lithium and risk for Alzheimer’s
disease in elderly patients with bipolar disorder. Br J Psychiatry.
2007;190:359–60.
357. Yucel K, Taylor VH, McKinnon MC, Macdonald K, Alda M, Young LT,
MacQueen GM. Bilateral hippocampal volume increase in patients with
bipolar disorder and short-term lithium treatment. Neuropsychopharmacology.
2008;33(2):361–7.
358. Mauer S, Vergne D, Ghaemi SN. Standard and trace-dose lithium: a
systematic review of dementia prevention and other behavioral benefits.
Aust N Z J Psychiatry. 2014;48(9):809–18. doi:10.1177/0004867414536932.
359. Freland L, Beaulieu JM. Inhibition of GSK3 by lithium, from single molecules
to signaling networks. Front Mol Neurosci. 2012;5:14. doi:10.3389/fnmol.
2012.00014.
360. Fuster-Matanzo A, Llorens-Martín M, Sirerol-Piquer MS, García-Verdugo JM,
Avila J, Hernández F. Dual effects of increased glycogen synthase kinase-
3β activity on adult neurogenesis. Hum Mol Genet. 2013;22(7):1300–15.
doi:10.1093/hmg/dds533.
361. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, et al. Inhibition of
glycogen synthase kinase-3 by lithium correlates with reduced tauopathy
and degeneration in vivo. Proc Natl Acad Sci U S A. 2005;102(19):6990–5.
362. Fiorentini A, Rosi MC, Grossi C, Luccarini I, Casamenti F. Lithium improves
hippocampal neurogenesis, neuropathology and cognitive functions in APP
mutant mice. PLoS One. 2010;5(12):e14382. doi:10.1371/journal.pone.
0014382.
363. Nunes MA, Schöwe NM, Monteiro-Silva KC, Baraldi-Tornisielo T, Souza SI,
Balthazar J, et al. Chronic microdose lithium treatment prevented memory
loss and neurohistopathological changes in a transgenic mouse model of
Alzheimer’s disease. PLoS One. 2015;10(11):e0142267. doi:10.1371/journal.
pone.0142267.
364. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-
modifying properties of long-term lithium treatment for amnestic mild
cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;
198(5):351–6. doi:10.1192/bjp.bp.110.080044.
365. Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized
cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer
Res. 2013;10(1):104–7.
366. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium
induces autophagy by inhibiting inositol monophosphatase. J Cell Biol.
2005;170(7):1101–11.
367. McColl G, Killilea DW, Hubbard AE, Vantipalli MC, Melov S, Lithgow GJ.
Pharmacogenetic analysis of lithium-induced delayed aging in
Caenorhabditis elegans. J Biol Chem. 2008;283(1):350–7.
368. Tam ZY, Gruber J, Ng LF, Halliwell B, Gunawan R. Effects of lithium on age-
related decline in mitochondrial turnover and function in Caenorhabditis
elegans. J Gerontol A Biol Sci Med Sci. 2014;69(7):810–20. doi:10.1093/
gerona/glt210.
369. Lazzara CA, Kim YH. Potential application of lithium in Parkinson’s and other
neurodegenerative diseases. Front Neurosci. 2015;9:403. doi:10.3389/fnins.
2015.00403.
370. Knight EM, Martins IV, Gümüsgöz S, Allan SM, Lawrence CB. High-fat diet-
induced memory impairment in triple-transgenic Alzheimer’s disease (3xTgAD)
mice is independent of changes in amyloid and tau pathology. Neurobiol
Aging. 2014;35(8):1821–32. doi:10.1016/j.neurobiolaging.2014.02.010.
371. Li L, Wang Z, Zuo Z. Chronic intermittent fasting improves cognitive
functions and brain structures in mice. PLoS One. 2013;8(6):e66069. doi:10.
1371/journal.pone.0066069.
372. Arumugam TV, Phillips TM, Cheng A, Morrell CH, Mattson MP, Wan R. Age
and energy intake interact to modify cell stress pathways and stroke
outcome. Ann Neurol. 2010;67(1):41–52. doi:10.1002/ana.21798.
373. Fann DY, Santro T, Manzanero S, Widiapradja A, Cheng YL, Lee SY, et al.
Intermittent fasting attenuates inflammasome activity in ischemic stroke.
Exp Neurol. 2014;257:114–9. doi:10.1016/j.expneurol.2014.04.017.
374. Vasconcelos AR, Yshii LM, Viel TA, Buck HS, Mattson MP, Scavone C,
Kawamoto EM. Intermittent fasting attenuates lipopolysaccharide-induced
neuroinflammation and memory impairment. J Neuroinflammation. 2014;11:
85. doi:10.1186/1742-2094-11-85.
375. Alirezaei M, Kemball CC, Flynn CT, Wood MR, Whitton JL, Kiosses WB. Short-
term fasting induces profound neuronal autophagy. Autophagy. 2010;6(6):
702–10.
376. Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A
periodic diet that mimics fasting promotes multi-system regeneration,
enhanced cognitive performance, and healthspan. Cell Metab. 2015;22(1):
86–99. doi:10.1016/j.cmet.2015.05.012.
377. Hornsby AK, Redhead YT, Rees DJ, Ratcliff MS, Reichenbach A, Wells T, et al.
Short-term calorie restriction enhances adult hippocampal neurogenesis and
remote fear memory in a Ghsr-dependent manner. Psychoneuroendocrinology.
2016;63:198–207. doi:10.1016/j.psyneuen.2015.09.023.
378. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical
applications. Cell Metab. 2014;19(2):181–92. doi:10.1016/j.cmet.2013.12.008.
379. Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotrophic factor
is required for basal neurogenesis and mediates, in part, the enhancement
of neurogenesis by dietary restriction in the hippocampus of adult mice. J
Neurochem. 2002;82(6):1367–75.
380. Cheng B, Mattson MP. NT-3 and BDNF protect CNS neurons against
metabolic/excitotoxic insults. Brain Res. 1994;640(1–2):56–67.
381. Duan W, Guo Z, Mattson MP. Brain-derived neurotrophic factor mediates an
excitoprotective effect of dietary restriction in mice. J Neurochem. 2001;
76(2):619–26.
382. Cunnane S, Nugent S, Roy M, Courchesne-Loyer A, Croteau E, Tremblay S,
et al. Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition. 2011;
27(1):3–20. doi:10.1016/j.nut.2010.07.021.
383. Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying
effects of the ketogenic diet. Behav Pharmacol. 2006;17(5–6):431–9.
384. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short-
chain fatty acids and ketones directly regulate sympathetic nervous system
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 46 of 52
via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A. 2011;
108(19):8030–5. doi:10.1073/pnas.1016088108.
385. Edwards C, Canfield J, Copes N, Rehan M, Lipps D, Bradshaw PC. D-beta-
hydroxybutyrate extends lifespan in C. elegans. Aging (Albany NY). 2014;
6(8):621–44.
386. Samoilova M, Weisspapir M, Abdelmalik P, Velumian AA, Carlen PL. Chronic
in vitro ketosis is neuroprotective but not anti-convulsant. J Neurochem.
2010;113(4):826–35. doi:10.1111/j.1471-4159.2010.06645.x.
387. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-
hydroxybutyrate protects neurons in models of Alzheimer’s and Parkinson’s
disease. Proc Natl Acad Sci U S A. 2000;97(10):5440–4.
388. Hertz L, Chen Y, Waagepetersen HS. Effects of ketone bodies in Alzheimer’s
disease in relation to neural hypometabolism, β-amyloid toxicity, and
astrocyte function. J Neurochem. 2015;134(1):7–20. doi:10.1111/jnc.13107.
389. Rahman M, Muhammad S, Khan MA, Chen H, Ridder DA, Müller-Fielitz H,
et al. The β-hydroxybutyrate receptor HCA2 activates a neuroprotective
subset of macrophages. Nat Commun. 2014;5:3944. doi:10.1038/
ncomms4944.
390. Sabokdast M, Habibi-Rezaei M, Moosavi-Movahedi AA, Ferdousi M,
Azimzadeh-Irani E, Poursasan N. Protection by beta-Hydroxybutyric acid
against insulin glycation, lipid peroxidation and microglial cell apoptosis.
Daru. 2015;23:42. doi:10.1186/s40199-015-0126-5.
391. Camberos-Luna L, Gerónimo-Olvera C, Montiel T, Rincon-Heredia R, Massieu L.
The Ketone Body, β-Hydroxybutyrate Stimulates the Autophagic Flux and
Prevents Neuronal Death Induced by Glucose Deprivation in Cortical Cultured
Neurons. Neurochem Res. 2015; www.ncbi.nlm.nih.gov/pubmed/26303508.
392. Puchowicz MA, Zechel JL, Valerio J, Emancipator DS, Xu K, Pundik S, et al.
Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J
Cereb Blood Flow Metab. 2008;28(12):1907–16. doi:10.1038/jcbfm.2008.79.
393. Hatori M, Vollmers C, Zarrinpar A, DiTacchio L, Bushong EA, Gill S, Leblanc
M, et al. Time-restricted feeding without reducing caloric intake prevents
metabolic diseases in mice fed a high-fat diet. Cell Metab. 2012;15(6):848–
60. doi:10.1016/j.cmet.2012.04.019.
394. Zilberter T, Zilberter EY. Breakfast and cognition: sixteen effects in nine
populations, no single recipe. Front Hum Neurosci. 2013;7:631. doi:10.3389/
fnhum.2013.00631.
395. Zilberter T, Zilberter EY. Breakfast: to skip or not to skip? Front Public Health.
2014;2:59. doi:10.3389/fpubh.2014.00059.
396. Mora F. Successful brain aging: plasticity, environmental enrichment, and
lifestyle. Dialogues Clin Neurosci. 2013;15(1):45–52.
397. Chakrabarti P, Kim JY, Singh M, Shin YK, Kim J, Kumbrink J, et al. Insulin
inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-
Egr1-ATGL-mediated pathway. Mol Cell Biol. 2013;33(18):3659–66. doi:10.
1128/MCB.01584-12.
398. Alberti KG, Johnston DG, Gill A, Barnes AJ, Orskov H. Hormonal regulation of
ketone-body metabolism in man. Biochem Soc Symp. 1978;43:163–82.
399. Yeh YY, Klein LB, Zee P. Long and medium chain triglycerides increase plasma
concentrations of ketone bodies in suckling rats. Lipids. 1978;13(8):566–71.
400. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, et al.
Effects of beta-hydroxybutyrate on cognition in memory-impaired adults.
Neurobiol Aging. 2004;25(3):311–4.
401. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of
the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a
randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab
(Lond). 2009;6:31. doi:10.1186/1743-7075-6-31.
402. Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y, et al.
Benefits of use, and tolerance of, medium-chain triglyceride medical food in
the management of Japanese patients with Alzheimer’s disease: a
prospective, open-label pilot study. Clin Interv Aging. 2016;11:29–36.
doi:10.2147/CIA.S95362.
403. Heininger K. A unifying hypothesis of Alzheimer’s disease. IV. Causation and
sequence of events. Rev Neurosci. 2000;11 Spec No:213–328
404. van Praag H. Exercise and the brain: something to chew on. Trends
Neurosci. 2009;32(5):283–90. doi:10.1016/j.tins.2008.12.007.
405. Stranahan AM, Lee K, Martin B, Maudsley S, Golden E, Cutler RG, Mattson
MP. Voluntary exercise and caloric restriction enhance hippocampal
dendritic spine density and BDNF levels in diabetic mice. Hippocampus.
2009;19(10):951–61. doi:10.1002/hipo.20577.
406. Stanhope KL. Role of fructose-containing sugars in the epidemics of obesity
and metabolic syndrome. Annu Rev Med. 2012;63:329–43. doi:10.1146/
annurev-med-042010-113026.
407. Monteiro CA, Moubarac JC, Cannon G, Ng SW, Popkin B. Ultra-processed
products are becoming dominant in the global food system. Obes Rev.
2013;14 Suppl 2:21–8. doi:10.1111/obr.12107.
408. Fernando WM, Martins IJ, Goozee KG, Brennan CS, Jayasena V, Martins RN.
The role of dietary coconut for the prevention and treatment of Alzheimer’s
disease: potential mechanisms of action. Br J Nutr. 2015;114(1):1–14. doi:10.
1017/S0007114515001452.
409. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al.
Global, regional, and national prevalence of overweight and obesity in
children and adults during 1980–2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81. doi:10.1016/
S0140-6736(14)60460-8.
410. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine
organ. Arch Med Sci. 2013;9(2):191–200. doi:10.5114/aoms.2013.33181.
411. Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism
accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249(1):218–38.
doi:10.1111/j.1600-065X.2012.01151.x.
412. Patel P, Abate N. Body fat distribution and insulin resistance. Nutrients.
2013;5(6):2019–27. doi:10.3390/nu5062019.
413. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced
hypertension: interaction of neurohumoral and renal mechanisms. Circ Res.
2015;116(6):991–1006. doi:10.1161/CIRCRESAHA.116.305697.
414. Luo Y, Ma X, Shen Y, Hao Y, Hu Y, Xiao Y, et al. Positive relationship
between serum low-density lipoprotein cholesterol levels and visceral fat in
a Chinese nondiabetic population. PLoS One. 2014;9(11):e112715. doi:10.
1371/journal.pone.0112715.
415. Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Eitzman DT. Visceral
adipose tissue and atherosclerosis. Curr Vasc Pharmacol. 2009;7(2):169–79.
416. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic
syndrome: contribution of visceral fat accumulation and its molecular
mechanism. J Atheroscler Thromb. 2011;18(8):629–39.
417. Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of
cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47,
e149. doi:10.1038/emm.2015.3.
418. Watts AS, Loskutova N, Burns JM, Johnson DK. Metabolic syndrome and
cognitive decline in early Alzheimer’s disease and healthy older adults. J
Alzheimers Dis. 2013;35(2):253–65. doi:10.3233/JAD-121168.
419. Paz-Filho G, Wong ML, Licinio J. The procognitive effects of leptin in the
brain and their clinical implications. Int J Clin Pract. 2010;64(13)):1808–12.
doi:10.1111/j.1742-1241.2010.02536.x.
420. Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, et al. Leptin
reduces pathology and improves memory in a transgenic mouse model of
Alzheimer’s disease. J Alzheimers Dis. 2010;19(4):1155–67. doi:10.3233/JAD-
2010-1308.
421. Milaneschi Y, Simonsick EM, Vogelzangs N, Strotmeyer ES, Yaffe K, Harris TB,
et al. Leptin, abdominal obesity, and onset of depression in older men and
women. J Clin Psychiatry. 2012;73(9):1205–11. doi:10.4088/JCP.11m07552.
422. Platt TL, Beckett TL, Kohler K, Niedowicz DM, Murphy MP. Obesity, diabetes,
and leptin resistance promote tau pathology in a mouse model of disease.
Neuroscience. 2016;315:162–74. doi:10.1016/j.neuroscience.2015.12.011.
423. Letra L, Santana I, Seiça R. Obesity as a risk factor for Alzheimer’s disease:
the role of adipocytokines. Metab Brain Dis. 2014;29(3):563–8. doi:10.1007/
s11011-014-9501-z.
424. Businaro R, Ippoliti F, Ricci S, Canitano N, Fuso A. Alzheimer’s disease
promotion by obesity: induced mechanisms-molecular links and perspectives.
Curr Gerontol Geriatr Res. 2012;2012:986823. doi:10.1155/2012/986823.
425. Arnoldussen IA, Kiliaan AJ, Gustafson DR. Obesity and dementia: adipokines
interact with the brain. Eur Neuropsychopharmacol. 2014;24(12):1982–99.
doi:10.1016/j.euroneuro.2014.03.002.
426. Lossi L, Mioletti S, Merighi A. Synapse-independent and synapse-dependent
apoptosis of cerebellar granule cells in postnatal rabbits occur at two
subsequent but partly overlapping developmental stages. Neuroscience.
2002;112(3):509–23.
427. Boyle PA, Buchman AS, Barnes LL, Bennett DA. Effect of a purpose in life on
risk of incident Alzheimer disease and mild cognitive impairment in
community-dwelling older persons. Arch Gen Psychiatry. 2010;67(3):304–10.
doi:10.1001/archgenpsychiatry.2009.208.
428. Hu YS, Xu P, Pigino G, Brady ST, Larson J, Lazarov O. Complex environment
experience rescues impaired neurogenesis, enhances synaptic plasticity, and
attenuates neuropathology in familial Alzheimer’s disease-linked APPswe/
PS1DeltaE9 mice. FASEB J. 2010;24(6):1667–81. doi:10.1096/fj.09-136945.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 47 of 52
429. Hsiao YH, Hung HC, Chen SH, Gean PW. Social interaction rescues memory
deficit in an animal model of Alzheimer’s disease by increasing BDNF-
dependent hippocampal neurogenesis. J Neurosci. 2014;34(49):16207–19.
doi:10.1523/JNEUROSCI.0747-14.2014.
430. Ertel KA, Glymour MM, Berkman LF. Effects of social integration on preserving
memory function in a nationally representative US elderly population. Am J
Public Health. 2008;98(7):1215–20. doi:10.2105/AJPH.2007.113654.
431. Kueider AM, Parisi JM, Gross AL, Rebok GW. Computerized cognitive training
with older adults: a systematic review. PLoS One. 2012;7(7):e40588. doi:10.
1371/journal.pone.0040588.
432. Unverzagt FW, Guey LT, Jones RN, Marsiske M, King JW, Wadley VG, et al.
ACTIVE cognitive training and rates of incident dementia. J Int
Neuropsychol Soc. 2012;18(4):669–77. doi:10.1017/S1355617711001470.
433. Gruenewald TL, Tanner EK, Fried LP, Carlson MC, Xue QL, Parisi JM et al. The
Baltimore Experience Corps Trial: Enhancing Generativity via
Intergenerational Activity Engagement in Later Life. J Gerontol B Psychol Sci
Soc Sci. 2015.
434. Carlson MC, Kuo JH, Chuang YF, Varma VR, Harris G, Albert MS, et al. Impact of
the Baltimore Experience Corps Trial on cortical and hippocampal volumes.
Alzheimers Dement. 2015;11(11):1340–8. doi:10.1016/j.jalz.2014.12.005.
435. Cinini SM, Barnabe GF, Galvão-Coelho N, de Medeiros MA, Perez-Mendes P,
Sousa MB, et al. Social isolation disrupts hippocampal neurogenesis in
young non-human primates. Front Neurosci. 2014;8:45. doi:10.3389/fnins.
2014.00045.
436. Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, Seckl JR,
et al. Epigenetic programming by maternal behavior. Nat Neurosci.
2004;7(8):847–54.
437. van der Knaap LJ, Riese H, Hudziak JJ, Verbiest MM, Verhulst FC, Oldehinkel
AJ, van Oort FV. Glucocorticoid receptor gene (NR3C1) methylation
following stressful events between birth and adolescence. The TRAILS study.
Transl Psychiatry. 2014;4, e381. doi:10.1038/tp.2014.22.
438. McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonté B, Szyf M, et al.
Epigenetic regulation of the glucocorticoid receptor in human brain
associates with childhood abuse. Nat Neurosci. 2009;12(3):342–8. doi:10.
1038/nn.2270.
439. Frodl T, Schaub A, Banac S, Charypar M, Jäger M, Kümmler P, et al. Reduced
hippocampal volume correlates with executive dysfunctioning in major
depression. J Psychiatry Neurosci. 2006;31(5):316–23.
440. Johansson L, Guo X, Hällström T, Norton MC, Waern M, Ostling S, et al.
Common psychosocial stressors in middle-aged women related to
longstanding distress and increased risk of Alzheimer’s disease: a 38-year
longitudinal population study. BMJ Open. 2013;3(9):e003142. doi:10.1136/
bmjopen-2013-003142.
441. Johansson L, Guo X, Duberstein PR, Hällström T, Waern M, Ostling S, Skoog
I. Midlife personality and risk of Alzheimer disease and distress: a 38-year
follow-up. Neurology. 2014;83(17):1538–44. doi:10.1212/WNL.
0000000000000907.
442. Hauner KK, Adam EK, Mineka S, Doane LD, DeSantis AS, Zinbarg R, et al.
Neuroticism and introversion are associated with salivary cortisol patterns in
adolescents. Psychoneuroendocrinology. 2008;33(10):1344–56. doi:10.1016/j.
psyneuen.2008.07.011.
443. Dedovic K, Ngiam J. The cortisol awakening response and major depression:
examining the evidence. Neuropsychiatr Dis Treat. 2015;11:1181–9. doi:10.
2147/NDT.S62289.
444. Leuner B, Caponiti JM, Gould E. Oxytocin stimulates adult neurogenesis
even under conditions of stress and elevated glucocorticoids.
Hippocampus. 2012;22(4):861–8. doi:10.1002/hipo.20947.
445. Cavanaugh J, Carp SB, Rock CM, French JA. Oxytocin modulates behavioral
and physiological responses to a stressor in marmoset monkeys.
Psychoneuroendocrinology. 2015;66:22–30. doi:10.1016/j.psyneuen.2015.12.027.
446. Kirsch P. Oxytocin in the socioemotional brain: implications for psychiatric
disorders. Dialogues Clin Neurosci. 2015;17(4):463–76.
447. Cohen H, Liu T, Kozlovsky N, Kaplan Z, Zohar J, Mathé AA. The
neuropeptide Y (NPY)-ergic system is associated with behavioral resilience
to stress exposure in an animal model of post-traumatic stress disorder.
Neuropsychopharmacology. 2012;37(2):350–63. doi:10.1038/npp.2011.230.
448. Geloso MC, Corvino V, Di Maria V, Marchese E, Michetti F. Cellular targets for
neuropeptide Y-mediated control of adult neurogenesis. Front Cell
Neurosci. 2015;9:85. doi:10.3389/fncel.2015.00085.
449. Ragu Varman D, Rajan KE. Environmental enrichment reduces anxiety by
differentially activating serotonergic and neuropeptide Y (NPY)-ergic system
in Indian field mouse (Mus booduga): an animal model of post-traumatic
stress disorder. PLoS One. 2015;10(5):e0127945. doi:10.1371/journal.pone.
0127945.
450. Lyons DM, Buckmaster PS, Lee AG, Wu C, Mitra R, Duffey LM, et al. Stress
coping stimulates hippocampal neurogenesis in adult monkeys. Proc Natl
Acad Sci U S A. 2010;107(33):14823–7. doi:10.1073/pnas.0914568107.
451. Reula JMHM, Collinsa A, Salibaa RS, Mifsuda KR, Cartera SD, Gutierrez-
Mecinasa M, et al. Glucocorticoids, epigenetic control and stress resilience.
Neurobiol Stress. 2015;1:44–59. doi:10.1016/j.ynstr.2014.10.001.
452. Nejati S, Zahiroddin A, Afrookhteh G, Rahmani S, Hoveida S. Effect of group
mindfulness-based stress-reduction program and conscious yoga on
lifestyle, coping strategies, and systolic and diastolic blood pressures in
patients with hypertension. J Tehran Heart Cent. 2015;10(3):140–8.
453. Fava GA, Tomba E. Increasing psychological well-being and resilience by
psychotherapeutic methods. J Pers. 2009;77(6):1903–34. doi:10.1111/j.1467-
6494.2009.00604.x.
454. Kreutzmann JC, Havekes R, Abel T, Meerlo P. Sleep deprivation and
hippocampal vulnerability: changes in neuronal plasticity, neurogenesis and
cognitive function. Neuroscience. 2015;309:173–90. doi:10.1016/j.
neuroscience.2015.04.053.
455. Joo EY, Kim H, Suh S, Hong SB. Hippocampal substructural vulnerability to
sleep disturbance and cognitive impairment in patients with chronic
primary insomnia: magnetic resonance imaging morphometry. Sleep.
2014;37(7):1189–98. doi:10.5665/sleep.3836.
456. Mueller AD, Meerlo P, McGinty D, Mistlberger RE. Sleep and adult
neurogenesis: implications for cognition and mood. Curr Top Behav
Neurosci. 2015;25:151–81. doi:10.1007/7854_2013_251.
457. Hardeland R, Cardinali DP, Brown GM, Pandi-Perumal SR. Melatonin and
brain inflammaging. Prog Neurobiol. 2015;127–128:46–63. doi:10.1016/j.
pneurobio.2015.02.001.
458. Ramirez-Rodriguez G, Ortíz-López L, Domínguez-Alonso A, Benítez-King GA,
Kempermann G. Chronic treatment with melatonin stimulates dendrite
maturation and complexity in adult hippocampal neurogenesis of mice.
J Pineal Res. 2011;50(1):29–37. doi:10.1111/j.1600-079X.2010.00802.x.
459. Lucey BP, Bateman RJ. Amyloid-β diurnal pattern: possible role of sleep in
Alzheimer’s disease pathogenesis. Neurobiol Aging. 2014;35 Suppl 2:S29–34.
doi:10.1016/j.neurobiolaging.2014.03.035.
460. Ju YE, McLeland JS, Toedebusch CD, Xiong C, Fagan AM, Duntley SP, et al.
Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):
587–93. doi:10.1001/jamaneurol.2013.2334.
461. Iadecola C. Dangerous leaks: blood–brain barrier woes in the aging
hippocampus. Neuron. 2015;85(2):231–3. doi:10.1016/j.neuron.2014.12.056.
462. Erickson MA, Banks WA. Blood–brain barrier dysfunction as a cause and
consequence of Alzheimer’s disease. J Cereb Blood Flow Metab. 2013;33(10):
1500–13. doi:10.1038/jcbfm.2013.135.
463. He J, Hsuchou H, He Y, Kastin AJ, Wang Y, Pan W. Sleep restriction impairs
blood–brain barrier function. J Neurosci. 2014;34(44):14697–706. doi:10.1523/
JNEUROSCI.2111-14.2014.
464. Gómez-González B, Hurtado-Alvarado G, Esqueda-León E, Santana-Miranda
R, Rojas-Zamorano JÁ. Velázquez-Moctezuma REM sleep loss and recovery
regulates blood–brain barrier function. J Curr Neurovasc Res. 2013;10(3):
197–207.
465. Lucke-Wold BP, Smith KE, Nguyen L, Turner RC, Logsdon AF, Jackson GJ,
et al. Sleep disruption and the sequelae associated with traumatic brain
injury. Neurosci Biobehav Rev. 2015;55:68–77. doi:10.1016/j.neubiorev.2015.
04.010.
466. Tsapanou A, Gu Y, Manly J, Schupf N, Tang MX, Zimmerman M, et al.
Daytime sleepiness and sleep inadequacy as risk factors for dementia.
Dement Geriatr Cogn Dis Extra. 2015;5(2):286–95. doi:10.1159/000431311.
467. Black DS, O’Reilly GA, Olmstead R, Breen EC, Irwin MR. Mindfulness meditation
and improvement in sleep quality and daytime impairment among older
adults with sleep disturbances: a randomized clinical trial. JAMA Intern Med.
2015;175(4):494–501. doi:10.1001/jamainternmed.2014.8081.
468. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in
Alzheimer’s disease. Neuro Endocrinol Lett. 2002;23 Suppl 1:20–3.
469. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Brusco LI. Melatonin therapy in
patients with Alzheimer’s disease. Antioxidants (Basel). 2014;3(2):245–77.
doi:10.3390/antiox3020245.
470. Saaltink DJ, Vreugdenhil E. Stress, glucocorticoid receptors, and adult
neurogenesis: a balance between excitation and inhibition? Cell Mol Life
Sci. 2014;71(13):2499–515. doi:10.1007/s00018-014-1568-5.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 48 of 52
471. Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus.
Proc Natl Acad Sci U S A. 2001;98(22):12320–2.
472. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, et al. The
ageing systemic milieu negatively regulates neurogenesis and cognitive
function. Nature. 2011;477(7362):90–4. doi:10.1038/nature10357.
473. Godbout JP, Johnson RW. Age and neuroinflammation: a lifetime of
psychoneuroimmune consequences. Immunol Allergy Clin North Am. 2009;
29(2):321–37. doi:10.1016/j.iac.2009.02.007.
474. Hoozemans JJ, Rozemuller AJ, van Haastert ES, Eikelenboom P, van Gool
WA. Neuroinflammation in Alzheimer’s disease wanes with age. J
Neuroinflammation. 2011;8:171. doi:10.1186/1742-2094-8-171.
475. Fuster-Matanzo A, Llorens-Martín M, Hernández F, Avila J. Role of
neuroinflammation in adult neurogenesis and Alzheimer disease:
therapeutic approaches. Mediators Inflamm. 2013;2013:260925. doi:10.1155/
2013/260925.
476. Munhoz CD, García-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC.
Stress-induced neuroinflammation: mechanisms and new pharmacological
targets. Braz J Med Biol Res. 2008;41(12):1037–46.
477. Zhao Y, Lukiw WJ. Microbiome-generated amyloid and potential impact on
amyloidogenesis in Alzheimer’s disease (AD). J Nat Sci. 2015;1(7).
478. Phillips C, Baktir MA, Srivatsan M, Salehi A. Neuroprotective effects of
physical activity on the brain: a closer look at trophic factor signaling. Front
Cell Neurosci. 2014;8:170. doi:10.3389/fncel.2014.00170.
479. Zhu B, Dong Y, Xu Z, Gompf HS, Ward SA, Xue Z, et al. Sleep disturbance
induces neuroinflammation and impairment of learning and memory.
Neurobiol Dis. 2012;48(3):348–55. doi:10.1016/j.nbd.2012.06.022.
480. Aguilar-Valles A, Inoue W, Rummel C, Luheshi GN. Obesity, adipokines and
neuroinflammation. Neuropharmacology. 2015;96(Pt A):124–34. doi:10.1016/
j.neuropharm.2014.12.023.
481. Mancini M, Grappasonni I, Scuri S, Amenta F. Oral health in Alzheimer’s
disease: a review. Curr Alzheimer Res. 2010;7(4):368–73.
482. Bibi F, Yasir M, Sohrab SS, Azhar EI, Al-Qahtani MH, Abuzenadah AM, et al.
Link between chronic bacterial inflammation and Alzheimer disease. CNS
Neurol Disord Drug Targets. 2014;13(7):1140–7.
483. Chesnokova V, Pechnick RN, Wawrowsky K. Chronic Peripheral Inflammation,
Hippocampal Neurogenesis, and Behavior. Brain Behav Immun. 2016.
(16)30017-4. doi: 10.1016/j.bbi.2016.01.017.
484. Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So
depression is an inflammatory disease, but where does the inflammation
come from? BMC Med. 2013;11:200. doi:10.1186/1741-7015-11-200.
485. Herring A, Yasin H, Ambrée O, Sachser N, Paulus W, Keyvani K.
Environmental enrichment counteracts Alzheimer’s neurovascular
dysfunction in TgCRND8 mice. Brain Pathol. 2008;18(1):32–9.
486. Yalak G, Ehrlich YH, Olsen BR. Ecto-protein kinases and phosphatases: an
emerging field for translational medicine. J Transl Med. 2014;12:165.
doi:10.1186/1479-5876-12-165.
487. Kumar S, Wirths O, Stüber K, Wunderlich P, Koch P, Theil S et al.
Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric
assembly and increases neurotoxicity. Acta Neuropathol. 2016; www.ncbi.
nlm.nih.gov/pubmed/?term=26898910.
488. Yin RH, Tan L, Jiang T, Yu JT. Prion-like mechanisms in Alzheimer’s disease.
Curr Alzheimer Res. 2014;11(8):755–64.
489. Prusiner SB. Biology and genetics of prions causing neurodegeneration.
Annu Rev Genet. 2013;47:601–23. doi:10.1146/annurev-genet-110711-
155524.
490. Lucey BP, Holtzman DM. How amyloid, sleep and memory connect. Nat
Neurosci. 2015;18(7):933–4. doi:10.1038/nn.4048.
491. Fu C, Chute DJ, Farag ES, Garakian J, Cummings JL, Vinters HV. Comorbidity
in dementia: an autopsy study. Arch Pathol Lab Med. 2004;128(1):32–8.
492. Gupta A, Iadecola C. Impaired Aβ clearance: a potential link between
atherosclerosis and Alzheimer’s disease. Front Aging Neurosci. 2015;7:115.
doi:10.3389/fnagi.2015.00115.
493. Castellani RJ, Smith MA, Perry G, Friedland RP. Cerebral amyloid angiopathy:
major contributor or decorative response to Alzheimer’s disease
pathogenesis. Neurobiol Aging. 2004;25(5):599–602. discussion 603–4.
494. Miklossy J.J. Neuroinflammation. Alzheimer’s disease - a neurospirochetosis.
Analysis of the evidence following Koch’s and Hill’s criteria. 2011;8:90.
doi: 10.1186/1742-2094-8-90.
495. Harris SA, Harris EA. Herpes simplex virus type 1 and other pathogens are
key causative factors in sporadic Alzheimer’s disease. J Alzheimers Dis. 2015;
48(2):319–53. doi:10.3233/JAD-142853.
496. de la Monte SM. Brain insulin resistance and deficiency as therapeutic
targets in Alzheimer’s disease. Curr Alzheimer Res. 2012;9(1):35–66.
497. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al.
Distinct tau prion strains propagate in cells and mice and define different
tauopathies. Neuron. 2014;82(6):1271–88. doi:10.1016/j.neuron.2014.04.047.
498. Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology
and neuroinflammation in Alzheimer’s disease. Mt Sinai J Med. 2010;77(1):
50–8. doi:10.1002/msj.20163.
499. Bruijnzeel AW, Bauzo RM, Munikoti V, Rodrick GB, Yamada H, Fornal CA,
et al. Tobacco smoke diminishes neurogenesis and promotes gliogenesis in
the dentate gyrus of adolescent rats. Brain Res. 2011;1413:32–42. doi:10.
1016/j.brainres.2011.07.041.
500. Rusanen M, Kivipelto M, Quesenberry Jr CP, Zhou J, Whitmer RA. Heavy
smoking in midlife and long-term risk of Alzheimer disease and vascular
dementia. Arch Intern Med. 2011;171(4):333–9. doi:10.1001/archinternmed.
2010.393.
501. Shingo AS, Kito S. Effects of nicotine on neurogenesis and plasticity of
hippocampal neurons. J Neural Transm (Vienna). 2005;112(11):1475–8.
502. Harwood DG, Kalechstein A, Barker WW, Strauman S, St George-Hyslop P,
et al. The effect of alcohol and tobacco consumption, and apolipoprotein E
genotype, on the age of onset in Alzheimer’s disease. Int J Geriatr
Psychiatry. 2010;25(5):511–8. doi:10.1002/gps.2372.
503. Taffe MA, Kotzebue RW, Crean RD, Crawford EF, Edwards S, Mandyam CD.
Long-lasting reduction in hippocampal neurogenesis by alcohol
consumption in adolescent nonhuman primates. Proc Natl Acad Sci U S A.
2010;107(24):11104–9. doi:10.1073/pnas.0912810107.
504. Piazza-Gardner AK, Gaffud TJ, Barry AE. The impact of alcohol on Alzheimer’s
disease: a systematic review. Aging Ment Health. 2013;17(2):133–46. doi:10.
1080/13607863.2012.742488.
505. Langballe EM, Ask H, Holmen J, Stordal E, Saltvedt I, Selbæk G, et al. Alcohol
consumption and risk of dementia up to 27 years later in a large,
population-based sample: the HUNT study, Norway. Eur J Epidemiol. 2015;
30(9):1049–56. doi:10.1007/s10654-015-0029-2.
506. Sommerfeld M. Trans unsaturated fatty acids in natural products and
processed foods. Prog Lipid Res. 1983;22(3):221–33.
507. Motard-Bélanger A, Charest A, Grenier G, Paquin P, Chouinard Y, Lemieux S,
et al. Study of the effect of trans fatty acids from ruminants on blood lipids
and other risk factors for cardiovascular disease. Am J Clin Nutr. 2008;87(3):
593–9.
508. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids:
experimental and observational evidence. Eur J Clin Nutr. 2009;63 Suppl 2:
S5–S21. doi:10.1038/sj.ejcn.1602973.
509. Laake I, Pedersen JI, Selmer R, Kirkhus B, Lindman AS, Tverdal A, Veierød MB.
A prospective study of intake of trans-fatty acids from ruminant fat, partially
hydrogenated vegetable oils, and marine oils and mortality from CVD. Br J
Nutr. 2012;108(4):743–54. doi:10.1017/S0007114511005897.
510. Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, Soininen H,
Kivipelto M. Fat intake at midlife and cognitive impairment later in life: a
population-based CAIDE study. Int J Geriatr Psychiatry. 2008;23(7):741–7. doi:
10.1002/gps.1969.
511. Crichton GE, Bryan J, Murphy KJ, Buckley J. Review of dairy consumption
and cognitive performance in adults: findings and methodological issues.
Dement Geriatr Cogn Disord. 2010;30(4):352–61. doi:10.1159/000320987.
512. Larqué E, Pérez-Llamas F, Puerta V, Girón MD, Suárez MD, Zamora S, Gil A.
Dietary trans fatty acids affect docosahexaenoic acid concentrations in
plasma and liver but not brain of pregnant and fetal rats. Pediatr Res. 2000;
47(2):278–83.
513. Rao JS, Ertley RN, Lee HJ, DeMar Jr JC, Arnold JT, Rapoport SI, Bazinet RP. n-
3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex
BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry. 2007;12(1):
36–46.
514. Kang JX, Gleason ED. Omega-3 Fatty acids and hippocampal neurogenesis
in depression. CNS Neurol Disord Drug Targets. 2013;12(4):460–5.
515. Grimm MO, Rothhaar TL, Grösgen S, Burg VK, Hundsdörfer B, Haupenthal VJ,
et al. Trans fatty acids enhance amyloidogenic processing of the Alzheimer
amyloid precursor protein (APP). J Nutr Biochem. 2012;23(10):1214–23.
doi:10.1016/j.jnutbio.2011.06.015.
516. Tong M, Neusner A, Longato L, Lawton M, Wands JR, de la Monte SM.
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2
diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer’s disease. J
Alzheimers Dis. 2009;17(4):827–44.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 49 of 52
517. Kim ME, Park HR, Gong EJ, Choi SY, Kim HS, Lee J. Exposure to bisphenol A
appears to impair hippocampal neurogenesis and spatial learning and
memory. Food Chem Toxicol. 2011;49(12):3383–9. doi:10.1016/j.fct.2011.09.017.
518. Eladak S, Grisin T, Moison D, Guerquin MJ, N’Tumba-Byn T, Pozzi-Gaudin S,
et al. A new chapter in the bisphenol A story: bisphenol S and bisphenol F
are not safe alternatives to this compound. Fertil Steril. 2015;103(1):11–21.
doi:10.1016/j.fertnstert.2014.11.005.
519. Kinch CD, Ibhazehiebo K, Jeong JH, Habibi HR, Kurrasch DM. Low-dose
exposure to bisphenol A and replacement bisphenol S induces precocious
hypothalamic neurogenesis in embryonic zebrafish. Proc Natl Acad Sci U S
A. 2015;112(5):1475–80. doi:10.1073/pnas.1417731112.
520. Cattani D, de Liz Oliveira Cavalli VL, Heinz Rieg CE, Domingues JT, Dal-Cim
T, Tasca CI, et al. Mechanisms underlying the neurotoxicity induced by
glyphosate-based herbicide in immature rat hippocampus: involvement of
glutamate excitotoxicity. Toxicology. 2014;320:34–45. doi:10.1016/j.tox.2014.
03.001.
521. Hossain MM, DiCicco-Bloom E, Richardson JR. Hippocampal ER stress and
learning deficits following repeated pyrethroid exposure. Toxicol Sci. 2015;
143(1):220–8. doi:10.1093/toxsci/kfu226.
522. Mishra D, Tiwari SK, Agarwal S, Sharma VP, Chaturvedi RK. Prenatal
carbofuran exposure inhibits hippocampal neurogenesis and causes
learning and memory deficits in offspring. Toxicol Sci. 2012;127(1):84–100.
doi:10.1093/toxsci/kfs004.
523. Walton JR. Chronic aluminum intake causes Alzheimer’s disease: applying Sir
Austin Bradford Hill’s causality criteria. J Alzheimers Dis. 2014;40(4):765–838.
doi:10.3233/JAD-132204.
524. Drago D, Cavaliere A, Mascetra N, Ciavardelli D, di Ilio C, Zatta P, Sensi SL.
Aluminum modulates effects of beta amyloid(1–42) on neuronal calcium
homeostasis and mitochondria functioning and is altered in a triple
transgenic mouse model of Alzheimer’s disease. Rejuvenation Res. 2008;
11(5):861–71. doi:10.1089/rej.2008.0761.
525. Ralston NV, Raymond LJ. Dietary selenium’s protective effects against
methylmercury toxicity. Toxicology. 2010;278(1):112–23. doi:10.1016/j.tox.
2010.06.004.
526. Ralston NV. Selenium health benefit values as seafood safety criteria.
Ecohealth. 2008;5(4):442–55. doi:10.1007/s10393-008-0202-0.
527. Obiorah M, McCandlish E, Buckley B, DiCicco-Bloom E. Hippocampal
developmental vulnerability to methylmercury extends into prepubescence.
Front Neurosci. 2015;9:150. doi:10.3389/fnins.2015.00150.
528. Freire C, Ramos R, Lopez-Espinosa MJ, Díez S, Vioque J, Ballester F,
Fernández MF. Hair mercury levels, fish consumption, and cognitive
development in preschool children from Granada, Spain. Environ Res. 2010;
110(1):96–104. doi:10.1016/j.envres.2009.10.005.
529. Mutter J, Curth A, Naumann J, Deth R, Walach H. Does inorganic mercury
play a role in Alzheimer’s disease? A systematic review and an integrated
molecular mechanism. J Alzheimers Dis. 2010;22(2):357–74. doi:10.3233/JAD-
2010-100705.
530. Wong BX, Duce JA. The iron regulatory capability of the major protein
participants in prevalent neurodegenerative disorders. Front Pharmacol.
2014;5:81. doi:10.3389/fphar.2014.00081.
531. Orlich MJ, Singh PN, Sabaté J, Jaceldo-Siegl K, Fan J, Knutsen S, et al.
Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA
Intern Med. 2013;173(13):1230–8. doi:10.1001/jamainternmed.2013.6473.
532. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al.
Targeting chelatable iron as a therapeutic modality in Parkinson’s disease.
Antioxid Redox Signal. 2014;21(2):195–210. doi:10.1089/ars.2013.5593.
533. Zhao L, Wang C, Song D, Li Y, Song Y, Su G, Dunaief JL. Systemic
administration of the antioxidant/iron chelator α-lipoic acid protects against
light-induced photoreceptor degeneration in the mouse retina. Invest
Ophthalmol Vis Sci. 2014;55(9):5979–88. doi:10.1167/iovs.14-15025.
534. Lal A, Atamna W, Killilea DW, Suh JH, Ames BN. Lipoic acid and acetyl-
carnitine reverse iron-induced oxidative stress in human fibroblasts. Redox
Rep. 2008;13(1):2–10. doi:10.1179/135100008X259150.
535. Ma Q, Ying M, Sui X, Zhang H, Huang H, Yang L, et al. Chronic copper
exposure causes spatial memory impairment, selective loss of hippocampal
synaptic proteins, and activation of PKR/eIF2α pathway in mice. J
Alzheimers Dis. 2015;43(4):1413–27. doi:10.3233/JAD-140216.
536. Brewer GJ. Divalent copper as a major triggering agent in Alzheimer’s
disease. J Alzheimers Dis. 2015;46(3):593–604. doi:10.3233/JAD-143123.
537. Yamamoto H, Watanabe T, Mizuno H, Endo K, Fukushige J, Hosokawa T,
et al. The antioxidant effect of DL-alpha-lipoic acid on copper-induced
acute hepatitis in Long-Evans Cinnamon (LEC) rats. Free Radic Res. 2001;
34(1):69–80.
538. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and
histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA.
2013;310(22):2435–42. doi:10.1001/jama.2013.280490.
539. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association
of proton pump inhibitors with risk of dementia: a
pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):
410–6. doi:10.1001/jamaneurol.2015.4791.
540. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al.
Cumulative use of strong anticholinergics and incident dementia: a
prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. doi:10.1001/
jamainternmed.2014.7663.
541. de Billioti GS, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al.
Benzodiazepine use and risk of Alzheimer’s disease: case–control study. BMJ.
2014;349:g5205. doi:10.1136/bmj.g5205.
542. Rosenberger DS, Falangola MF, Ledreux A, Nie X, Suhre WM, Boger HA,
Granholm AC. Memory and hippocampal architecture following short-term
midazolam in western diet-treated rats. Neurosci Lett. 2016;621:68–74.
doi:10.1016/j.neulet.2016.04.021.
543. Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS, et al.
Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient
supplementation on cognitive function: the AREDS2 randomized clinical
trial. JAMA. 2015;314(8):791–801. doi:10.1001/jama.2015.9677.
544. Spiro A, Buttriss JL. Vitamin D: an overview of vitamin D status and intake in
Europe. Nutr Bull. 2014;39(4):322–50.
545. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G,
et al. A conceptual framework for research on subjective cognitive decline
in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52.
doi:10.1016/j.jalz.2014.01.001.
546. Langa KM, Levine DA. The diagnosis and management of mild cognitive
impairment: a clinical review. JAMA. 2014;312(23):2551–61. doi:10.1001/jama.
2014.13806.
547. Bredesen DE. Reversal of cognitive decline: a novel therapeutic program.
Aging (Albany NY). 2014;6(9):707–17.
548. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to
remission? Science. 2012;338(6103):72–5. doi:10.1126/science.1222941.
549. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine
stimulates maturation and synaptic plasticity of adult-born hippocampal granule
cells. J Neurosci. 2008;28(6):1374–84. doi:10.1523/JNEUROSCI.3632-07.2008.
550. Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An
antidepressant decreases CSF Aβ production in healthy individuals and in
transgenic AD mice. Sci Transl Med. 2014;6(236):236re4. doi:10.1126/
scitranslmed.3008169.
551. Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al.
Serotonin signaling is associated with lower amyloid-β levels and plaques in
transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108(36):14968–73.
doi:10.1073/pnas.1107411108.
552. Cissé M, Duplan E, Guillot-Sestier MV, Rumigny J, Bauer C, Pagès G, et al.
The extracellular regulated kinase-1 (ERK1) controls regulated alpha-
secretase-mediated processing, promoter transactivation, and mRNA levels
of the cellular prion protein. J Biol Chem. 2011;286(33):29192–206. doi:10.
1074/jbc.M110.208249.
553. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an
endogenous negative regulator of the gamma-secretase activity. FASEB J.
2006;20(1):157–9.
554. Linde K, Berner MM, Kriston L. St John’s wort for major depression.
Cochrane Database Syst Rev. 2008;4:CD000448. doi:10.1002/14651858.
CD000448.pub3.
555. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum
perforatum in major depressive disorder in comparison with selective
serotonin reuptake inhibitors: a meta-analysis. Prog Neuropsychopharmacol
Biol Psychiatry. 2009;33(1):118–27. doi:10.1016/j.pnpbp.2008.10.018.
556. Abbott AC, Calderon Toledo C, Aranguiz FC, Inestrosa NC, Varela-Nallar L.
Tetrahydrohyperforin increases adult hippocampal neurogenesis in wild-
type and APPswe/PS1ΔE9 mice. J Alzheimers Dis. 2013;34(4):873–85. doi:10.
3233/JAD-121714.
557. Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, et al.
Reduced Alzheimer’s disease pathology by St. John’s Wort treatment is
independent of hyperforin and facilitated by ABCC1 and microglia
activation in mice. Curr Alzheimer Res. 2013;10(10):1057–69.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 50 of 52
558. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M, et al. St.
John’s Wort reduces beta-amyloid accumulation in a double transgenic
Alzheimer’s disease mouse model-role of P-glycoprotein. Brain Pathol. 2014;
24(1):18–24. doi:10.1111/bpa.12069.
559. Cavieres VA, González A, Muñoz VC, Yefi CP, Bustamante HA, Barraza RR, et al.
Tetrahydrohyperforin Inhibits the Proteolytic Processing of Amyloid Precursor
Protein and Enhances Its Degradation by Atg5-Dependent Autophagy. PLoS
One. 2015;10(8):e0136313. doi:10.1371/journal.pone.0136313.
560. Inestrosa NC, Tapia-Rojas C, Griffith TN, Carvajal FJ, Benito MJ, Rivera-Dictter
A, et al. Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau
phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of
Alzheimer’s disease: a possible effect on APP processing. Transl Psychiatry.
2011;1:e20. doi:10.1038/tp.2011.19.
561. Fuller S, Richard AJ, Ribnicky DM, Beyl R, Mynatt R, Stephens JM. St. John’s
Wort Has metabolically favorable effects on adipocytes in vivo. Evid Based
Complement Alternat Med. 2014;2014:862575. doi:10.1155/2014/862575.
562. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin
KD. Effect of St John’s wort on drug metabolism by induction of
cytochrome P450 3A4 enzyme. JAMA. 2003;290(11):1500–4.
563. Gorąca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, Skibska B. Lipoic
acid - biological activity and therapeutic potential. Pharmacol Rep.
2011;63(4):849–58.
564. Raddatz G, Bisswanger H. Receptor site and stereospecifity of
dihydrolipoamide dehydrogenase for R- and S-lipoamide: a molecular
modeling study. J Biotechnol. 1997;58(2):89–100.
565. Streeper RS, Henriksen EJ, Jacob S, Hokama JY, Fogt DL, Tritschler HJ.
Differential effects of lipoic acid stereoisomers on glucose metabolism in
insulin-resistant skeletal muscle. Am J Physiol. 1997;273(1 Pt 1):E185–91.
566. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, et al.
Lipoic acid as a novel treatment for Alzheimer’s disease and related
dementias. Pharmacol Ther. 2007;113(1):154–64.
567. Genuis SJ, Kelln KL. Toxicant exposure and bioaccumulation: a common and
potentially reversible cause of cognitive dysfunction and dementia. Behav
Neurol. 2015;2015:620143. doi:10.1155/2015/620143.
568. Suh JH, Zhu BZ, de Szoeke E, Frei B, Hagen TM. Dihydrolipoic acid lowers
the redox activity of transition metal ions but does not remove them from
the active site of enzymes. Redox Rep. 2004;9(1):57–61.
569. Liu J, Atamna H, Kuratsune H, Ames BN. Delaying brain mitochondrial decay
and aging with mitochondrial antioxidants and metabolites. Ann N Y Acad
Sci. 2002;959:133–66.
570. Voloboueva LA, Lee SW, Emery JF, Palmer TD, Giffard RG. Mitochondrial
protection attenuates inflammation-induced impairment of neurogenesis in
vitro and in vivo. J Neurosci. 2010;30(37):12242–51. doi:10.1523/JNEUROSCI.
1752-10.2010.
571. Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with
potential therapeutic use in diabetes and other chronic diseases. Diabetol
Metab Syndr. 2014;6(1):80. doi:10.1186/1758-5996-6-80.
572. Jiang T, Yin F, Yao J, Brinton RD, Cadenas E. Lipoic acid restores age-
associated impairment of brain energy metabolism through the modulation
of Akt/JNK signaling and PGC1α transcriptional pathway. Aging Cell. 2013;
12(6):1021–31. doi:10.1111/acel.12127.
573. Fu B, Zhang J, Zhang X, Zhang C, Li Y, Zhang Y, et al. Alpha-lipoic acid
upregulates SIRT1-dependent PGC-1α expression and protects mouse brain
against focal ischemia. Neuroscience. 2014;281C:251–7. doi:10.1016/j.
neuroscience.2014.09.058.
574. Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic
acid on improving age-associated mitochondrial and cognitive dysfunction:
an overview. Neurochem Res. 2008;33(1):194–203.
575. Choi KH, Park MS, Kim HS, Kim KT, Kim HS, Kim JT, Kim BC, et al. Alpha-lipoic
acid treatment is neurorestorative and promotes functional recovery after
stroke in rats. Mol Brain. 2015;8:9. doi:10.1186/s13041-015-0101-6.
576. Zhang L, Xing GQ, Barker JL, Chang Y, Maric D, Ma W, et al. Alpha-lipoic
acid protects rat cortical neurons against cell death induced by amyloid
and hydrogen peroxide through the Akt signalling pathway. Neurosci Lett.
2001;312(3):125–8.
577. Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendrikx
EM, et al. Lipoic acid affects cellular migration into the central nervous
system and stabilizes blood–brain barrier integrity. J Immunol. 2006;177(4):
2630–7.
578. Francis PT. The interplay of neurotransmitters in Alzheimer’s disease. CNS
Spectr. 2005;10(11 Suppl 18):6–9.
579. Campbell NR, Fernandes CC, Halff AW, Berg DK. Endogenous signaling
through alpha7-containing nicotinic receptors promotes maturation and
integration of adult-born neurons in the hippocampus. J Neurosci. 2010;
30(26):8734–44. doi:10.1523/JNEUROSCI.0931-10.2010.
580. Itou Y, Nochi R, Kuribayashi H, Saito Y, Hisatsune T. Cholinergic activation of
hippocampal neural stem cells in aged dentate gyrus. Hippocampus. 2011;
21(4):446–59. doi:10.1002/hipo.20761.
581. Zhao RR, Xu F, Xu XC, Tan GJ, Liu LM, Wu N, et al. Effects of alpha-lipoic
acid on spatial learning and memory, oxidative stress, and central
cholinergic system in a rat model of vascular dementia. Neurosci Lett. 2015;
587:113–9. doi:10.1016/j.neulet.2014.12.037.
582. Kotani S, Yamauchi T, Teramoto T, Ogura H. Donepezil, an
acetylcholinesterase inhibitor, enhances adult hippocampal neurogenesis.
Chem Biol Interact. 2008;175(1–3):227–30. doi:10.1016/j.cbi.2008.04.004.
583. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in
mild cognitive impairment: a systematic review of randomised trials. PLoS
Med. 2007;4(11):e338.
584. Fitzpatrick-Lewis D, Warren R, Ali MU, Sherifali D, Raina P. Treatment for mild
cognitive impairment: a systematic review and meta-analysis. CMAJ Open.
2015;3(4):E419–27. doi:10.9778/cmajo.20150057.
585. Fava A, Pirritano D, Plastino M, Cristiano D, Puccio G, Colica C, et al. The
effect of lipoic acid therapy on cognitive functioning in patients with
Alzheimer’s disease. J Neurodegener Dis. 2013;2013:454253. doi:10.1155/
2013/454253.
586. Hager K, Kenklies M, McAfoose J, Engel J, Münch G. Alpha-lipoic acid as a
new treatment option for Alzheimer’s disease–a 48 months follow-up
analysis. J Neural Transm Suppl. 2007;72:189–93.
587. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake
of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J
Neurol Sci. 2000;173(1):40–4.
588. Zempleni J, Trusty TA, Mock DM. Lipoic acid reduces the activities of biotin-
dependent carboxylases in rat liver. J Nutr. 1997;127(9):1776–81.
589. Suter A, Niemer W, Klopp R. A new ginkgo fresh plant extract increases
microcirculation and radical scavenging activity in elderly patients. Adv
Ther. 2011;28(12):1078–88. doi:10.1007/s12325-011-0083-4.
590. Le Bars PL. Magnitude of effect and special approach to Ginkgo biloba
extract EGb 761 in cognitive disorders. Pharmacopsychiatry. 2003;36 Suppl
1:S44–9.
591. Shi C, Liu J, Wu F, Yew DT. Ginkgo biloba extract in Alzheimer’s disease:
from action mechanisms to medical practice. Int J Mol Sci. 2010;11(1):107–23.
doi:10.3390/ijms11010107.
592. Shi C, Zhao L, Zhu B, Li Q, Yew DT, Yao Z, Xu J. Protective effects of Ginkgo
biloba extract (EGb761) and its constituents quercetin and ginkgolide B
against beta-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol
Interact. 2009;181(1):115–23. doi:10.1016/j.cbi.2009.05.010.
593. Wu Y, Wu Z, Butko P, Christen Y, Lambert MP, Klein WL, Link CD, Luo Y.
Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo
biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis
elegans. J Neurosci. 2006;26(50):13102–13.
594. Yao ZX, Han Z, Drieu K, Papadopoulos V. Ginkgo biloba extract (Egb 761)
inhibits beta-amyloid production by lowering free cholesterol levels. J Nutr
Biochem. 2004;15(12):749–56.
595. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract.
Cell Mol Life Sci. 2003;60(9):1779–92.
596. Eckert A. Mitochondrial effects of Ginkgo biloba extract. Int Psychogeriatr.
2012;24 Suppl 1:S18–20. doi:10.1017/S1041610212000531.
597. Banin RM, Hirata BK, Andrade IS, Zemdegs JC, Clemente AP, Dornellas AP,
et al. Beneficial effects of Ginkgo biloba extract on insulin signaling cascade,
dyslipidemia, and body adiposity of diet-induced obese rats. Braz J Med Biol
Res. 2014;47(9):780–8.
598. Shi C, Fang L, Yew DT, Yao Z, Xu J. Ginkgo biloba extract EGb761 protects
against mitochondrial dysfunction in platelets and hippocampi in
ovariectomized rats. Platelets. 2010;21(1):53–9. doi:10.3109/
09537100903395180.
599. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo
biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-
kappaBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm. 2006;
2006(5):92642.
600. Osman NM, Amer AS, Abdelwahab S. Effects of Ginkgo biloba leaf extract
on the neurogenesis of the hippocampal dentate gyrus in the elderly mice.
Anat Sci Int. 2015; www.ncbi.nlm.nih.gov/pubmed/26297531.
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 51 of 52
601. Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Wang C, et al. Efficacy and
adverse effects of ginkgo biloba for cognitive impairment and dementia: a
systematic review and meta-analysis. J Alzheimers Dis. 2015;43(2):589–603.
doi:10.3233/JAD-140837.
602. Hashiguchi M, Ohta Y, Shimizu M, Maruyama J, Mochizuki M. Meta-analysis
of the efficacy and safety of Ginkgo biloba extract for the treatment of
dementia. J Pharm Health Care Sci. 2015;1:14. doi:10.1186/s40780-015-0014-7.
603. Zhou XW, Ma Z, Geng T, Wang ZZ, Ding G, Yu-an B, Xiao W. Evaluation of in
vitro inhibition and induction of cytochrome P450 activities by hydrolyzed
ginkgolides. J Ethnopharmacol. 2014;158(Pt A):132–9. doi:10.1016/j.jep.2014.
10.023.
604. Hauge JG. Glucose dehydrogenase of bacterium anitratum: an enzyme with
a novel prosthetic group. J Biol Chem. 1964;239:3630–9.
605. Bauerly K, Harris C, Chowanadisai W, Graham J, Havel PJ, Tchaparian E, et al.
Altering pyrroloquinoline quinone nutritional status modulates
mitochondrial, lipid, and energy metabolism in rats. PLoS One. 2011;6(7):
e21779. doi:10.1371/journal.pone.0021779.
606. Rucker R, Chowanadisai W, Nakano M. Potential physiological importance of
pyrroloquinoline quinone. Altern Med Rev. 2009;14(3):268–77.
607. Killgore J, Smidt C, Duich L, Romero-Chapman N, Tinker D, Reiser K, et al.
Nutritional importance of pyrroloquinoline quinone. Science. 1989;
245(4920):850–2.
608. Bauerly KA, Storms DH, Harris CB, Hajizadeh S, Sun MY, Cheung CP, et al.
Pyrroloquinoline quinone nutritional status alters lysine metabolism and
modulates mitochondrial DNA content in the mouse and rat. Biochim
Biophys Acta. 2006;1760(11):1741–8.
609. Paz MA, Flückiger R, Torrelio BM, Gallop PM. Methoxatin (PQQ), coenzyme
for copper-dependent amine and mixed-function oxidation in mammalian
tissues. Connect Tissue Res. 1989;20(1–4):251–7.
610. Kasahara T, Kato T. Nutritional biochemistry: A new redox-cofactor vitamin
for mammals. Nature. 2003;422(6934):832.
611. Zhang Y, Feustel PJ, Kimelberg HK. Neuroprotection by pyrroloquinoline
quinone (PQQ) in reversible middle cerebral artery occlusion in the adult
rat. Brain Res. 2006;1094(1):200–6.
612. Kobayashi M, Kim J, Kobayashi N, Han S, Nakamura C, Ikebukuro K, Sode K.
Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein.
Biochem Biophys Res Commun. 2006;349(3):1139–44.
613. Kim J, Kobayashi M, Fukuda M, Ogasawara D, Kobayashi N, Han S, et al.
Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins. Prion.
2010;4(1):26–31.
614. Zhang JJ, Zhang RF, Meng XK. Protective effect of pyrroloquinoline quinone
against Abeta-induced neurotoxicity in human neuroblastoma SH-SY5Y
cells. Neurosci Lett. 2009;464(3):165–9. doi:10.1016/j.neulet.2009.08.037.
615. Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker
RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through
cAMP response element-binding protein phosphorylation and increased
PGC-1alpha expression. J Biol Chem. 2010;285(1):142–52. doi:10.1074/jbc.
M109.030130.
616. Harris CB, Chowanadisai W, Mishchuk DO, Satre MA, Slupsky CM, Rucker RB.
Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation
and mitochondrial-related metabolism in human subjects. J Nutr Biochem.
2013;24(12):2076–84. doi:10.1016/j.jnutbio.2013.07.008.
617. Nakano M, Yamamoto T, Okamura H, Tsuda A, Kowatari Y. Effects of oral
supplementation with pyrroloquinoline quinone on stress, fatigue, and
sleep. Functional Foods in Health and Disease. 2012;2:307–24.
618. Nakano M, et al. Effect of pyrroloquinoline quinone (PQQ) on mental status
of middle-aged and elderly persons. Food Style. 2009;13:50–3.
619. Zhao L, Gong N, Liu M, Pan X, Sang S, Sun X, et al. Beneficial synergistic
effects of microdose lithium with pyrroloquinoline quinone in an
Alzheimer’s disease mouse model. Neurobiol Aging. 2014;35(12):2736–45.
doi:10.1016/j.neurobiolaging.2014.06.003.
620. Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention
and recovery from Alzheimer’s disease: allopregnanolone as a proof of
concept neurogenic agent. Curr Alzheimer Res. 2006;3(3):185–90.
621. Gomez-Nicola D, Suzzi S, Vargas-Caballero M, Fransen NL, Al-Malki H,
Cebrian-Silla A, et al. Temporal dynamics of hippocampal neurogenesis in
chronic neurodegeneration. Brain. 2014;137(Pt 8):2312–28. doi:10.1093/
brain/awu155.
622. Martinez-Canabal A. Reconsidering hippocampal neurogenesis in
Alzheimer’s disease. Front Neurosci. 2014;8:147. doi:10.3389/fnins.2014.00147.
623. Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S,
Iqbal K, Grundke-Iqbal I. Failure of neuronal maturation in Alzheimer disease
dentate gyrus. J Neuropathol Exp Neurol. 2008;67(1):78–84.
624. Llorens-Martín M, Rábano A, Ávila J. The ever-changing morphology of
hippocampal granule neurons in physiology and pathology. Front Neurosci.
2016;9:526. doi:10.3389/fnins.2015.00526.
625. Seward ME, Swanson E, Norambuena A, Reimann A, Cochran JN, Li R,
Roberson ED, Bloom GS. Amyloid-β signals through tau to drive ectopic
neuronal cell cycle re-entry in Alzheimer’s disease. J Cell Sci. 2013;126(Pt 5):
1278–86. doi:10.1242/jcs.1125880.
626. Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J.
Neurogenic abnormalities in Alzheimer’s disease differ between stages of
neurogenesis and are partly related to cholinergic pathology. Neurobiol Dis.
2012;47(2):155–62. doi:10.1016/j.nbd.2012.03.033.
627. Shen WX, Chen JH, Lu JH, Peng YP, Qiu YH. TGF-β1 protection against Aβ1-
42-induced neuroinflammation and neurodegeneration in rats. Int J Mol Sci.
2014;15(12):22092–108. doi:10.3390/ijms151222092.
628. Battista D, Ferrari CC, Gage FH, Pitossi FJ. Neurogenic niche modulation by
activated microglia: transforming growth factor beta increases neurogenesis
in the adult dentate gyrus. Eur J Neurosci. 2006;23(1):83–93.
629. Kandasamy M, Lehner B, Kraus S, Sander PR, Marschallinger J, Rivera FJ, et al.
TGF-beta signalling in the adult neurogenic niche promotes stem cell
quiescence as well as generation of new neurons. J Cell Mol Med. 2014;
18(7):1444–59. doi:10.1111/jcmm.12298.
630. von Bernhardi R, Cornejo F, Eugenín J. Role of TGFβ signaling in the
pathogenesis of Alzheimer’s disease. Front Cell Neurosci. 2015;9:426.
doi:10.3389/fncel.2015.00426.
631. Martinez-Canabal A, Wheeler AL, Sarkis D, Lerch JP, Lu WY, Buckwalter MS,
et al. Chronic over-expression of TGFβ1 alters hippocampal structure and
causes learning deficits. Hippocampus. 2013;23(12):1198–211. doi:10.1002/
hipo.22159.
632. Daynac M, Pineda JR, Chicheportiche A, Gauthier LR, Morizur L, Boussin FD,
Mouthon MA. TGFβ lengthens the G1 phase of stem cells in aged mouse
brain. Stem Cells. 2014;32(12):3257–65. doi:10.1002/stem.1815.
633. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer’s
disease. Mol Neurodegener. 2011;6:85. doi:10.1186/1750-1326-6-85.
634. Wang Z, Peng W, Zhang C, Sheng C, Huang W, Wang Y, Fan R. Effects of
stem cell transplantation on cognitive decline in animal models of
Alzheimer’s disease: a systematic review and meta-analysis. Sci Rep. 2015;5:
12134. doi:10.1038/srep12134.
635. Lee JK, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells
attenuate amyloid β-induced memory impairment and apoptosis by
inhibiting neuronal cell death. Curr Alzheimer Res. 2010;7(6):540–8.
636. Frautschy SA, Cole GM. Why pleiotropic interventions are needed for
Alzheimer’s disease. Mol Neurobiol. 2010;41(2–3):392–409. doi:10.1007/
s12035-010-8137-1.
637. Murray F. Can Alzheimer’s disease be prevented? Intractable Rare Dis Res.
2013;2(4):136–8. doi:10.5582/irdr.2013.v2.4.136.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Nehls Journal of Molecular Psychiatry  (2016) 4:3 Page 52 of 52
